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Abstract 
The role of non-myocytes in drug-induced cardiovascular toxicity. 
Stephanie Ravenscroft, The University of Liverpool 
Submitted for the degree of Doctor of Philosophy (PhD), 2014 
Cardiovascular toxicity is a leading cause of drug attrition at the preclinical and 
clinical stages of drug development. The specific mechanisms of drug-induced 
cardiovascular toxicities, however, are not well understood and can occur via direct 
interactions of the drug with cardiomyocytes or indirectly through interactions with 
other components of the cardiovascular system. Indirect drug effects can target non-
cardiomyocyte cells such as fibroblasts, macrophages, vascular smooth muscle cells 
and endothelial cells. Evidence suggests interactions between these cell types are 
essential to the metabolism, growth, contractile performance and rhythmicity of the 
myocardium (Brutsaert, 2003). Preclinical and clinical drug safety tests primarily 
focus on cardiomyocytes, ignoring the other cellular components of the myocardium. 
High content biology in combination with ATP content as a measure of cytotoxicity 
was used to assess the sensitivities of endothelial and fibroblast cells from different 
vascular beds to known structural cardiotoxins. This assay principle has previously 
been successful in the detection of structural cardiotoxicity in human embryonic stem 
cell derived cardiomyocytes (hESC-CM’s) (Pointon et al., 2013). The endothelial 
cells displayed no significant difference in their compound responses, while the 
fibroblasts showed variation; imatinib was more potent in the cardiac fibroblasts and 
lapatinib more potent in the dermal fibroblasts. When the sensitivities of the cells 
from the myocardium (human cardiac fibroblasts (hCFs), human cardiac 
microvascular endothelial cells (hCMECs) and hESC-CMs) were globally compared 
the non-myocytes were sensitive to structural cardiotoxicity at the acute time point of 
6 hour (h), whereas the hESC-CMs display toxicity only after 72 h. The conclusions 
from this work are that non-myocyte cells play a role in drug-induced cardiovascular 
toxicity since early sensitivity is displayed, however current in vitro models lack the 
complexity required to investigate the translation of this in vivo. 
Multiple types of cardiac microtissue models were developed and their responses to 
reference structural cardiotoxins and inotropes evaluated using ATP content and 
video-based edge monitoring of contractility, respectively. Compound responses 
highlighted the promotion of maturity in the cardiac tri-cultured microtissue. Further 
investigations into gene expression and calcium (Ca2+) handling suggested SR 
function and Ca2+ handling maturity had been promoted and that the ca2+ handling 
protein S100A1 plays a critical role in this maturity. These findings show adult 
cardiac non-myocyte cells can be used to promote contractile maturity of hESC-CM’s 
in vitro when co-cultured as a three dimensional (3D) microtissue. The induction of 
maturity was very much multi-parameter dependent requiring a) both non-myocyte 
cell types, b) cells of cardiac origin and c) a 3D culture environment. More advanced 
human relevant in vitro models that better reconstitute the in vivo cellular physiology 
of the heart could allow improved in vitro to in vivo correlation in future drug safety 
screens.  
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1.1  Cardiovascular system 
In all vertebrates, a complex vascular system is vital for the adequate supply of 
essential oxygen and nutrients to the organs, and for the concomitant removal of 
metabolic waste products. The transport of endocrine signals from their sites of 
secretion to their effector organs and the movement of immune cells to sites of 
infection and inflammation, are also functions of the vascular system. Hence, the 
cardiovascular system is the first functional organ to develop during embryogenesis 
(Rossant & Howard, 2002). The cardiovascular system comprises the heart and the 
peripheral vascular system, forming part of the closed circulatory system within the 
body. The peripheral vascular system comprises blood vessels sub-divided into 
macrovascular and microvascular vessels which extend throughout the body. The 
heart is central to the cardiovascular system (figure 1.1) and comprises four 
chambers built from striated cardiac muscle called myocardial tissue. This tissue has 
a dense coronary microvascular network which allows delivery, via the bloodstream, 
of the free fatty acids and oxygen required to meet the high metabolic demands of 
the myocardial tissue (Aird, 2007a) (figure 1.1).  
 
 
 
Figure 1.1 Cardiovascular system comprising the peripheral and coronary 
vasculature.  
(a) The macro- and microvasculature of the peripheral vascular system. (b) The 
macro- and microvasculature of the coronary vascular system. Image courtesy of 
Professor Nicholas Smith (Kings College London). 
 
a b 
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The structure of the large, macrovascular vessels such as arteries and veins, 
consists of an inner layer (tunica intima) comprising a monolayer of endothelial cells 
surrounded by a sheet-like basement membrane home to the extracellular matrix 
proteins (ECM). This basement membrane is surrounded by the tunica media layer, 
which consists of vascular smooth muscle cells, whose function it is to allow vessel 
contraction. The outmost tunica adventia layer provides the supporting connective 
tissue. By contrast, the structure of the microvascular vessels, such as capillaries 
and arterioles, comprises a monolayer of endothelial cells surrounded by basement 
membrane and stabilised by a layer of specialised smooth muscle cells, known as 
pericytes (figure 1.2) (Aird, 2007b).  
Figure 1.2 Diagram of blood vessel structure.  
(a) Macrovascular vessel showing the inner layer (tunica intima), the tunica media 
layer and the outmost tunica adventia. (b) Microvascular vessel showing the 
monolayer of endothelial cells surrounded by smooth muscle cells and pericytes. 
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1.2  Cardiomyocytes- the fundamental work unit of the myocardium 
The myocardial tissue (myocardium) is composed of 30% cardiomyocytes (Brutsaert, 
2003); the fundamental work unit of the myocardium. The ultimate role of the heart is 
to maintain a constant circulation of blood around the vascular system which 
requires a non-stop pumping action by the heart, cycling between relaxing to fill with 
blood (diastole) and contracting to eject the blood (systole). This rhythmic action is 
brought about by the tight coordination of cardiomyocyte contractions within the 
myocardium. Blood circulation is fundamental to life therefore the heart is one of the 
earliest organs to develop during embryogenesis. Cell tracing studies in mice have 
suggested that the cardiac lineage arises from a population of cells expressing the 
vascular endothelial growth factor receptor 2 (VEGFR2, Flk-1) indicating that it may 
develop from a progenitor with vascular potential (Kattman et al., 2006). During 
embryogenesis, cardiomyocytes differentiate from stem cells. Stem cells are defined 
as undifferentiated cells capable of self-renewal or propagation as well as the 
capacity to transform into specialised cells under the appropriate conditions (Kumar, 
Kamp & LeWinter, 2005). The conditions required for cardiomyocyte differentiation 
are not fully understood, however the transcription factors Nkx-2.5 and GATA4 are 
known to play an important role in the specification of myocardial progenitors from 
the mesoderm since their expression is upregulated during the in vitro differentiation 
of embryonic stem cells into cardiomyocytes (Kumar, Kamp & LeWinter, 2005). 
Neuregulin-1 (NRG1) has recently been suggested to drive myocardial progenitors 
towards mature chamber cardiomyocytes (LaFlamme and Murray 2011) with faster 
conductance and a larger cell size. In the mature form these cells have a highly 
organised arrangement of functional units termed sarcomeres. Figure 1.3 shows the 
mature cardiomyocyte ultrastructure. Sarcomeres consist of myofilaments 
comprising groups of thin actin filaments and thick myosin filaments, which upon 
activation ‘slide’ past one another to shorten the sarcomere length; coordinated 
multi-sarcomere shortening thus contracts the cardiomyocyte. With coordinated 
cardiomyocyte contractions, the ventricular muscle contracts pushing blood out and 
around the body (Katz, 2006). 
 
As with skeletal muscle, the activation of cardiomyocyte sarcomere filaments is 
regulated by calcium (Ca2+) binding to elicit contraction, and dissociating to relax the 
contraction (Fabiato & Fabiato, 1975). Calcium homeostasis is perhaps considered 
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even more vital in the myocardium since the level of calcium signalling is solely 
responsible for the contractile force (inotropy) of the cardiomyocyte, whereas in 
skeletal muscle this depends upon the number of muscle fibers available (Eisner et 
al., 2012).  
 
 
Figure 1.3 Ultrastructure of the cardiomyocyte.   
Adapted from Katz, 2006. 
1.2.1 Excitation-contraction coupling 
Excitation-contraction coupling is the translation of an electrical excitation into a 
mechanical contraction force. A review by Bers in 2002 describes this process. 
Excitation is in the form of an action potential (AP) initiated by the pacemaker cells of 
the heart. This action potential travels through the heart causing membrane 
depolarisation. The action potential travels into the ventricular muscle, along the 
sarcolemma and deep into the cardiomyocyte by utilising the tranverse tubules (T-
tubules). This membrane depolarisation opens the L-type Ca2+ channels (LTCC), 
Ca2+ ions now enter the cardiomyocytes. The mature cardiomyocyte has an 
Z-line Thick 
filaments 
Thin 
filaments 
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abundant T-tubule network, which carries membrane depolarisation deep into the 
cardiomyocyte and spatially localises Ca2+ entering through the L-type Ca2+ 
channels with the ryanodine receptors (RyRs) of the sarcoplasmic reticulum (SR) 
(McNary et al., 2012). Extracellular Ca2+ binds to the RyRs to release a much greater 
amount of Ca2+ from the intracellular calcium stores of the SR (Fabiato & Fabiato, 
1977; 1979). This results in a rapid rise in free cytosolic Ca2+. This free Ca2+ binds to 
troponin C of the thin actin filaments causing an allosteric change, freeing the 
inhibitory troponin I from actin and unblocking the myosin binding site. Cross-bridge 
cycling can now occur, the myosin ‘heads’ of the thick filaments bind to the actin of 
the thin filaments, via the hydrolysis of adenosine triphosphate (ATP) and a resulting 
conformational change the thick and thin filaments ‘slide’ past one another 
shortening the sarcomere (Bers, 2002; Bers, 2001). Muscle contraction is therefore 
dependent upon Ca2+ and ATP. Figure 1.4 illustrates the excitation-contraction 
coupling network within the cardiomyocyte. 
 
Relaxation of the cardiomyocytes now occurs to allow the heart to re-fill with blood 
during its diastole phase. Ca2+ dissociates from troponin C and is either pumped 
back into the SR by the sarcoplasmic reticulum Ca2+ ATPase (SERCA) or effluxed 
from the cell using the sodium-calcium exchangers (NCX) which swap the one Ca2+ 
for three Na+ (Bers, 2002; Díaz et al., 2005). This loss of Ca2+ inhibits the cross-
bridge cycling and relaxation of the ventricular muscle occurs. 
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Figure 1.4 Excitation-contraction coupling in the cardiomyocyte.  
An action potential enters the tranverse tubules (T-tubules). Membrane 
depolarisation opens L-type Ca2+ channels (LTCC), Ca2+ ions enter the 
cardiomyocytes. Extracellular Ca2+ binds to the RyRs to release Ca2+ from the 
sarcoplasmic reticulum (SR).  Ca2+ binds to troponin C of the myofilaments. Upon 
repolarisation, sarcoplasmic reticulum Ca2+ ATPase (SERCA) loads Ca2+ back into 
the SR, sodium-calcium exchanger (NCX) transports Ca2+ out of the cell. Ca2+ 
dissociates from troponin C and the cardiomyocyte relaxes. Figure adapted from 
Volkers et al, 2010. 
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1.2.2 Role of S100A1 in cardiomyocyte excitation-contraction coupling 
S100A1 is a Ca2+ binding protein of the EF-hand type and a member of the S100 
protein family. The S100 family are a group of low molecular weight proteins found in 
vertebrates and characterised by their two calcium binding sites that have a helix-
loop-helix (EF-hand) conformation. The 19 members of the S100 protein family have 
varied biological activities including cell differentiation and cell cycle progression but 
also transduction of intracellular Ca2+ signalling. S100A1 is the most abundant S100 
protein in striated muscle and shows preferential myocardial tissue expression 
(Duarte-Costa et al., 2014). Studies have shown co-localisation of S100A1 with the 
intracellular SR Ca2+ stores and the contractile filaments of cardiomyocytes (Völkers 
et al., 2010). Given its preferential cardiac expression and localisation pattern, 
S100A1 has become a target of interest with respect to cardiac contractility. S100A1 
has been shown to regulate and improve the function of key proteins involved in the 
control of sarcoplasmic reticulum Ca2+ handling as well as myofilament and 
mitochondrial function, thereby enhancing the heart's inotropic and lusitropic state 
(Brinks et al., 2011; Duarte-Costa et al., 2014; Ritterhoff & Most et al., 2007; Rohde 
et al., 2014; Völkers et al., 2010). Figure 1.5 illustrates S100A1 interactions duing 
excitation-contraction coupling within the cardiomyocyte. Additionally, heart failure 
studies have highlighted a marked reduction in S100A1 protein expression 
correlating with a reduction in β-adrenergic and inotropy response therefore 
highlighting S100A1 as a promising target for cardiac gene therapy (Bennett et al., 
2014). Other commonly known cardiac calcium binding proteins include the 
troponins, calmodulin and myosin. 
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Figure 1.5 S100A1 in cardiomyocyte excitation-contraction coupling.  
An action potential enters the tranverse tubules (T-tubules). Membrane 
depolarisation opens L-type Ca2+ channels (LTCC); Ca2+ ions enter the 
cardiomyocytes. Extracellular Ca2+ binds to the ryanodine receptors (RyRs) to 
release Ca2+ from the sarcoplasmic reticulum (SR).  Ca2+ binds to troponin C of the 
myofilaments. Upon repolarisation, sarcoplasmic reticulum Ca2+ ATPase (SERCA) 
loads Ca2+ back into the SR, sodium-calcium exchanger (NCX) transports Ca2+ out 
of the cell. Ca2+ dissociates from troponin C and the cardiomyocyte relaxes. S100A1 
binds to and improves the functioning of RyR2, SERCA, myofilaments and 
mitochondria. Figure adapted from Volkers et al, 2010. 
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1.2.3 Caffeine and modulation of Ca2+ 
In electrophysiology studies using isolated cardiomyocytes a high concentration of 
caffeine (10 mM) has traditionally been used to measure sarcoplasmic reticulum 
(SR) function through caffeine-induced calcium release (caff-ICR) (Trafford et al., 
1998). Caffeine acts to increase the open probability of the RyRs therefore rendering 
the SR leaky and allowing the intracellular Ca2+ stores to be released into the 
cytosolic domain (Rousseau & Meissner, 1989; Trafford et al., 1998; Xu & Meissner, 
1998). This large and rapid Ca2+ signal throughout the cell allows cross-bridge 
cycling between the thin and thick filaments of the cardiomyocyte sarcomeres. In the 
myocardium the strength of the contraction (inotropy) is dependent upon the 
magnitude of Ca2+ transient and ATP available, therefore a steep relationship 
between intracellular Ca2+ store concentration and inotropy response exists. This 
inotropy is short lived however because the bulk of this Ca2+ is quickly transported 
out of the cell on NCX; normal Ca2+ reloading into the SR via SERCA is redundant 
due to the open RyRs on the SR surface therefore intracellular Ca2+ stores become 
depleted. This depletion occurs incredibly rapidly and results in an abrupt halt in 
cardiomyocyte contractions in unpaced conditions. Upon removal of caffeine, field 
stimulation of the cells allows an AP to activate the L-type Ca2+ channels causing an 
influx of Ca2+into the cardiomyocyte cytosol and re-loading of the now sealed SR can 
occur via the SERCA channels. This effect is seen in adult cardiomyocytes because 
their dominant role for intracellular Ca2+ release is gated by RyRs (Liu et al., 2007). 
 
SR are found to be relatively sparse in the immature myocyte with inositol 1,4,5-
trisphosphate (IP3)-gated Ca2+ release channels (IP3Rs) playing significant roles in 
Ca2+ mobilization from them (Liu et al., 2007). Research has suggested that reliance 
upon RyRs for intracellular Ca2+ release increases with maturity (Liu et al., 2007). 
Caffeine response can therefore be utilized as a marker of cardiomyocyte maturity; 
as RyR reliance and SR numbers increase, the magnitude of calcium released 
increases in correlation with contractile inotropy. 
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1.3  Non-cardiomyocytes- support cells of the myocardium 
1.3.1 Cardiac fibroblasts 
The remaining 70% of the cells in the myocardium are non-cardiomyocyte cells, with 
the majority being cardiac fibroblasts.  These fibroblast cells are situated between 
cardiomyocytes (figure 1.6), their main role being the maintenance of the 
extracellular matrix (ECM).  They are spindle shaped connective tissue cells that do 
not form a basement membrane but are responsible for the majority of the ECM 
proteins found in the myocardium. Their close proximity to myocytes and ability to 
manipulate the ECM provides them with the potential to influence the cardiomyocyte 
phenotype. Until recent years fibroblasts have been viewed as uniform cells, 
whereby phenotype is not subject to the local environment but gene expression 
studies are now suggesting they possess a high degree of phenotypic plasticity. For 
example, the cell surface receptor discoidin domain receptor 2 (DDR2) is specifically 
expressed by cardiac derived fibroblasts (Souders et al., 2009). In addition to this, 
preliminary reporting suggests cardiac fibroblasts possess contractile transducing 
abilities not seen in other fibroblasts (Kamkin et al., 2005), this characteristic may 
facilitate communications between cardiomyocytes. Fibroblasts also support the 
microvascular system of the heart by secreting basement membrane proteins; 
fibronectin, laminin, collagen I and III. In this way they are heavily involved in cardiac 
remodeling (Calderone et al., 1998; Ottaviano & Yee, 2011; Souders et al., 2009). 
 
The Ca2+ binding protein S100A1, (see section 1.2.2), has recently been suggested 
by Rohde et al, (2014) to possess an alarmin role during cardiac damage and a 
potential interaction with localized cardiac fibroblasts. Alarmin is a relatively new 
term referring to a protein released from a damaged cell, which acts upon 
neighbouring cells as a ‘distress’ signal allowing maintenance of tissue homeostasis. 
Rohde et al, have shown that S100A1 protein is released from iscahemic 
cardiomyocytes following tissue damage. S100A1 is then internalized via 
endolysosomal trafficking utilizing Toll-like receptor 4 in cardiac fibroblasts. 
Internalized S100A1 activates MAPK/SAPK and NFkB to initiate an anti-fibrotic 
immunomodulatory role in cardiac fibroblasts (Rohde et al., 2014). Rohde et al. 
(2014) also highlighted a lack of internalization in endothelial and smooth muscle 
cells suggesting S100A1 has a specific alarmin role between cardiomyocytes and 
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cardiac fibroblasts to protect against fibrosis. This is one example of the important 
interplay that exists between cardiomyocytes and non-myocytes of the myocardium 
in order to maintain a finely tuned tissue even during times of environmental stress. 
 
 
Figure 1.6 Immunofluorescence image of cardiomyocytes and cardiac 
fibroblasts within a rat heart left ventricle section.   
Rat hearts were sectioned at 10 M and stained with cell specific markers, images 
use Hoescht as a nuclei stain. Myocytes are stained using cardiac troponin I (cTnI) 
shown in green and fibroblasts with collagen 1 in red. Scale bar represents 20 m. 
Image courtesy of Emma Smith (The University of Liverpool). 
 
1.3.2 Cardiac microvascular endothelial cells 
The next most abundant cells in the myocardium are the cardiac endothelial cells 
(figure 1.7). When considering the cardiovascular system, it is important to 
distinguish between the cardiac endothelium and the vascular endothelium as the 
latter interacts with smooth muscle cells as opposed to cardiomyocytes. The cardiac 
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endothelium represents two types of endothelial cells, those present within the 
endocardium and the microvascular endothelial cells of the intramyocardial 
capillaries. In the normal myocardium, the ratio of capillaries to myocytes is at least 
1:1 with endothelial cells outnumbering myocytes 3:1, this minimal cell-to-cell 
diffusion distance is crucial to ensure the cardiomyocytes obtain the nutrients and 
oxygen required to meet their high metabolic demands, while also allowing signalling 
factors to be communicated between cells (Brutsaert, 2003; Hsieh et al., 2006). 
Endothelial cells form a barrier to thrombus formation, regulate the adherence of 
immune cells and maintain vascular homeostasis (Aird, 2007a).  
 
 
Figure 1.7 Immunofluorescence image of cardiomyocytes and cardiac 
microvascular endothelial cells within a rat heart left ventricle section.   
Rat hearts were sectioned at 10 M and stained with cell specific markers, images 
use Hoescht as a nuclei stain. Myocytes are stained using cardiac troponin I (cTnI) 
shown in green and endothelial cells with rat endothelial cell antibody (RECA1) 
shown in white. Scale bar represents 20 m. Image courtesy of Emma Smith (The 
University of Liverpool). 
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It is generally accepted that the development of blood vessels involves two 
consecutive processes, vasculogenesis followed by angiogenesis (Starke et al., 
2006). Vasculogenesis in the early embryo involves the in situ differentiation of 
pluripotent mesodermal cells from the primitive streak into haemangioblasts which 
migrate to the extra-embryonic mesodermal layer in the yolk sac (Suburo & 
D’Amore, 2006). These haemangioblasts form aggregates known as primitive blood 
islands which comprise an outer layer of primitive endothelial cells, known as 
angioblasts, and an inner mass of primitive haemapoetic cells, known as 
haemangioblasts. Cells at the outer aspect of the blood island assume a spindle 
shape as they undergo differentiation into endothelial cells; whereas the inner cells 
differentiate into primitive blood cells by progressively losing their intercellular 
attachments. This results in the formation of mature blood islands. Fusion of these 
blood islands gives rise to a primary capillary plexus in the yolk sac that surrounds 
the embryo. A similar, but distinct route of vasculogenesis occurs within the embryo 
proper whereby the pluripotent mesoderm cells differentiate directly into angioblasts 
and subsequently into endothelial cells. The establishment of this primary vascular 
plexus is critical for the survival of murine embryos beyond day 9.5 (E9.5) (Flamme 
et al., 1997). 
 
Angiogenesis is the subsequent stage of vascular development; it involves the 
formation of new blood vessels from pre-existing vessels (Clauss & Breier, 2005; 
Starke et al., 2006). The newly formed primary capillary plexus undergoes vascular 
remodelling to allow blood vessels to extend into the avascular extremities of the 
developing embryo (Clauss & Breier, 2005). This stage of vascularisation is critical to 
embryonic development but is a rare postnatal event in mammals occurring only 
during specialised physiological processes such as the female reproductive cycle 
and wound healing (Clauss & Breier, 2005). Angiogenesis plays roles in various 
pathologies such as rheumatoid arthritis and diabetic retinopathy as well as tumour 
development and metastasis. A lack of angiogenesis can, in contrast, also be 
disruptive as in the case of cardiac ischaemia. Many factors are involved in the 
regulation of sprouting angiogenesis creating a tightly regulated but dynamic multi-
step process. Endothelial cells are normally quiescent in mature tissues, however, 
an upregulation in the concentration of pro-angiogenic factors or a down-regulation 
in anti-angiogenic factors in the surrounding microenvironment can lead to an 
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‘angiogenic switch’ and the endothelial cells adopting an angiogenic phenotype. Pro-
angiogenic factors include vascular endothelial growth factor (VEGF) and fibroblast 
growth factor-2 (FGF-2). Anti-angiogenic factors include angiostatin and endostatin. 
 
In recent years it has become increasingly apparent that, like fibroblasts, endothelial 
cells originating from different vascular beds show considerable heterogeneity 
(Hendrickx et al., 2004). While endothelial cells are united in certain common 
features, their heterogeneity has been described at the level of morphology, function, 
antigen composition and signalling networks, suggesting each endothelial cell type is 
uniquely adapted to meet the demands of its local environment. Recently, data 
indicates that the embryological origin of macro- and microvascular endothelium are 
distinct; evidence suggests that microvasculature arises from vasculogenesis 
whereby angiogenesis is responsible for the creation of macrovascular segments. 
Therefore, endothelial cell responses are now thought to be the result of the 
environment in which an endothelial cell resides and it’s genetically ‘programmed’ 
function (Aird, 2012), providing endothelial cells residing within different tissues with 
the potential to respond to a common signal in a unique manner. Research is also 
suggesting a common ancestry for cardiac microvascular endothelial cells and 
cardiomyocytes, which could allow a hypothesis for common drug sensitivities (Garry 
& Olson, 2006; Laflamme & Murry, 2011; Moretti et al., 2006; Wu et al., 2006). 
Specific progenitor cells, which ultimately make up the myocardium, arise from a 
common embryonic epiblast. Endothelial cells have two routes to their final 
endothelial phenotype; the signalling factor wingless-related integration site (wnt)  
can direct this epiblast into haemangioblast and subsequently endothelium or 
alternatively, the epiblast is directed towards pre-cardiac mesoderm upon which 
VEGF directs a subsequent and final endothelial cell fate. Alternatively this pre-
cardiac mesoderm can develop into chamber cardiomyocytes directed by 
neuregulin-1 (NRG-1)  (Laflamme & Murry, 2011).  
 
1.3.3 Cardiac pericytes 
The microvasculature in human hearts contains abundant pericytes (figure 1.8), and 
on average each endothelial cell is associated with two to three pericytes (Nees et 
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al., 2013). These pericytes are contractile cells which wrap themselves around the 
microvasculature and support the normal functioning of the endothelial cells; these 
cells have only recently been highlighted as a target of interest with respect to 
cardiotoxicity (Chintalgattu et al., 2013; Nees et al., 2013; Nees et al., 2012). They 
play many physiological roles from barrier function, regulation of homeostasis, 
facilitation of angiogenesis to initiation of coagulation. 
 
Figure 1.8 Immunofluorescence image of cardiac microvascular endothelial 
cells and cardiac pericytes within a rat heart left ventricle section.  
 Rat hearts were sectioned at 10 m thickness and stained with cell specific 
markers, images use Hoescht as a nuclei stain. Endothelial cells are stained using 
rat endothelial cell antibody (RECA1) shown in white and pericytes with chondroitin 
sulfate proteoglycan (NG2) shown in red. Scale bar represents 20 m. Image 
courtesy of Emma Smith (The University of Liverpool). 
1.4 Cellular communications within the myocardium 
1.4.1 Physical communications 
As with many organs, cell communications within the myocardium are highly 
abundant in order to coordinate the fast and continual rhythmic contractions. Both 
cardiomyocytes and non-cardiomyocyte cells are rich in gap junctions, and as with 
other cell types this allows the direct passage of ions and small solutes between 
cells.  These types of gap junctions are important in the myocardium for the transfer 
of oxygen and nutrients between the cardiomyocytes and the endothelial cells of the 
microvasculature. Gap junctions play an additional role between cardiac cells; a 
family of gap junction proteins, known as connexins, are critical in the fast 
conduction of electrical impulses. Global deletion of Connexin 43 (Cx43) in mice 
causes neonatal death (Tirziu et al., 2010). The role of gap junctions has been best 
described between cells of the same type i.e. cardiomyocyte to cardiomyocyte 
(homotypic), but heterotypic connections also exist, for example cardiomyocytes 
form gap junctions with other cell types such as adjacent cardiac fibroblasts (Tirziu et 
al., 2010) or endothelial cells of neighbouring microvasculature (Brutsaert, 2003; 
Hsieh et al., 2006). These connections allow an uninterrupted conduction of 
electrical impulses throughout the myocardium. Cells of the myocardium also form 
connections with the extracellular matrix. The synthesis and degradation of the ECM 
is primarily the role of the cardiac fibroblasts; it provides a 3D scaffold for the 
cardiomyocytes and microvasculature. Cardiac fibroblasts are able to respond to 
extracellular stimuli (chemical, mechanical or electrical) in order to maintain a healthy 
3D scaffold (Souders et al., 2009).  
 
1.4.2 Chemical communications 
In addition to physical communications between cells; autocrine and paracrine 
signalling is present within the myocardium as a dense and complex cross-talk 
between cardiomyocytes and non-cardiomyocytes in order to regulate cardiac 
structure and function. Combinations of secretion factors act to regulate 
cardiomyocyte health and therefore cardiac performance. It is widely accepted that 
cardiomyocytes, as with most muscle cell types including vascular smooth muscle 
cells, respond to increased cellular demands by increasing in cell size rather than 
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number (Brutsaert, 2003). Numerous signalling pathways are involved in the 
hypertrophy and survival of cardiomyocytes. Nitric oxide (NO) is a low molecular 
weight signalling molecule which acts by passively diffusing through target cell 
membranes to regulate intracellular signalling. NO is synthesised by the enzyme 
nitric oxide synthase (NOS) expressed under normal physiological conditions in 
cardiac endothelial cells (Brutsaert, 2003). The major eicosanoids synthesised by 
endothelial cells are prostacyclin (PGI2) and prostaglandin E2 (PGE2) which are 
synthesised by the enzyme cyclooxygenase (COX) (Campbell and Falck, 2007). It 
has been suggested that NO and PGI2 have an anti-growth effect on the heart 
(Calderone et al., 1998; Harding et al., 1995; Hayakawa and Railj, 1997). Bradykinin 
has been shown to induce a direct growth response on cardiomyocytes in 
monoculture, however when co-cultured with cardiac endothelial cells, this growth 
response is inhibited (Ritchie et al., 1998a; 1998b). It was therefore suggested that 
bradykinin stimulates endothelial release of NO and PGI2 by acting upon the B2 
receptors on the endothelial cell surface which would therefore explain the beneficial 
effects of the angiotensin converting enzyme (ACE) inhibitors (ACEI) on ventricular 
remodelling; ACE breaks down bradykinin thereby inhibition results in an 
accumulation of bradykinin. The mechanism through which NO and PGI2 block 
hypertrophy is unclear, however evidence suggests an increase in cGMP levels in 
the cardiomyocytes (Calderone et al., 1998).  
 
An additional role for NO released by endothelial cells is to regulate the onset of 
ventricular relaxation, however it can also be synthesised by eNOS and nNOS 
present within cardiomyocytes (Grocott-Mason, 1994; Paulus, 1999). This autocrine 
signalling from cardiomyocytes can regulate β-adrenergic and muscarinic control of 
contractile state. NO diffuses into cardiomyocytes and can activate soluble guanylate 
cyclase leading to an increase in cGMP levels within the cell (Castro, 2010). This 
increased concentration of cGMP activates cGMP-dependent protein kinase which 
acts via numerous pathways e.g inhibition of ATP synthesis and closure of voltage-
gated calcium channels (Brutsaert, 2003). Endothelin-1 (ET-1) is also thought to be 
involved in cardiac contractility (Iwanaga, 1998; Cingolani et al., 2006). It is released 
by endothelial cells and activates two endothelin-1 receptors, ET-A and ET-B, found 
on cardiomyocytes; ET-B is also found on endothelial cells. These receptors are 
coupled to a Gq-protein and activation leads to an increase in IP3. IP3 stimulates 
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enhanced calcium release from the sarcoplasmic reticulum; this causes muscle 
contraction therefore increasing contractility and heart rate. As a second route of 
action to allow tight control of contractility, ET-1 acts to activate ET-B receptors on 
the endothelial cell surface (Hsieh et al., 2006). This receptor activation induces NO 
synthesis (Hsieh et al., 2006), which can diffuse into the cardiomyocyte and 
counteract the contraction signal produced by the ET-A and ET-B receptors.  
 
Cardiac rhythmicity is thought to be a principle role of the endocardial endothelial 
cells rather than the microvascular capillary endothelium. However, NO released by 
human cardiac microvascular endothelial cells (hCMECs) is also suggested to play a 
role in the regulation of myocardial rhythmicity; although this is not fully understood it 
is thought that NO together with PGI2 is involved in the tight balancing of 
cGMP:cAMP levels in cardiomyocytes (Brutsaert, 2003). 
 
A final role for NO within the myocardium is regulation of cardiac metabolism; it has 
been shown to decrease myocardial tissue oxygen consumption in the normal as 
well as failing human heart (Brutsaert, 2003). This reduction in myocardial oxygen 
consumption was further reduced by ACE inhibitors (Loke, 1999); ACE inhibitors 
prevent the breakdown of bradykinin which leads to an increase in NO levels and 
therefore reduced oxygen consumption.  
 
Growth factors also play complex roles within the myocardium. VEGF is a potent 
mitogen whose activity is specific to endothelial cells. Substantial amounts of VEGF 
mRNA expression have been determined in cardiac microvascular endothelial cells 
(CMEC’s) as well as cardiomyocytes (Maruyama, 1999). mRNA of the VEGF 
receptor KDR/Flk-1 was found in the CMECs but not the cardiomyocytes 
(Maruyama, 1999) therefore explaining the lack of mitogenic activity on 
cardiomyocytes. Platelet derived growth factor (PDGF-AB/PDGF-α) signalling 
pathway between cardiomyocytes, cardiac fibroblasts and CMEC’s was found to 
increase expression of VEGF and its receptor FLK-1 in the CMEC’s (Edelberg, 
1998). VEGF produced either by the cardiomyocytes or the CMECs can in turn 
influence the expression of NO and PGI2 by the endothelial cells, thereby effecting 
cardiomyocyte remodelling and performance (Murphy, 2001; Ziche, 1997).  
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Cardiomyocyte survival is regulated by several signalling molecules. Growth factors 
such as insulin, IGF-1, erythropoietin and cytokines can antagonise apoptosis by 
activating PI3K which acts through Akt/PKB (Chen et al., 2010). Activated Akt acts to 
inhibit the pro-apoptotic Bcl-2 family member Bad, Bax, caspase-9, GSK-3 and 
FOX01 by phosphorylation (Chen et al., 2010; Oudit, 2009). PTEN negatively 
regulates the PI3K/Akt pathway (Oudit, 2009). An alternative activation route 
involves the activation of G-protein coupled receptors by peptide agonists or B2- 
adrenergic stimulation. Endothelial cell survival is also regulated in this way. These 
examples highlight the vast complexity of the signalling interplay that exists between 
cells of the myocardium. This expanse communication network is susceptible to 
interruptions by cardiotoxic drugs. 
 
While fibroblasts and endothelial cells share many of the same activating stimuli 
such as hypoxia (Brutsaert, 2003; Souders, 2009; Pohlman & Harlan, 2000), more 
recently data suggests cardiac non-myocytes can also respond to mechanical strain 
(Tirziu et al., 2010). Activation of angiogenesis or fibroblast proliferation can lead to 
changes in the vasculature or cardiac remodeling, this can be beneficial to the 
cardiomyocytes or as is the case in drug-induced cardiotoxicity, it can be detrimental 
and lead to reduced cardiac output.  
 
1.5 Introduction to cardiovascular toxicity 
Cardiovascular toxicity can be defined as ‘chemically induced heart disease’, which 
can occur with many different drug classes treating a range of diseases (Brana & 
Tabernero, 2010). Drug development has improved drastically over recent years, 
particularly with respect to cancer therapeutics. The cardiac safety of drugs, 
however, is slow to catch up meaning we are now facing an era of replacing one 
disease with another. Anthracyclines, such as doxorubicin, are a common form of 
chemotherapy used in anti-cancer treatment. It has been estimated that two million 
women in the USA are at risk of delayed anthracycline toxicity as a result of breast 
cancer treatment (Gianni et al., 2008). Not only are these drug-induced 
cardiovascular toxicity events a cause of serious health problems in patients, they 
are also the primary cause of drug withdrawal from the market and attrition during 
drug development; 28% over the past ten years (Laverty et al., 2011). For example, 
the non-steroidal anti-inflammatory drug (NSAID) rofecoxib (Vioxx®) was withdrawn 
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in 2004 due to fatal cardiotoxicity in man and the anti-diabetic drug rosiglitazone 
(Avandia®) is now withdrawn or greatly restricted due to an increased risk of 
cardiovascular events (Laverty et al., 2011).  
 
Ultimately the problematic endpoint of drug-induced cardiotoxicity is the inability of 
the heart to efficiently pump blood around the body. The specific mechanisms of 
drug-induced cardiovascular toxicities, however, are not well understood and can 
occur via direct interactions of the drug with cardiomyocytes or indirectly through 
interactions with other components of the cardiovascular system. Drug induced 
cardiovascular toxicity results from both functional effects (acute alteration of the 
mechanical function of the myocardium) and structural changes (morphological 
damage to cardiomyocytes or loss of viability) to the heart (figure 1.9). These 
adverse effects result in conditions such as arrhythmia or a more serious reduction in 
left ventricular ejection fraction (LVEF), which can lead to heart failure and death 
(Senkus, 2011; Minami, 2010). Indirect drug effects can target non-cardiomyocyte 
cells such as fibroblasts, macrophages, vascular smooth muscle cells and 
endothelial cells. Evidence suggests interactions between these cell types are 
essential to the metabolism, growth, contractile performance and rhythmicity of the 
myocardium (Brutsaert, 2003). Preclinical and clinical drug safety tests primarily 
focus on cardiomyocytes, ignoring the other cellular components of the myocardium 
(see section 1.7).  
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Figure 1.9 Functional, structural or indirect drug-induced cardiovascular 
toxicities. 
1.5.1 Drug-induced structural cardiotoxicity 
Damage to the myocardial cells can occur due to reduced blood supply in ischaemia 
or via direct drug-induced toxicity, leading to changes in myocardial morphology, 
physiology and biochemistry.  This compromises cardiac function and can lead to 
cardiac failure (Brana & Tabernero, 2010) (figure 1.9). Figure 1.10 provides an 
overview of the changes that can occur as a result of drug-induced cardiovascular 
injury. The initiating event in cardiac dysfunction was originally believed to be at the 
myocyte level.  However, it is now becoming apparent that endothelial dysfunction 
can influence surrounding cells (Ajithkumar et al., 2011; Mikaelian et al., 2010; 
Ritchie et al., 1998a; Higashi et al., 2009).  Furthermore, cardiac fibroblasts are 
known to affect both cardiac myocyte and endothelial cell function (Calderone et al., 
1998; Ottaviano & Yee, 2011; Rohde et al., 2014). Recent data have shown that 
drugs associated with clinical cardiotoxicity such as doxorubicin and tubulin-binding 
drugs (Mikaelian et al., 2010) can adversely affect cardiac endothelial cells. 
Doxorubicin (Adriamycin) is a member of the anthracycline family and many studies 
have highlighted doxorubicin-induced hydrogen peroxide production in endothelial 
cells and cardiomyocytes as a cause of cellular dysfunction (Ajithkumar et al., 2011). 
This oxidative stress is thought to have the ability to modulate the production levels 
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of NO and ET-1 leading to decreased NO and increased ET-1 (Ajithkumar et al., 
2011). This could potentially perturb cardiomyocyte-endothelial interactions. In 
addition to this doxorubicin is thought to lead to reactive oxygen species (ROS) and 
iron accumulation within the mitochondria of cardiomyocytes (Ichikawa et al., 2014). 
Oxidative stress can result in the activation of mitogen or stress activated kinases 
involved in an apoptotic response, this would explain the high level of cardiomyocyte 
cell death seen with doxorubicin (Ajithkumar et al., 2011). The redox cycling and 
generation of reactive oxygen species by doxorubicin has long been acknowledged 
and recently a mechanism for the initiation of this toxicity has been suggested. 
Zhang et al have shown that cardiomyocyte specific deletion of Top2b (encoding 
topoisomerase-IIβ) protects cardiomyocytes from doxorubicin-induced DNA double-
strand breaks that are responsible for defective mitochondrial biogenesis and ROS 
formation (Zhang et al., 2012). Doxorubicin has also been shown to increase 
endothelial apoptosis in the coronary microvasculature of the myocardium. Wu et al, 
measured an increase in Caspase 3 activity and resulting apoptosis in adriamycin-
induced cardiomyopathy both in vitro and in vivo (Wu et al., 2002; Ueno et al., 2006). 
 
The advent of molecularly targeted cancer therapy and concomitant development of 
protein kinase inhibitors represents an emerging cardiovascular toxicity problem 
(Mellor et al., 2011).  These drugs have the potential to interfere with the autocrine 
and paracrine growth factor/cytokine-stimulated signalling pathways utilized by the 
cardiomyocytes, endothelial cells and fibroblasts to maintain cellular homeostasis 
and respond to environmental factors (Brutsaert, 2003; Chintalgattu et al., 2010; 
Chintalgattu & Khakoo, 2010; Chintalgattu et al., 2013; Ottaviano & Yee, 2011; 
Chiusa et al., 2012). Examples include bevacizumab, sunitinib and sorafenib, all of 
which are protein kinase inhibitors (PKI). Inhibition of VEGF activity inhibits NO 
release (Mellor et al., 2011), since NO is thought to have cardioprotective roles in the 
myocardium it seems likely that this inhibition of endothelial cell activity would have 
an effect on cardiomyocytes. Sorafenib is a multi-kinase inhibitor which acts upon 
several protein kinases including the Raf family of kinases; Raf-1, β-Raf, VEGFR1, 
2, 3 and PDGFR members (Mellor et al., 2011). Alternative multi-kinase inhibitors 
exist with different PKI specificities, for example dasatinib targets Bcr-Abl, c-kit, 
PDGF-β and members of the Src family (Mellor et al., 2011). Recent data has shown 
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that the PKI sunitinib (Sutent), which also targets a range of kinases (VEGF 
receptors, c-Kit, PDGF receptors and Flt-3) in order to inhibit tumour angiogenesis, 
can adversely affect cardiac pericytes resulting in cardiac toxicity (Chintalgattu et al., 
2013; Nees et al., 2013; Nees et al., 2012).  
 
A potent method of chemotherapy treatment is often a combination of an 
anthracycline and an ErbB2 inibitor, for example breast cancer patients are often 
treated with lapatinib and doxorubicin. Seemann et al investigated whether this 
presents further complications with regard to cardiotoxicity. Cardiac irradiation of 
mice decreased microvascular density and increased endothelial damage in 
surviving capillaries but these changes were not exacerbated when followed with 
lapatinib treatment. Lapatinib pre-treatment did not enhance the risk of radiation or 
anthracycline-induced cardiac toxicity in mice up to 40 weeks after treatment, but 
endothelial and myocyte mitochondrial damage was more severe with doxorubicin-
lapatinib combination therapy (Seemann et al., 2014). One mechanism being 
explored is the hypothesis that ErbB2 receptors, expressed abundantly in mature 
cardiomyocytes, offer anti-apoptotic protection against anthracycline toxicity when 
activated by endothelial released NRG-1, thus inhibition of this interaction facilitates 
anthracycline toxicity. An alternative hypothesis by Hasinoff et al, is the blockade of 
doxorubicin efflux transporters by lapatinib thus increasing intracellular doxorubicin 
concentrations and cardiotoxic effects (Hasinoff et al., 2013). 
 
Cancer chemotherapies are not alone in their cardiotoxicity, Refocoxib is a NSAID 
which was withdrawn in 2004 due to adverse cardiovascular events; it inhibits COX-2 
which is responsible for the conversion of arachidonic into prostaglandin E2, a 
hormone involved in inflammation (Nalbant et al., 2006). Since prostaglandins are 
thought to have an anti-growth effect on cardiomyocytes, it could be hypothesised 
that this reduction in the optimisation of cardiomyocyte hypertrophy and rthythmicity 
is responsible for the adverse cardiovascular events witnessed. 
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Figure 1.10 Mechanisms of drug-induced structural cardiovascular toxicity. 
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1.5.2 Drug-induced functional cardiotoxicity 
Functional cardiotoxicity is essentially disruption of the contraction strength (left 
ventricular ejection fraction; LVEF) or rhythm of the heart (arrthymia, QT 
prolongation), ultimately resulting in heart failure. Functional cardiotoxicity can be 
secondary to structural cardiotoxicity i.e. damage to the muscle tissue results in 
weaker myocardial contraction and a reduction in LVEF. Alternatively, functional 
cardiotoxicity can arise from the direct effects of a drug, for example the 
antagonistic effect of atenolol at the beta-1 (β1)-adrenergic receptor allows 
atenolol to reduce hypertension but this can also lead to bradycardia (slow beat 
rate) and a reduction in LVEF. In this study, drug-induced changes to myocardial 
contraction force (negative and positive inotropy) will be focused on. An inotrope 
is defined as an agent that alters the force or energy of muscular contractions. 
Negatively inotropic agents weaken the force of muscular contractions. Positively 
inotropic agents increase the strength of muscular contraction. Very little is 
known regarding the role of non-myocytes in drug-induced functional 
cardiotoxicity. Recent data has begun to suggest that cardiac fibroblasts have 
electro-competence; this could potentially be perturbed by functional cardiotoxins 
(Souders et al., 2009). 
 
1.6 Current in vitro models and assays of cardiotoxicity  
 
Cardiovascular toxicity can be structural, involving morphological change or 
necrosis of cardiomyocytes, reduced myocardial microvascular density and 
fibrosis, or functional cardiotoxicity whereby the mechanical contractions of the 
heart are altered in frequency or strength. These toxicities can ultimately lead to 
a reduction in LVEF, meaning blood is not pumped around the body efficiently 
and can lead to heart failure. Cardiovascular toxicities are one of the leading 
causes of drug attrition at the clinical level of drug development suggesting our 
current pre-clinical models lack human in vivo relevance. This section will cover 
current in vitro models and assays utilised to study drug-induced structural and 
functional cardiovascular toxicity. 
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1.6.1 Human stem cell-derived cardiomyocytes and their immature phenotypes 
Recent in vitro assays for structural and functional cardiovascular toxicity are 
utilising human embryonic and pluripotent stem cell derived cardiomyocytes 
monolayer models (Goldring et al., 2011; Srivastava & Ivey, 2006; Gepstein, 
2002). These cell models lack the mature phenotype of an adult cardiomyocyte 
(Liu et al., 2007), they are however, considered more in vivo relevant than 
traditional cell line models such as the immortalised rat cardiomyoblast H9c2 cell 
line. The stem cell models, whether embryonic or induced pluripotent derived, 
exhibit a spontaneous beat, immunofluorescent staining for cardiac striations and 
expression of important ion channels/ receptors validated through gene 
expression and electrophysiology analysis. Classically these cells are seeded as 
confluent spontaneously beating monolayer models. Human embryonic stem cell 
derived cardiomyocytes will be utilised during this study. 
 
It has been widely reported that hESC-CMs structurally resemble embryonic or 
fetal cardiomyocytes (Kehat et al., 2003; Robertson et al., 2013). In a review by 
Robertson et al the various differences between embryonic cardiomyocytes and 
mature cardiomyocytes are discussed. Adult cardiomyocytes (CM) are large and 
cylindrical, approximately 150 μm (micrometer) in length, while embryonic and 
fetal cardiomyocytes are smaller (~30 μm). In addition, most adult CM are bi- or 
multinucleated, whereas hESC-CMs are mononucleated. The extensive t-tubule 
network present in adult ventricular CM is absent in hESC-CMs (Kehat et al., 
2003; Lieu et al., 2009; Robertson et al., 2013), resulting in slower excitation-
contraction coupling and calcium entry primarily through the sarcolemma instead 
of releasing from the sarcoplasmic reticulum (SR). Experiments with long-term 
monolayer culture of hESC-CMs has shown a degree of maturity towards adult 
CM morphology but never development of a T-tubule network or multinucleation 
(Lieu et al., 2009). Contractile machinery and mitochondria fill two-thirds of the 
cytoplasmic volume in adult CM, where as in hESC-CMs we see smaller 
sarcomeric regions and have more moderate numbers of mitochondria. Similarly, 
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expression of contractile and cytoskeletal genes is much lower compared to fetal 
(20 weeks) or adult cardiomyocytes (Robertson et al., 2013). 
In the adult CM, isoproterenol, a β1-adrenergic receptor agonist displays positive 
inotropy (increase in contraction force) and positive chronotropy (increase in 
contraction rate). With hESC-CMs we see positive chronotropy but no positive 
inotropy suggesting hESC-CMs have some degree of β1-adrenergic receptor 
expression but again highlighting the immaturity of this cell model (Robertson et 
al., 2013).  
 
In adult CM, calcium induced calcium release (CICR) from the SR contributes 
almost 70% of the total calcium release. In contrast, immature cardiomyocytes 
demonstrate calcium transients that are smaller and slower (Robertson et al., 
2013), with most cation influx of Ca2+ through the cell membrane (Liu et al., 
2007). This results in abnormal diffusion of calcium into the cell and reduces the 
synchrony in contraction necessary for large force generation. There is also 
consensus that intracellular calcium stores are smaller than in adult CM. Calcium 
handling and response to compounds that modify calcium handling varies greatly 
between immature and mature CMs. However, over time in culture increased 
sarcoplasmic reticulum function is seen, as assessed by caffeine-induced 
calcium release (caff-ICR) (see section 1.3.3 for details on caffeine effects on 
cardiomyocyte Ca2+ homeostasis). 
 
For a cardiomyocyte to respond with positive inotropy i.e. increase its contraction 
force, an extensive t-tubule network is thought to be required to ensure that the 
entire cell depolarizes rapidly and homogeneously. Immature cardiomyocytes 
rely primarily on calcium entry through the cell across the cell membrane which 
diffuses though the cytoplasm, a slower process. Some evidence suggests that 
non-SR calcium stores play a key role in excitation-contraction coupling in 
immature cardiomyocytes. IP3 receptor (IP3R) is expressed and colocalizes with 
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sarcomeres, suggesting it may play a role in release of non-SR calcium stores. In 
adult CM, IP3R appears to regulate non-contractile calcium signalling only, with 
greater reliance upon ryanodine receptors for calcium induced calcium release 
(CICR). 
Despite these immaturities, the lack of a readily available source of human adult 
CM for routine drugs testing means these cells along with human induced 
pluripotent stem cell derived cardiomyocytes (IPS-CMs) have become 
fundamental to many in vitro cardiotoxicity assays. 
 
1.6.2 3D in vitro cell culture models 
Various types of 3D cell culture techniques have been developed, some utilising 
scaffolds, others utilising the innate interactions of cells (Breslin & O'Driscoll, 
2013; Hirt et al., 2014 ), all developed with the aim of reconstituting the in vivo 
cellular morphology and physiology (Maltman & Przyborski, 2010). The most 
traditional scaffold-free 3D cell culture technique is the hanging drop method, 
whereby cells are suspended in a droplet of cell culture media where they 
aggregate to form a ‘ball’ of cells. More recently this technique has been replaced 
with the use of ultra low adhesion round bottomed plates whereby the cells sink 
to the well bottom and aggregate into a spheroid. The use of scaffolds to 
‘manually’ manipulate a cell into a more in vivo like shape are popular since this 
maintains a 2D platform that allows visualisation of the cells for image-based 
cytotoxicity assays (see section 1.7.3), which becomes technically challenging 
with spheroid models. One example are NanoFiber™ plates; a nanofiber matrix 
of approximately 700 nm (nanometer) diameter electrospun polycaprolactone 
(PCL) which creates an artificial tissue matrix for cells to adhere to. Although 3D 
cell culture techniques have existed for some time, it is only since the recent 
development of stem cell derived cardiomyocytes that efforts have been directed 
towards utilizing these techniques to potentially increase model maturity for 
cytotoxicity screening. 
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1.6.3 In vitro structural cardiotoxicity assays 
Until recently structural cardiotoxicity detection in vitro went largely untested in 
preclinical studies. In 2013 Pointon et al developed an approach whereby 
structural cardiotoxicity could be predicted in multiple cardiomyocyte cell models 
by staining cells with fluorescent dyes towards mitochondria, Ca2+ mobilisation, 
endoplasmic reticulum integrity and membrane permeability (Pointon et al., 
2013). This is a method whereby fluorescently labelled cells are utilised as the 
basic unit of molecular discovery is known as high-content biology (HCB).  
 
Healthy active mitochondria have a relative negative charge. Upon damage or 
inactivity, depolarisation occurs and this negative charge is reduced. 
Tetramethylrhodamine ethyl ester (TMRE) is a cell permeant, positively charged, 
red-orange fluorescent dye which is readily sequestered by active, negatively 
charged mitochondria (Life Technologies™ (Paisley, U.K.)). A change in 
mitochondrial membrane potential can therefore be detected by staining cells 
with TMRE and fluorescently imaging with an orange-red excitation filter.  
 
Structural changes to the endoplasmic reticulum, in particular a loss of ER 
density, can be detected using cell permeant, live cell dyes highly selective for 
the ER. ER dyes are available at the DAPI, FITC and TRITC wavelengths to 
allow multiplexing of dyes. Various dyes exist to allow the detection of Ca2+ 
mobilisation; the most commonly used for cell-based high-throughput drug 
discovery are the Fluo-calcium indicators. Fluo-3 was developed by Tsien (Tsien 
et al., 1988) and colleagues and has been utilised in drug discovery since about 
1996. It is essentially non-fluorescent unless bound to Ca2+ and exhibits at least 
a 100-fold Ca2+-dependent fluorescence enhancement (Life Technologies™ 
(Paisley, U.K.)). Fluo-3 & 4, a new derivative of 3, are essentially identical except 
Fluo-4 exhibits stronger fluorescence at the FITC (488 nm) wavelength. For this 
reason Fluo-4 AM was selected to monitor Ca2+ changes.  
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The endpoint of toxicity is generally cell death (necrosis); this is detected by 
staining cells with a cell membrane impermeable, dimeric cyanine nucleic acid 
dye which exhibits 100-1000 fold DNA-dependent fluorescence enhancement 
(Life Technologies™ (Paisley, U.K.)). The fluorescence spectra of the 10 
available dimeric cyanine dyes covers the entire visible wavelength range. Given 
TMRE and Fluo-4 AM are only available as dyes detectable at the red-orange 
(~555 nm; TRITC) and green (488 nm; FITC) wavelengths, respectively, the 
blue-white ER Tracker dye will be used (~350 nm; DAPI) and a far red (633 
nm;Cy5) nuclei acid dye, TOTO-3, will be multiplexed. With each dye emitting 
fluorescence at a different wavelength, MMP, ER integrity, Ca2+ mobilization and 
cell death can be simultaneously monitored as shown in figure 4.2. This HCB 
approach was combined with a cytotoxicity assay to measure intracellular 
adenosine triphosphate (ATP) content (Promega., Southhampton, U.K.). Figure 
1.11 summarises the parameters measured by HCB and ATP assessment. By 
combining the two assay types Pointon et al were able to increase the predictive 
strength of the overall assay (Pointon et al., 2013). 
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Figure 1.11 High content biology approaches to simultaneously monitor 
MMP, ER integrity, Ca2+ mobilisation and cell death in endothelial & 
fibroblast cells.  
Tetramethylrhodamine ethyl ester (TMRE) (30 pM) to measure mitochondrial 
membrane potential (MMP), ER-Tracker™ blue-white (1 nM) to measure ER 
integrity, Fluo-4 AM (1 nM) to measure calcium mobilization and TOTO®-3 (1 
nM) to indicate necrosis of cells. CellTiter-Glo reagent to measure intracellular 
ATP content to indicate apoptosis/ necrosis. Stained cells were subjected to 
automated live-cell fluorescent image acquisition using an ImageXpress high 
content analysis system (Molecular Devices, 20x objective). Fluorescent images 
were captured according to the optimal excitation and emission wavelengths of 
each probe. ATP luminescence was recorded using a Wallac 1450 Microbeta 
Trilux Scintillation Counter (PerkinElmer Life Sciences, Fremont, CA, U.S.A.). 
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1.6.4 In vitro functional cardiotoxicity assays 
Current functional cardiotoxicity assays involve classical electrophysiology 
techniques such as patch clamping whereby an individual cardiomyocyte is either 
impaled or suctioned onto a microelectrode and ion currents throughout the 
membrane of a cell are measured. Ion channels perform many essential roles 
and specifically regulate electrical activity in excitable cells such as muscles and 
neurons (Harmer et al., 2008). Alternatively, changes in the contractility 
parameters of isolated cardiomyocytes can be monitored by utilizing the IonOptix 
cell geometry system which utilises video-based detection of sarcomere 
shortening (Harmer et al., 2012). In this technique optical intensity data is 
collected representing dark and light bands present within the sarcomere, the 
movement of these bands translates into transients of peaks and troughs. These 
contractility transients are analysed using IonWizard software to provide 
quantification of contractility (contraction displacement measurements). These 
animal models however, are relatively poor predictors of human responses.  
 
With the development of human stem cell derived cardiomyocyte monolayer 
models (described in section 1.6.1) a new era of multi-electrode array (MEA) 
technology has arrived. MEAs are plate based assays whereby a monolayer of 
cells are seeded on to an electrode array printed to the well bottom. MEA 
recordings allow the simultaneous electrophysiological measuring of beat rate, 
field potential duration, amplitude and conduction velocity. Unlike the traditional 
patch-clamp assays which look at one ion channel at a time, MEA assesses 
changes in all major ion channels implicated in an action potential. Human stem 
cell derived cardiomyocyte monolayer models are also being utilized in calcium 
fluorescence based electrophysiology assays. The FLIPR system developed by 
Molecular Devices is one such system. Monolayer cells are pre-incubated with 
an intracellular calcium indicator dye, as the cells spontaneously beat and their 
intracellular Ca2+ levels flux, these peaks and troughs in fluorescence intensity 
are recorded. This system allows changes in contraction force i.e. peak 
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amplitude and frequency to be quantified. Despite these assays advancing to 
multi-parameter, higher throughput levels, their predictive strengths are often 
limited by the models applied to them. The non-human models are poor at 
predicting human-specific toxicities and the human stem cell derived 
cardiomyocyte monolayer models lack the mature complexity of myocardial 
tissue. 
 
1.7 Aims 
 
The high prevalence of drug-induced cardiovascular events at the pre-clinical 
and clinical stages of drug development suggests our current models of 
cardiovascular toxicity are lacking human in vivo relevance. Current in vitro 
models focus mainly on the cardiomyocytes of the myocardium, however data is 
mounting suggesting important roles for the non-cardiomyocytes in maintaining 
normal heart function.  
 
The aim of this study is to firstly determine the cardiotoxin sensitivities of cardiac 
microvascular endothelial and cardiac fibroblast cells relative to cardiomyocytes 
in order to highlight potential roles for non-myocytes in drug-induced 
cardiovascular toxicity. Dermal endothelial and fibroblast cells will be used 
alongside coronary artery endothelial cells in order to elucidate any myocardial 
specific cardiotoxic sensitivities. A high content biology assay, which uses 
fluorescently labelled cells as the basic unit of molecular discovery, will be 
combined with a measure of cytotoxicity. This assay principle has previously 
been successful in the detection of structural cardiotoxicity in human ESC 
cardiomyocytes (Pointon et al., 2013) 
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The ultimate aim of this work is to develop a human relevant in vitro model, which 
better reconstitutes the in vivo cellular physiology of the heart. Multiple types of 
cardiac microtissue models will be developed and their responses to reference 
inotropes evaluated using video-based edge monitoring of contractility. The 
microtissues will be further assessed for calcium handling and gene expression 
maturity. More advanced human relevant in vitro models will mean improved in 
vitro to in vivo correlation in future drug safety screens.  
 
Chapter three will discuss the development of in vitro cell based models to study 
cardiovascular toxicity, chapter four will evaluate the sensitivities of non-
myocytes to structural cardiotoxins using high content biology and cytotoxicity 
while chapter five will discuss contractile maturity in multicellular cardiac 
microtissues. 
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Chapter Two 
 
Materials & Methods 
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2.1 Materials 
2.1.1 Reagents 
5-Tetramethylrhodamine (TMRE); endoplasmic reticulum (ER)-Tracker™ Blue-
White DPX; Fluo-4 AM; TOTO®-3 Iodide; MitoTracker® Deep Red FM; Hoescht 
33342; DiI-AcLDL (Human Plasma Acetylated LDL, DiI complex (1,1′-
dioctadecyl-3,3,3′,3′-tetramethyl-indocarbocyanine perchlorate)) and Alexa 
Fluor® 568 phalloidin were purchased from Molecular Probes (Life 
Technologies™ (Paisley, U.K.). CellTiter-Glo® Luminescent Cell Viability Assay 
Kit was purchased from Promega (Madison, WI). Lactate dehydrogenase (LDH) 
cytotoxicity detection kit was purchased from Roche Applied Science (Welwyn 
Garden City, U.K.). Triton X-100; dimethyl sulfoxide (DMSO), 37% Formaldehyde 
and Tris buffered saline (10x, pH 8.0) were purchased from Sigma-Aldrich 
(Poole, U.K.). RNeasy mini RNA (RiboNucleic Acid) extraction kit was bought 
from Qiagen (Crawley, U.K.).  Lipofectamine™ RNAiMAX transfection reagent 
was purchased from Life Technologies™ (Paisley, U.K.).  
 
Water 
Distilled, deionised water (ddH2O) was passed through a 0.22 μm filter and 
treated with ultra violet (UV) light in a Millipore Synergy 185 unit (Millipore Ltd., 
Watford, U.K.) prior to use in the preparation of buffers and solutions. 
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2.1.2 Cell types 
Table 2.1 Cell types 
Name Cell Type Source 
hCMECs 
Human cardiac microvascular endothelial 
cells (Lot-No. 9090701.2 and 1122702) 
PromoCell (Heidelberg, 
Germany) 
hCAECs 
Human coronary artery endothelial cells 
(Lot-No. 1111804.1 and 113008.7) 
  
 
PromoCell (Heidelberg, 
Germany) 
hDMECs 
Human dermal microvascular endothelial 
cells (Lot-No. 0092101.2) 
PromoCell (Heidelberg, 
Germany) 
hCFs 
Human cardiac fibroblasts (Lot-No. 
1062201.5) 
PromoCell (Heidelberg, 
Germany) 
NhDFs 
Normal human dermal fibroblasts (Lot-
No. 2061206.2) 
PromoCell (Heidelberg, 
Germany) 
hESC-
CMs 
Cytiva human embryonic stem cell 
cardiomyocytes (Lot-No. 7396634) 
GE Healthcare Life 
Sciences 
(Buckinghamshire, U.K.) 
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2.1.3 Cell culture media & solutions 
Table 2.2 Cell culture media 
Name Composition Source 
Endo FGM 
Endothelial MV2 basal medium supplemented 
with 5% (v/v) foetal calf serum (FCS), EGF (5.0 
ng/ ml), hydrocortisone (0.2 μg/ ml), VEGF (0.5 
ng/ ml), FGF-2 (10.0 ng/ ml), insulin-like growth 
factor-1 (20.0 ng/ ml) and ascorbic acid (1.0 μg/ 
ml), (Cat. No.: C-22121). 
PromoCell 
(Heidelberg, 
Germany). 
Endo SFM 
Endothelial MV2 basal medium supplemented 
with EGF (5.0 ng/ ml), hydrocortisone (0.2 μg/ 
ml), VEGF (0.5 ng/ ml), FGF-2 (10.0 ng/ ml), 
insulin-like growth factor-1 (20.0 ng/ ml) and 
ascorbic acid (1.0 μg/ ml) (Cat. No.: C-22121). 
PromoCell 
(Heidelberg, 
Germany). 
Endo LSM 
Endothelial MV2 basal medium supplemented 
with 1% (v/v) foetal calf serum (FCS). 
PromoCell 
(Heidelberg, 
Germany). 
Endo -GF 
Endothelial MV2 basal medium supplemented 
with 5% (v/v) foetal calf serum (FCS). 
PromoCell 
(Heidelberg, 
Germany). 
F2 media 
Fibroblast growth medium 2 supplemented with 
2% (v/v) foetal calf serum (FCS), basic FGF (1.0 
ng/ ml) and human recombinant insulin (5 μg/ 
ml), (Cat. No.: C-23120). 
PromoCell 
(Heidelberg, 
Germany). 
F3 media 
Fibroblast growth medium 3 supplemented with 
10% (v/v) foetal calf serum (FCS), basic FGF 
(1.0 ng/ ml) and human recombinant insulin (5 
μg/ ml), (Cat. No.: C-23130). 
PromoCell 
(Heidelberg, 
Germany). 
CM media 
RPMI 1640 + glutamax (Cat. No.: 61870044) 
supplemented with B27 supplement (Cat. No.: 
17504-044). 
Life 
Technologies™ 
(Paisley, U.K.) 
5050 
Microtissue  
media 
50% CM media mixed with 50% Endo FGM In-house 
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Table 2.3 Cell culture solutions 
Solution Composition Source 
1x ACCUTASE 
enzymes 
in Dulbecco’s PBS 
KCl (0.2 g/L), KH2PO4 (0.2 g/L), NaCL (8 
g/L) and Na2HPO4 (1.15 g/L) containing 
0.5 mM EDTA·4Na and Phenol Red (3 
mg/L). 
Sigma-Aldrich 
(Poole, U.K.). 
0.1% (w/v) gelatin 
solution 
0.1% (w/v) gelatin from porcine skin, 
(type A, cell culture tested) in ddH2O, 
autoclaved and filter sterilised. 
Sigma-Aldrich 
(Poole, U.K.). 
Dulbecco's 
phosphate-buffered 
saline (without 
Ca2+/Mg2+) 
KCl (200 mg/l), KH2PO4 (200 mg/l), NaCl 
(8,000 mg/l), Na2HPO4•7H2O (2,160 
mg/l). 
Lonza (Basel, 
Switzerland). 
 
2.1.4 Cell culture materials 
Polystyrene, filter cap cell culture flasks with growth areas of 25 cm², 75 cm² and 
175 cm², 6-, 12-, 24- and 96-well cell-culture plates, black-walled clear bottomed 
96-well cell culture plates, centrifuge tubes, cryovials, filter pipette tips and 
serological pipettes were bought from Greiner Bio-One (Stonehouse, U.K.). 
Corning® Costar® round bottomed ultra-low adhesion plates (CLS7007) from 
Sigma-Aldrich (Poole, U.K.). Nunc™ Thermanox Coverslips, 13 mm diameter 
from Thermo Fisher Scientific (Loughborough, U.K.). 
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2.1.5 Compounds 
Table 2.4 Compounds 
Compound Known targets 
Total Cmax 
/ μM 
Source 
Catalogue 
no. 
Imatinib 
Mesylate 
Inhibitor of the Bcr-Abl, 
PDGF & c-kit receptors. 
3.54 
AZ in 
house 
supply 
AZ10049442 
Sunitinib malate 
Inhibitor of PDGFRa, 
PDGFRb, VEGFR1, 
VEGFR2, VEGFR3, 
KIT, FLT3, CSF-1R, and 
RET. 
0.25 
 
AZ in 
house 
supply 
AZ11755299 
Sorafenib 
tosylate 
Inhibitor of KIT, FLT-3, 
VEGFR-2, VEGFR-3, 
and PDGFR-ß. 
16.57 
 
AZ in 
house 
supply 
AZ10406510 
Dasatinib 
Inhibitor of BCR-ABL, 
SRC family (SRC, LCK, 
YES, FYN), c-KIT, 
EPHA2, and PDGFRβ. 
0.0072 
AZ in 
house 
supply 
AZ12384652 
Lapatinib 
Inhibitor of 
HER1/EGFR/ERBB1 
and HER2/ERBB2 
4.18 
 
AZ in 
house 
supply 
AZ10402704 
Doxorubicin 
HCl 
Intercalation of DNA, 
inhibits topoisomerase II 
activity 
15.34 
 
Sigma-
Aldrich 
(Poole, 
U.K.). 
D1515 
Idarubicin HCl 
Intercalation of DNA, 
inhibits topoisomerase II 
activity 
0.12 
Sigma-
Aldrich 
(Poole, 
U.K.). 
I1656 
Fluorouracil HCl 
Pyrimidine analogue. 
Irreversible inhibition of 
thymidylate synthase. 
4.61 
 
AZ in 
house 
supply 
AZ10090045 
Amoxacillin β-lactam antibiotic 
0.87 
 
AZ in 
house 
supply 
AZ12192757 
Sildenafil PDE-5 inhibitor 
0.24 
 
AZ in 
house 
supply 
AZ11779205 
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Enalapril 
Angiotensin-converting 
enzyme 
inhibitor 
0.83 
 
AZ in 
house 
supply 
AZ10215522 
Tolbutamide 
ATP-sensitive 
potassium channel 
inhibitor 
203 
 
AZ in 
house 
supply 
AZ10013036 
Paracetamol 
Cyclooxygenase 
inhibitor 
33.08 
 
AZ in 
house 
supply 
AZ10009025 
Verapamil 
L-type Ca2+ channel 
blocker 
0.6 
 
AZ in 
house 
supply 
AZ10049213 
Flecainide 
Cardiac Na+ channel 
block 
0.36 
 
AZ in 
house 
supply 
AZ10591336 
Haloperidol 
Dopamine D2-receptor 
antagonist 
0.024 
 
AZ in 
house 
supply 
AZ10047978 
Ivabradine 
Inhibits pacemaker If 
current 
0.04 
 
AZ in 
house 
supply 
AZ13525484 
Phentolamine 
Non-selective α 
adrenergic receptor 
antagonist 
0.0097 
 
AZ in 
house 
supply 
AZ10039017 
Nifedipine 
L-type Ca2+ channel 
blocker 
0.39 
 
AZ in 
house 
supply 
AZ10027237 
Bepridil 
L-type Ca2+ channel 
blocker 
1.9 
 
AZ in 
house 
supply 
AZ10134609 
Atenolol β1 receptor antagonist 
0.0023 
 
AZ in 
house 
supply 
AZ10000568 
Diltiazem 
L-type Ca2+ channel 
blocker 
0.38 
 
AZ in 
house 
supply 
AZ10180667 
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Milrinone PDE-3 inhibitor 
1.43 
 
AZ in 
house 
supply 
AZ10064577 
Glibenclamide 
ATP-sensitive 
potassium channel 
inhibitor 
0.73 
 
AZ in 
house 
supply 
AZ10102123 
Dobutamine β1-adrenergic agonist 
0.44 
 
AZ in 
house 
supply 
AZ10471493 
Digoxin 
Inhibits Na+ / K+ 
ATPase membrane 
pump 
0.0032 
 
AZ in 
house 
supply 
AZ12127481 
Levosimenden 
Calcium sensitiser 
(binds to cardiac 
troponin C) 
0.22 
 
AZ in 
house 
supply 
AZ13401595 
Isoproterenol 
β -adrenergic receptor 
agonist 
0.0071 
 
AZ in 
house 
supply 
AZ10064045 
Epinephrine 
Non-selective 
adrenergic receptor 
agonist 
0.17 
 
AZ in 
house 
supply 
AZ12136154 
 
Total plasma Cmax  (bound and unbound drug) values taken from FDA approval 
packages accessed through Pharmapendium. 
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2.1.6 Antibodies and fluorescent dyes 
Table 2.5 Fluorescent dyes 
Stain Target Wavelength D.F Source 
Catalogue 
no. 
TMRE Mitochondrial 
Membrane 
Potential 
TRITC 1:2000 Life 
Technologies™ 
(Paisley, U.K.) 
T-668 
ER-
Tracker™ 
Blue-
White 
DPX 
Endoplasmic 
Reticulum 
integrity 
DAPi 1:1000 Life 
Technologies™ 
(Paisley, U.K.) 
E12353 
Fluo-4 AM Ca2+ 
mobilization 
FITC 1:650 Life 
Technologies™ 
(Paisley, U.K.) 
F36205 
TOTO®-3 
Iodide 
Dead cell 
indicator 
Cy5 1:1000 Life 
Technologies™ 
(Paisley, U.K.) 
T3604 
DiI-AcLDL ac-Low 
Density 
Lipoprotein 
uptake 
TRITC 1:1000 Life 
Technologies™ 
(Paisley, U.K.) 
L3484 
Alexa 
Fluor® 
568 
phalloidin 
F-actin Texas Red 1:500 Life 
Technologies™ 
(Paisley, U.K.) 
A12380 
Hoescht 
33342 
Nuclei DAPi 1:5000 Life 
Technologies™ 
(Paisley, U.K.) 
H3470 
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Table 2.6 Primary Antibodies 
Host Target Dilution factor Supplier Catalogue no. 
Mouse 
Alpha 
sarcomeric 
actinin 
(ActN2) 
1:500 
Thermo 
Scientific™ 
Pierce™ 
MA1 22863 
Sheep CD31 1:500 R&D systems AF806 
Rabbit Collagen I 1:500 Abcam Ab34710 
Rabbit 
Cardiac 
troponin I 
(cTNI) 
1:200 Abcam Ab47003 
Goat 
Discoidin 
domain 
receptor 2 
(DDR2) 
1:200 
Santa Cruz 
Biotechnology 
SC-7555 
 
Table 2.7 Secondary Antibodies 
Host Target Dilution factor Wavelength Supplier Catalogue no. 
Donkey Sheep 1:1000 Alexa Fluor 
488 
Life 
Technologies™ 
(Paisley, U.K.) 
A11015 
Donkey Rabbit 1:1000 Alexa Fluor 
568 
Life 
Technologies™ 
(Paisley, U.K.) 
A10042 
Donkey Mouse 1:1000 Alexa Fluor 
680 
Life 
Technologies™ 
(Paisley, U.K.) 
A10038 
Donkey  Goat  1:1000 Alexa Fluor 
488 
Life 
Technologies™ 
(Paisley, U.K.) 
A11055 
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2.1.7 RT-PCR probes 
Table 2.8 TaqMan® Probes 
Gene 
TaqMan® gene expression 
assay probe 
Catalogue 
no. 
Source 
ADRB1 Hs02330048_s1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
ATP2A1 Hs01092295_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
ATP2A2 Hs00544877_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
ATP5B Hs00969569_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
CACNA1C Hs00167681_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
CACNA1H Hs00234934_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
GAPDH Hs02758991_g1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
GJA1 Hs00748445_s1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
IRX4 Hs00212560_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
KCND3 Hs00542597_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
KCNH2 Hs04234270_g1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
KCNJ2 Hs01876357_s1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
KCNQ1 Hs00923522_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
MYH6 Hs01101425_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
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MYH7 Hs01110632_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
NKX2.5 Hs00231763_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
NOS3 Hs01574659_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
PDE3A Hs01012698_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
PECAM1 Hs00169777_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
RYR2 Hs00892883_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
S100A1 Hs00984741_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
SCN5A Hs00165693_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
TCAP Hs00985784_g1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
THY1 Hs00264235_s1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
TNNC1 Hs00896999_g1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
TNNI3 Hs00165957_m1 
Cat. # 
4331182 
Life Technologies™ 
(Paisley, U.K.) 
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2.2 Methods 
2.2.1 Manipulation of mammalian cells 
2.2.1.1 Cell culture techniques 
Sterile conditions were maintained at all times during culturing and manipulation 
of mammalian cells by wearing nitrile examination gloves, using sterile cell 
culture equipment and working in a BioMAT2 Class II Microbiological Safety 
Cabinet (Medical Air Technology, Oldham, U.K.). Culture medium was warmed to    
37 degrees celcius (°C) in a water bath prior to use. All work surfaces were 
disinfected by wiping with 70% (v/v) ethanol before and after cell culture work. 
 
2.2.1.2 Gelatin-coating of cell culture plates and dishes 
Primary cells were routinely cultured in sterile polystyrene, filter cap cell culture 
flasks. Flasks were coated with 10 ml of autoclaved and sterile-filtered gelatin 
solution (0.1% (w/v) in ddH2O) per 75 cm2 growth area, and incubated at 37 °C 
in a humidified, 5% (v/v) carbon dioxide (CO2), atmosphere in a Heraeus® 
HERAcell® CO2 Incubators (Thermo Scientific, Hampshire, U.K.) for 15 minutes 
(min) prior to use. Gelatin was aspirated from the flasks prior to the seeding of 
cells. 
 
2.2.1.3 Thawing of cryopreserved cell stocks 
Cryopreserved cells stored at -135 °C were thawed in a 37 °C water bath for 2-3 
min with gentle agitation. The exterior of each cryovial was carefully disinfected 
with 70% (v/v) ethanol prior to pipetting the contents of the vial into a falcon tube 
containing 8 ml of pre-warmed growth medium. One millilitre (ml) of growth 
media was used to wash the cryovial before also being added to the falcon tube. 
The cell suspension was centrifuged at 1200 revolutions per minute (rpm) for 2 
mins and the cells re-suspended in 16 ml of growth media which was 
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subsequently transferred into two T25 cell culture flasks. The flasks were then 
incubated at 37 °C, 5% CO2.  
 
2.2.1.4 Passaging of primary cells and routine cell culture 
Following incubation at 37 °C, 5% CO2, for 3-5 days in the appropriate cell 
growth culture medium, to expand cell numbers, cells were briefly washed with 
10 ml of Dulbecco’s-Phosphate Buffered Saline (D-PBS) (without Ca2+/Mg2+) per 
75 cm2 growth area. D-PBS was then aspirated, and 10 ml of 1x accutase 
enzymes in Dulbecco’s PBS per 75 cm2 was added. Flasks were returned to the 
incubator for 5 min and tapped gently to aid cell detachment. When 95-100% of 
the cells had detached, as judged by viewing under an inverted light microscope, 
the cell suspension was transferred to a falcon tube and centrifuged at 1200 rpm 
for 3 min. The supernatant was aspirated and the cells re-suspended in the 
appropriate cell culture medium and split as described in Table 2.9. 
 
Table 2.9 Summary of cell usage 
Cell Type 
Cell culture 
medium used 
for routine 
culture 
Cell splits 
Passages 
used 
Seeding 
density in 96 
well plate 
(cells well-1) 
hCMECs Endo FGM 
1:4, every 4-5 
days 
p2-p9 6,000 
hCAECs Endo FGM 
1:5, every 4-5 
days 
p2-p9 6,000 
hDMECs Endo FGM 
1:4, every 4-5 
days 
p2-p9 8,000 
hCFs F3 media 
1:4, every 4-5 
days 
p2-p15 6,000 
NhDFs F2 media 
1:6, every 4-5 
days 
p2-p15 3,000 
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2.2.1.5 Thawing of hESC-CMs 
Cytiva 1E5 hESC-CMs were purchased cryopreserved and stored at -135°C until 
use. Each vial was thawed in a 37 °C water bath for 2-3 min with gentle agitation. 
The exterior of each cryovial was carefully disinfected with 70% (v/v) ethanol 
prior to pipetting the contents of the vial into a falcon tube. One millilitre of CM 
media was used to wash the cryovial before also being added to the falcon tube. 
Eight millilitres of CM media was slowly added to the cells over 2-3 mins. The cell 
suspension was centrifuged at 400 rpm for 4 mins and the cells re-suspended in 
CM media. Fifty microlitres of the cell suspension was then pipetted onto a Fast-
Read 102® (0.0025 mm2 and 0.100 mm depth) haemocytometer (Immune 
Systems Ltd, Paignton U.K.) for counting. The cell suspension was diluted to the 
appropriate cell density ml-1 and used in the downstream experiment. 
 
2.2.1.6 Cell plating for experiments 
Prior to use in experiments, cells growing in a cell culture flask were detached by 
briefly washing with 10 ml of D-PBS (without Ca2+/Mg2+) per 75 cm2 growth area. 
D-PBS was then aspirated, and 10 ml of 1x accutase enzymes in D-PBS per 75 
cm2 was added. Flasks were returned to the incubator for 5 min and tapped 
gently to aid cell detachment. When 95-100% of the cells had detached, as 
judged by viewing under an inverted light microscope, the cell suspension was 
transferred to a falcon tube and centrifuged at 1200 rpm for 3 min. The 
supernatant was aspirated and the cells re-suspended in the appropriate volume 
of cell culture medium. Fifty microlitres of the cell suspension was then pipetted 
onto a Fast-Read 102® (0.0025 mm2 and 0.100 mm depth) haemocytometer 
(Immune Systems Ltd, Paignton U.K.) for counting. The cell suspension was 
diluted to the appropriate cell density ml-1 for the required seeding density (Table 
2.9) using cell culture medium and 95 μL pipetted into each well of a black-
walled, 96 well plate. Plates were incubated for 4 days with media replaced every 
48 h. 
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2.2.1.7 Freezing of cell stocks 
Cells were purchased cryopreserved at passage 2 (p2). Following their initial 
thawing, cells were passaged twice and prepared for freezing at p4, by 
detachment and re-suspension of confluent T25 cell culture flasks. Re-
suspension followed a ratio of one T25: 1 ml of cell freezing medium (90% (v/v) 
cell culture medium and 10% (v/v) DMSO). Resultant cell suspensions were 
aliquotted into sterile cryovials and stored overnight at -80 oC before being 
transferred to the -135 °C freezer for long-term storage. 
 
2.2.1.8 Preparation of cardiac microtissues 
All primary cells were sub-cultured prior to microtissue formation, see section 
2.2.1.4. All primary cells were detached and counted according to section 
2.2.1.6. Cell suspensions were diluted and stored at 37oC, 5% CO2 for up to one 
hour while hESC-CM cell suspensions were prepared. A vial of Cytiva 
cardiomyocytes was thawed and suspended in CM media according to section 
2.2.1.5. Cell suspensions were mixed together at desired ratio, see table 2.10 for 
details on ratios, total cell numbers and cell media used. 100 μl of cell 
suspension was subsequently seeded into round bottom ultra- low adhesion 96- 
well plates (Corning® Costar®, CLS7007). Plates were incubated at 37oC, 5% 
CO2. At day 4 100 μl of appropriate cell culture media (see table 2.10) was added 
to each well. Microtissues were incubated for a further 10 days with 100 μl media 
refreshed every 3-4 days. 
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Table 2.10 Summary of microtissue combinations, ratios and media types 
Microtissue 
type 
Cell types 
used 
Total cells 
well-1 
Cell ratio 
(CM:Fibro:Endo) 
Cell culture 
media 
CM hESC-CMs 1000 - CM 
CMEF 
hESC-CMs 
hCFs 
hCMECs 
500 4:2:1 
5050 
microtissue 
DMEF 
hESC-CMs 
NhDFs 
hDMECs 
500 4:2:1 
5050 
microtissue 
CME 
hESC-CMs 
hCMECs 
500 2:1 
5050 
microtissue 
CMF 
hESC-CMs 
hCFs 
500 2:1 
5050 
microtissue 
 
2.2.2 Fluorescent imaging techniques 
2.2.2.1 Dil-ac-LDL uptake 
Cells in a black-walled, 96 well plate were stained with DiI-acLDL and Hoescht 
33342 in Endothelial basal media (EBM) MV2 growth medium for 4 h at dilutions 
shown in Table 2.5. Following staining, media was replaced with 100 μL D-PBS 
(without Ca2+/Mg2+) and the cells subjected to automated live-cell fluorescent 
image acquisition using an ImageXpress high content analysis system (Molecular 
Devices, 20x objective). Fluorescent images were captured according to the 
optimal excitation and emission wavelengths of each probe (Table 2.5). 
 
2.2.2.2 Fixation and labeling of F-actin 
Immediately after the Dil-AcLDL imaging assay was performed, the imaging 
medium was replaced with fixing solution; 3.7 % (v/v) paraformaldehyde (PFA) 
and 0.1% (v/v) Triton X-100 (polyethyrene glycol mono-p-iso-octylphenyl ether) in 
D-PBS (without Ca2+/Mg2+) (pH 7.4), the cells were then incubated at 37 oC, 5% 
CO2 for 20 mins. Paraformaldehyde fixes the cells by forming crosslinks between 
proteins. These crosslinks are methylene bridges formed between nitrogen 
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containing side chains of basic amino acids.  Following fixation, the cells were 
washed twice in D-PBS (without Ca2+/Mg2+) and blocking solution was added (0.2 
% (v/v) Triton X-100 and 1.1 % (w/v) bovine serum albumin (BSA) in Tris 
buffered saline (TRIS) (10x)) for 30 mins at room temperature. Following this 
incubation period, the blocking solution was removed and 50 μL/ well of Alexa 
Fluor® 568 phalloidin in D-PBS (without Ca2+/Mg2+) at a 1:500 dilution was added 
and the cells incubated in the dark for 1h at room temperature. The cells were 
washed once with D-PBS (without Ca2+/Mg2+) and 50 μL/ well of Hoescht 33342 
in D-PBS (without Ca2+/Mg2+) at a dilution of 1:12500 was added and the cells 
incubated in the dark for 20 mins at room temperature. Following incubation, the 
cells were washed twice with D-PBS (without Ca2+/Mg2+) and a final volume of 
100 μL added. The cells were subjected to automated live-cell fluorescent image 
acquisition using an ImageXpress high content analysis system (Molecular 
Devices, Sunnyvale, CA, U.S.A., 20x objective) or stored in the dark at 4 oC until 
needed. Fluorescent images were captured according to the optimal excitation 
and emission wavelengths of each probe (Table 2.5).  
 
2.2.2.3. Monolayer Immunofluorescence 
Monolayer cell media was replaced with 4% (v/v) formaldehyde in D-PBS and 
cells incubated at 37oC, 5% CO2 for 20 mins. Cells were washed in D-PBS three 
times. They can now be stored at 4oC. Cells were permeabilised with 0.2% (v/v) 
triton X-100/ PBS at room temperature for 10 mins and then blocked in 1.1% 
(w/v) BSA /TBST block (with 0.2% (v/v) Triton X-100) for 30 mins at room 
temperature. Primary antibody was diluted as required in 1.1% (w/v) BSA /TBST 
(with 0.2% (v/v) Triton X-100), block reagent was removed and primary antibody 
added for 2 h at room temperature. Cells were washed in D-PBS and secondary 
antibody applied at desired concentration in 1.1% (w/v) BSA/TBST (with 0.1% 
(v/v) Triton X-100) for 1 hour at room temperature. Finally cells were stained with 
Hoescht 33342 in D-PBS (with 0.1% (v/v) Triton X-100)  (1:5000 dilution) for 10 
mins at room temperature. Cells were washed and imaged in D-PBS. 
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2.2.2.4 Microtissue immunofluorescence 
Microtissues are washed in D-PBS until no remaining media can be seen. 
Microtissues are fixed in 4% (v/v) formaldehyde for 1 hour at 4oC, following which 
they are washed 6 times in PBS. They can now be stored at 4oC. Microtissues 
were permeabilised with 0.5% (v/v) triton X-100/ PBS overnight at 4oC then 
blocked in 3% (w/v) BSA /TBST block (with 0.1% (v/v) Triton X-100) for 2 h at 
room temperature. Primary antibody was diluted as required in 1% (w/v) BSA 
/TBST (with 0.1% (v/v) Triton X-100), block reagent was removed and primary 
antibody added overnight at 4°C. Microtissues were washed three times with 
TBST (with 0.1% (v/v) Triton X-100) at room temperature, each time incubated 
for 1 hour. Secondary antibody was diluted 1:1000 in 1% (w/v) BSA/TBST (with 
0.1% (v/v) Triton X-100) and added to the microtissues overnight at 4°C. 
Microtissues were washed for 1 hour with TBST (with 0.1% (v/v) Triton X-100) at 
room temperature and stained with Hoescht 33342 in TBST (with 0.1% (v/v) 
Triton X-100)  (1:5000 dilution) for 1 hour at room temperature. Microtissues 
were washed briefly in TBST (with 0.1% (v/v) Triton X-100) before mounting onto 
a microscope slide with ProLong Gold. Microtissues were imaged using a Zeiss 
fluorescence microscope. 
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2.2.4 Gene expression analysis & manipulation techniques 
2.2.4.1 RNA samples 
All stages of the RNA extraction procedures were carried out using sterile, 
RNase-free plastic ware, filter-tip pipette tips, and RNase-free water. RNA 
samples were kept on ice at all times, to minimise the possibility of RNA 
degradation by RNases. Adult left ventricle, foetal heart and smooth muscle total 
RNA were purchased from US Biological life sciences. hESC-CM total RNA was 
purchased from GE Healthcare. All primary cells were washed twice in DPBS 
(without Ca2+/Mg2+), detached with pre-warmed Accutase (Sigma, A6964) for 5 
mins at 37oC, 5% CO2, centrifuged for 3 mins at 1200 xg before lysis in 500 μl 
Buffer RLT containing 1% (v/v) 2-mercaptoethanol and stored at −80 °C until 
processing. Microtissues were pooled and transferred into a falcon tube, 
centrifuged at 1200 xg for 2 mins and re-suspended in pre-warmed DPBS. 
Microtissues were re-centrifuged at 1200 xg for 2 mins and lysed in 500 μl Buffer 
RLT containing 1% (v/v) 2-mercaptoethanol. Total RNA was extracted from cells 
using the RNeasy mini kit (Qiagen, Crawley, U.K.). A NanoDrop 
spectrophotometer (NanoDrop Technologies) was used to quantify RNA 
samples.  
 
2.2.4.2 Preparation of cDNA 
Total RNA was used for cDNA synthesis. Reverse transcription reactions were 
carried out in sterile, RNase- and DNase-free 0.2 ml PCR tubes. Total RNA was 
diluted to 20 ng and reverse transcribed using a SuperScript® III first-strand 
synthesis supermix kit (Life Technologies™ (Paisley, U.K.)) following 
manufacturers instructions. cDNA was stored at -80 °C, or immediately 
preamplified. cDNA samples were preamplified using the TaqMan® PreAmp 
Master mix kit with TaqMan® Probes (see table 2.8), manufacturers instructions 
were followed using 10 cycles and final stock diluted 1:250. 
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2.2.4.3 Quantitative real-time polymerase chain reaction (qRT-PCR)  
QRT-PCR reactions were performed in a 7900 HT Fast Real-Time PCR System 
(Applied Biosystems, Foster City, CA, U.S.A.), 2.5 μl of preamplified cDNA was 
used with TaqMan® Gene Expression probes (Table 2.8) and master mix to 
monitor amplification under standard cycling conditions. All reagents were 
thoroughly mixed by vortexing prior to use. Following the loading of each 384-
well PCR plate, plates were sealed with optically clear sealing film, and the plate 
was vortexed gently. Sealed plates were centrifuged for 1 min at 3,000 r.p.m. at 4 
°C in a Beckman Coulter Allegra™ 25R centrifuge (Beckman Coulter (U.K.) Ltd, 
High Wycombe, U.K.) prior to loading the plate into the RT-PCR machine.  
 
Absolute quantification and relative quantification are the most commonly used 
methods to analyze data from qRT-PCR experiments (Livak & Schmittgen, 
2001). Both methods of qRT-PCR data analysis involve the use of cycle 
threshold (CT) values. CT values can be defined as the number of cycles at 
which the amplification curve of a gene crosses a certain threshold of 
fluorescence. CT values were recorded by SDS2.3 software linked to the 7900 
HT Fast Real-Time PCR machine. The expression of an invariant endogenous 
control (housekeeping gene) can be used as an active reference to correct minor 
intra- and inter-assay variations (sample-to-sample and run-to-run variations 
respectively) (Pfaffl & Hageleit, 2001). In each case, the level of expression of 
the mRNA of interest was normalized to the expression level of GAPDH mRNA. 
Three identical replicates of each sample were included on each plate. CT values 
for the mRNA of the gene of interest and for the GAPDH control were recorded, 
and changes in gene expression were determined by the comparative CT 
(2−ΔΔCT) method.  
 
Firstly, the mean, and standard deviation (SD), of three replicate samples was 
calculated. Secondly, the ΔCT value of each sample was calculated by 
subtracting the CT value for GAPDH from the CT value of the target gene (gene 
of interest). Thirdly, the ΔΔCT value was then calculated by subtracting the ΔCT 
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of the reference sample from the ΔCT of the test sample. Finally, the fold-change 
in gene expression was calculated using the following formula: 
 
Fold change= 2^-ΔΔCT 
 
 As the SD of the ΔCT values is the same as the SD ΔΔCT value in each case, 
this value was used to calculate the range of the fold-change in expression of the 
target relative to that of the GAPDH, which was calculated as follows:  
 
From: 2−(ΔΔCT) + (SD(ΔΔCT)) To: 2−(ΔΔCT) - (SD(ΔΔCT)) 
 
2.2.4.4 Microtissue transfection with small interfering RNA (siRNA) 
Microtissues were formed and incubated for 14 days prior to use (see section 
2.2.1.8). Microtissues were transfected with siRNA and Lipofectamine™ 
RNAiMAX transfection reagent. S100A1 siRNA was purchased from Life 
Technologies™ (Paisley, U.K.). Negative control siRNA was purchased from Life 
Technologies™ (Paisley, U.K.). SiRNA stock solution was diluted in 250 μl of 
OptiMEM®, and in a separate tube, Lipofectamine™ RNAiMAX transfection 
reagent was diluted to give a 0.1% (v/v) final concentration in 250 μl of 
OptiMEM® per sample. The diluted Lipofectamine™ RNAiMAX and siRNA 
components were combined, mixed well by gentle pipetting and incubated for 5 
min at room temperature. One hundred microliters of cell culture media was 
removed from the microtissues and replaced with 100 μl of transfection solution, 
this was repeated twice to dilute the remaining cell culture media. The plates 
were swirled gently to ensure even distribution of the siRNA. Microtissues were 
incubated with the transfection solution at 37 °C, 5% CO2 for 24 h prior to use.
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2.2.5 Compound preparation and treatment 
2.2.5.1 HCB and cytotoxicity assay compounds 
All compounds were dissolved in 100% dimethyl sulfoxide (DMSO) as 20 mM 
(milimolar) stock solutions.  At 20 mM no insolubility and precipitation were observed 
with any compound (assessed by visual inspection). Test compounds were prepared 
using 6 concentrations in a 3-fold dilution scheme. An initial compound plate was 
produced in a polypropylene 96-well plate by serially diluting the 20 mM stock 1 in 5 to 
generate 6 concentration points. Intermediate plates were generated by transferring 10 
μL from each well of the compound plate to the corresponding wells of a polypropylene 
plate containing 90 μL of cell culture media and mixed thoroughly. From one compound 
plate, two intermediate plates were produced. 5 μL from each well of an intermediate 
plate was added to the corresponding wells of a black-walled, 96-well plate containing 
cells previously seeded at the appropriate density in a volume of 95 μl (Table 2.9) and 
incubated at 37 oC for 4 days. One intermediate plate was used to treat one black-
walled, 96-well plate which was then incubated at 37 oC, 5 % CO2. Final DMSO 
concentration was 0.5% (v/v). Compounds were screened in duplicates on separate 
plates, on three separate occasions.  The final compound concentrations were 0.01 μM-
100 μM.   
 
2.2.5.2 IonOptix contractility assay compounds 
Compounds were obtained from Sigma-Aldrich (Dorset, UK) or the AstraZeneca 
compound collection. Compounds were initially formulated in DMSO as a 1000x stock 
solution. This stock solution was subsequently serially diluted down to lower 
concentrations using DMSO. The DMSO stock solutions were diluted 1000x into the 
5050 microtissue media to give the final test concentrations. The final DMSO 
concentration was 0.1% (v/v). Where compounds were insoluble in DMSO, Dulbecco’s 
PBS (Lonza (Basel, Switzerland)) was used. Caffeine was formulated directly in 5050 
microtissue media at 10 mM. 
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2.2.6 Cytotoxicity assays 
2.2.6.1 LDH cytotoxicity detection 
After compound treatment, 50 μL of conditioned growth medium from each well of the 
treated black-walled, 96-well plate was transferred into a clear 96-well cell-culture plate 
and 50 μL of LDH cytotoxicity reaction reagent added (prepared as per the 
manufacturer’s instructions). The reaction was incubated in the dark for 30 mins at room 
temperature and fluorescence recorded using an EnVision® multilabel reader 
(PerkinElmer Life Sciences, Fremont, CA, U.S.A.). 
 
2.2.6.2 Measuring cellular ATP content 
Immediately after the imaging assay was performed, a commercially available CellTiter-
Glo® luminescent cell viability kit (Promega, Southampton, U.K.), was used to 
determine the number of viable cells in culture. This assay utilises the luciferin-
luciferase reaction to detect the amount of ATP present in cultured cells, which is 
directly correlated with the number of viable cells, and has been shown to be an 
accurate measure of cytokine-dependent proliferation in cultured cells (Crouch et al., 
1993). CellTiter-Glo® reagent lyses cell membranes to release ATP and inhibits 
endogenous ATPases, whilst also providing beetle luciferin and recombinant firefly 
luciferase to the reaction mixture. The manufacturer’s instructions were followed, 
however, media was removed and replaced with 100 μl of fresh cell culture media prior 
to the addition of the CellTiter-Glo® reagent. Luminescence was recorded using a 
Wallac 1450 Microbeta Trilux Scintillation Counter (PerkinElmer Life Sciences, Fremont, 
CA, U.S.A.).  
 
2.2.7 High content biology 
2.2.7.1 Mitochondrial and nuclei staining 
Cells were stained with fluorescent probes in D-PBS (without Ca2+/Mg2+) at 37oC for 20 
mins. The fluorescent probes used were MitoTracker® Deep Red FM and Hoescht 
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33342 at dilutions shown in Table 2.5.  Following staining, staining media was replaced 
with 100 μL D-PBS (without Ca2+/Mg2+) and the cells subjected to automated live-cell 
fluorescent image acquisition using an ImageXpress high content analysis system 
(Molecular Devices, 20x objective).  Fluorescent images were captured according to the 
optimal excitation and emission wavelengths of each probe (Table 2.5). 
 
2.2.7.2 Multiplex imaging assay 
After 6, 24 or 72 h of compound treatment at 37oC, 5% CO2, the media was removed 
and the cells were stained with fluorescent probes in serum-free medium at 37oC for 1 
h.  The fluorescent probes used were 5-Tetramethylrhodamine (TMRE); ER-Tracker™ 
Blue-White DPX; Fluo-4 AM and TOTO®-3 Iodide at dilutions shown in Table 2.5.  
Following staining, staining media was replaced with 100 ul D-PBS (without Ca2+/Mg2+) 
and the cells subjected to automated live-cell fluorescent image acquisition using an 
ImageXpress high content analysis system (Molecular Devices, Sunnyvale, CA, U.S.A., 
20x objective).  Fluorescent images were captured according to the optimal excitation 
and emission wavelengths of each probe (Table 2.5). Immediately after imaging, cellular 
ATP content was measured as described in section 2.2.6.2. 
 
Image analysis was performed using metaXpress software (Molecular Devices, 
Sunnyvale, CA, U.S.A.).   A series of measurements of each fluorescent probe were 
obtained for each drug.  They were mean nuclei integrated intensity for TOTO®-3 
(wavelength Cy5), and mean cell integrated intensity for the three remaining 
wavelengths.  The sum of these numerical measurements from the four image fields 
within the same well were divided by the sum of the nuclei count from the same four 
image fields to obtain values that were standardised by cell number.  Values were 
normalized by the average values from the 6 vehicle treated wells and then wells of the 
same treatment on duplicate plates were averaged.  
 
Cellular ATP data was normalized by the average values from the 6 vehicle treated 
wells and then wells of the same treatment on duplicate plates were averaged. 
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Concentration-effect curves were plotted for each compound and expressed relative to 
vehicle (0.5% (v/v) DMSO).  The molar concentration of test compound producing 50% 
inhibition (IC50) or 50% response (EC50) for each cellular parameter; mitochondrial 
membrane potential, ER integrity, Ca2+ mobilization and cellular ATP content, were 
calculated using Graphpad Prism™ (La Jolla, CA). IC50 values for each parameter were 
divided by the total Cmax of the test compound to give the therapeutic index; a 
comparison of the amount of a therapeutic agent that causes the therapeutic effect to 
the amount that causes toxicity. The cellular parameter with the lowest therapeutic 
index was selected for each compound and correlations between cell types were 
generated using Graphpad Prism™ (La Jolla, CA). 
 
2.2.8 IonOptix contractility and calcium flux analysis 
2.2.8.1 Video-based edge detection of contractions 
Microtissues were transferred onto 0.1% (w/v) gelatin-coated 13 mm plastic coverslips 
(Thermanox) within a 12 well plate and incubated at 37oC, 5% CO2 for at least one hour 
before mounting onto the IonOptix contractility system. Contractile properties of 
spheroids were assessed using a video-based edge detection method (IonOptix™, 
Dublin, Ireland). A gelatin-attached microtissue was placed in a perfusion chamber 
(FHC Inc., Bowdoinham, ME, USA) mounted on the stage of an inverted Nikon TE200 
microscope (Nikon UK, Surrey, UK). The microscope stage (Prior Scientific Instruments, 
Cambridge, U.K.) was motorized and controlled remotely. Microtissues were 
continuously perfused from a gravity fed system at 2 mL/ min with microtissue media 
heated to 35.5 ± 1 °C using a line heater (Cell MicroControls, Norfolk, VA, USA). The 
microtissues were field stimulated with suprathreshold voltage at a pacing frequency of 
1 or 1.5 Hertz (Hz), with a bipolar pulse of 6 miliseconds (ms) duration, using a pair of 
platinum wires placed on opposite sides of the chamber connected to a MyoPacer EP 
stimulator (IonOptix™). Microtissues were imaged at 240 Hz using an IonOptix™ 
Myocam-S CCD camera. Digitised images were displayed within the IonWizard™ 
acquisition software (IonOptix™). The edge of the microtissue of interest was aligned 
parallel to the video raster line, by means of a semi-automated dovecote prism optical 
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system that could be controlled remotely (Cairn Research, Faversham, UK). Optical 
intensity data was collected representing dark and light bands at the edge of the 
spheroid of interest. The IonWizard™ software analyzes the periodicity in the optical 
density by means of a fast Fourier transform algorithm. The output of this analysis is a 
direct real-time measurement of microtissue contraction displacement.  
 
Compound response was measured from one microtissue on triplicate occasions. After 
microtissues were added to the microscope stage, perfusion with microtissue media 
(with 0.1% DMSO as the vehicle control) was immediately started. At this time field 
stimulation was also started, and microtissues were left to acclimatise for approximately 
2 mins at ~ 37 °C, after which at least 30 seconds (s) of basal contractions were 
recorded for each spheroid. Test compounds were applied in a cumulative manner with 
each concentration applied for 250 s or until steady-state was achieved. Every 3-4 days, 
10 μM verapamil was applied as a positive control. 
 
Initial analysis was performed using the IonWizard™ software. For each test condition, 
data for 10 to 15 contractions were averaged, using the stimulation time as common 
reference point, to give a single representative monotonic contractility transient. This 
transient was analysed using the “monotonic transient analysis” function of the 
IonWizard™ software. From this analysis, 3 key parameters were used to quantify 
microtissue dynamics: 1) peak height, which indicates the percentage of peak 
contraction displacement relative to the resting length. 2) Maximum contraction velocity, 
calculated as the maximum rate of change in peak height during the contraction phase. 
3) Maximum relaxation velocity, calculated as the maximum rate of change in peak 
height during the relaxation phase.  Concentration-effect curves were plotted for each 
compound and expressed relative to vehicle (0.1% (v/v) DMSO). The molar 
concentration of test compound producing 50% inhibition (IC50) or 50% response 
(EC50), were calculated using Graphpad Prism™ (La Jolla, CA). 
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2.2.8.2 Ca2+ transient measurements 
Microtissues were loaded with 0.2 µmol/L Fura-2-acetoxymethyl ester (Invitrogen), a 
calcium-sensitive, ratiometric fluorescence dye, for 30 min at room temperature (RT) 
and kept in the dark. The same experimental design used for performing contractility 
recordings was applied to carry out intracellular calcium measurements. An IonOptix 
system was used to conduct the experiments, including the Xenon arc lamp, 
hyperswitch and myopacer for microtissue stimulation and fluorescence excitation, 
myocam-S for the measurement of edge contraction, and a fluorescence system 
interface to integrate the different components (IonOptix Ltd). The Xenon arc lamp and 
fluorescence hyperswitch containing a galvanised mirror were used to alternate 
between wavelengths of 340 and 380 nm (nanometer) at a high frequency. Calcium 
fluorescence was recorded at 510 nm. Calcium traces represent the ratio of calcium 
bound: calcium free Fura-2- acetoxymethyl ester dye, and hence changes in free 
intracellular calcium. Simultaneous contraction and calcium recordings for microtissues 
were taken while perfusing with their standard cell culture media (see table 2.10) 
containing DMSO 0.1% (v/v) as the vehicle control when appropriate. A transition period 
of 250 s was conducted between test concentrations, allowing any compound induced 
effects to reach a steady state. Analysis was performed using the IonWizard™ software 
as for contractility measurements. 
 
2.2.9 Statistical analysis 
In order to define statistical significance the unpaired students t-test function in 
Graphpad Prism™ (La Jolla, CA) was used to calculate P values of significance. The t 
test investigates the likelihood that the difference between the means of the two groups 
could have been caused by chance. P values of less than 0.05 are deamed significant. 
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Chapter Three 
 
Development of in vitro cell 
models for the study of drug-
induced cardiotoxicity 
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3.1 Introduction 
Routine cardiac safety screens primarily focus on cardiomyocytes in isolation, ignoring 
other cellular components of the myocardium such as the endothelial and fibroblast 
cells. However, it is now becoming apparent that endothelial dysfunction can influence 
neighbouring cells (Ajithkumar et al., 2011; Brutsaert, 2003; Chen et al., 2010; Chiusa et 
al., 2012; Jiang, 2007; Mikaelian et al., 2010; Ritchie et al., 1998a) and cardiac 
fibroblasts are known to affect both cardiac myocyte and endothelial cell function 
(Calderone et al., 1998; Ottaviano & Yee, 2011). Aberration of these interactions could 
lead to changes in myocardial morphology, physiology and biochemistry and ultimately 
cardiac failure. 
 
This chapter describes, firstly, the optimisation of human primary endothelial and 
fibroblast monolayer models originating from cardiac and dermal origins. These models 
are optimised as a confluent cell monolayer for use in plate based cytotoxicity assays. 
In recent years it has become clear that the same cell type originating from different 
organs show considerable heterogeneity. While endothelial and fibroblast cells are 
united in certain common features, their heterogeneity is becoming increasingly 
apparent. Endothelial heterogeneity has been described at the level of morphology, 
function, antigen composition and signalling networks suggesting each endothelial cell 
type is uniquely adapted to meet the demands of its local environment (Aird, 2012; 
Hendrickx et al., 2004; Ishii et al., 2009). Recent data also indicates that the 
embryological origin of macro- and microvascular endothelium are distinct (Rossant & 
Howard, 2002). Therefore, cell responses are now thought to be the result of the 
environment in which a cell resides combined with it’s genetically ‘programmed’ 
function, providing cells residing within different tissues with the potential to respond to 
a common signal in a unique manner. Monolayer models will be developed for human 
coronary artery endothelial cells (hCAECs), human dermal microvascular endothelial 
cells (hDMECs) and normal human dermal fibroblast (NhDFs) alongside human cardiac 
microvascular endothelial cells (hCMECs) and human cardiac fibroblasts (hCFs) to 
eventually allow any cardiac myocardial specific toxicities to be highlighted. 
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Secondly, this chapter describes the development of in vitro 3D cardiac microtissue 
models for use in both structural and functional cardiotoxicity assays. The aim of 3D cell 
culture is to increase the physiological relevance of the cells microenvironment and 
therefore create an in vitro model which better recapitulates the in vivo tissue. Here a 
technique based on the more traditional scaffold-free hanging drop technique will be 
used to generate microtissue spheroids. 
 
3.2 Optimisation of primary human endothelial monolayer models 
3.2.1 High seeding density for short term culture  
Initial experiments using primary human cardiac microvascular endothelial cells 
(hCMECs) investigated seeding cells at a high density using cell attachment overnight 
to create a usable model the following day, however preliminary experiments to 
establish the optimal number of hCMECs per well repeatedly displayed a significant loss 
in cell number. hCMECs were seeded into gelatin-coated 96 well plates at 10,000; 
15,000; 20,000 and 25,000 cells per well (well-1) in endothelial full growth media (FGM). 
Following 24h incubation, nuclei were stained with Hoescht 33342, fluorescent images 
taken and automated algorithms used to approximate cell numbers per well. When 
seeded at 20,000 cells well-1, the resulting cell number was approximately 60% lower 
than the initial seeding density (figure 3.1). There are numerous reasons why this “cliff-
edge effect” should be avoided. Firstly, the ethical issues, the high costs and limited 
supply of human primary cells mean efficient use of available stock is highly important. 
Secondly, prior to cell treatment it is important that the cells are in a stable, healthy 
environment; a drastic increase in cell death is likely to influence the interactions and 
survival of the remaining cells. Therefore, an alternative approach was considered 
whereby cells were seeded at a lower density and incubated for a longer time period to 
allow a confluent monolayer to develop (section 3.2.3), thus reducing the “cliff- edge 
effect” seen with the overnight method, maintaining cell health and improving stock 
utility. First optimal cell culture media was established. 
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Figure 3.1 Number of cells well-1 24 h post seeding at varying densities.  
hCMECs were seeded at 10,000, 15,000, 20,000 and 25,000 cells well-1  on gelatin-
coated 96 well plates in endothelial full growth media (Endo-FGM) for 24 h. The cells 
were stained with Hoescht 33342 and fluorescent images taken at the DAPI wavelength 
using an ImageXpress machine (MolecularDevices, Sunnyvale, CA, U.S.A., 20x 
objective). From these images nuclei were counted to give the number of cells well-1. 
Data shown is from a single experiment mean of n=6 with SD error bars. hCMEC, 
human cardiac microvascular endothelial cells.  
 
3.2.2 Selection of assay media 
The survival of the hCMECs under differing media conditions was studied. Endothelial 
MV2 basal medium supplemented with 5% (v/v) foetal calf serum (FCS), EGF (5.0 ng/ 
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ml), hydrocortisone (0.2 μg/ ml), VEGF (0.5 ng/ ml), FGF-2 (10.0 ng/ ml), insulin-like 
growth factor-1 (20.0 ng/ ml) and ascorbic acid (1.0 μg/ ml), (Cat. No.: C-22121) was the 
full growth media (Endo FGM) recommended by the manufacturers, PromoCell 
(Heidelberg, Germany). However when studying the toxicity of kinase inhibitors upon 
endothelial cells the capability to treat the cells in the absence of growth factors was 
desirable. hCMECs were therefore cultured at 20,000 cells well-1 in gelatin-coated 96 
well plates in three subtypes of endothelial media; Endothelial full growth media (Endo-
FGM), Endothelial low serum media (Endo-LSM) (1% (v/v) foetal calf serum (FCS)) and 
Endothelial media without growth factors (Endo–GF) (5% (v/v) FCS for 5 days to cover 
the maximum treatment period of 72 h.  
 
Figure 3.2 shows that when hCMECs are cultured in 5% FCS in the absence of any 
supplemented growth factors (Endo -GF), an initial increase in cell number is followed 
by a steep decline until a recovery period appears to begin. When hCMECs are cultured 
in low serum and no supplemented growth factors (Endo LSM), a gradual decline in cell 
number can be seen over the experiment time course. These preliminary experiments 
suggested that endo FGM would be the only media capable of maintaining a stable cell 
monolayer over the treatment period. 
 
Data shown in figure 3.2 for hCMECs grown in endo FGM shows a slight decline in cell 
number from the initial seeding density of 20,000 cells well-1 to a baseline density of 
approximately 15,000 cells well-1 between days 3 and 4. This suggested that a seeding 
density of 20,000 was still too high to allow avoidance of an initial death phase, 
therefore further seeding density optimisation was required using densities below that of 
20,000 cells well-1. 
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Figure 3.2 Effect of various endothelial media subtypes upon hCMEC survival.  
hCMECs were seeded at 20,000 cells well-1 on gelatin-coated 96 well plates in Endo 
FGM, Endo LSM (1% (v/v) foetal calf serum (FCS)) and Endo –GF (5% (v/v) foetal calf 
serum (FCS)). At 24 h intervals for 5 consecutive days, cells were stained with Hoescht 
33342 and fluorescent images taken at the DAPI wavelength using an ImageXpress 
high content analysis system (MolecularDevices, Sunnyvale, CA, U.S.A., 20x objective). 
From these images nuclei were counted to give the number of cells well-1. Data shown 
is from a single experiment mean of n=3 with SD error bars. hCMEC, human cardiac 
microvascular endothelial cells; FGM, full growth media; GF, growth factor; FCS, Foetal 
calf serum. 
 
3.2.3 Optimisation of seeding density in endothelial full growth media 
hCMECs were seeded into gelatin-coated 96 well plates at densities of 6,000; 8,000 
and 10,000 cells well-1 in endothelial full growth media (FGM). Previous data (figure 3.1 
and figure 3.2) suggested 10,000 cells well-1 as a maximum seeding density therefore 
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this was selected as a maximum cell density with 6,000 and 8,000 as lower densities. 
The aim of this experiment was to determine a seeding density which avoids an initial 
death phase and after a period of incubation allows the formation of a stable confluent 
endothelial cell monolayer capable of surviving the maximum treatment period with 
minimal fluctuations in cell number. Using Hoescht nuclei staining as a measure of cell 
number, figure 3.3 shows that when hCMECs were seeded at 10,000, 8,000 and 6,000 
cells well-1, an increase in cell number to approximately 15,000 to 20,000 cells well-1 
occurs until day 3. The 10,000 cells well-1 sample displays a subtle decline in cell 
number from 20,000 to 15,000 cells well-1 followed by a cell number recovery between 
days 6 and 7 (figure 3.3). When seeded at 8,000 cells well-1, cell number fluctuates 
throughout the treatment period (figure 3.3). A seeding density of 6,000 cells well-1 
proved optimal for the following reasons; hCMECs gradually increase in cell number 
until approximately 20,000 cells well-1 is reached, this occurs by day 4 (figure 3.3). From 
day 4 until day 7, no large fluctuations in cell number were seen suggesting a healthy 
equilibrium has been reached whilst avoiding a so called “cliff-edge effect”. 
Furthermore, as discussed previously, the cost and availability of human primary cells 
greatly limits their use as a cell model; shown here a low seeding density of 6,000 cells 
well-1 is enough to provide a stable cell monolayer over the maximum treatment period 
of 72 h (days 4-7), while also increasing throughput capabilities. This data has also 
identified day 4 as the optimal time to dose the cells; this is the beginning of the stable 
growth period.  
 
Similar experiments were performed to optimise the seeding densities of hDMECs and 
hCAECs, again, with the aim of achieving a confluent stable monolayer for plate based 
toxicity assays. hDMECs were seeded into gelatin-coated 96 well plates at densities of 
6,000, 8,000 and 10,000 cells well-1 in endothelial FGM. Previous work with hCMECs 
(figure 3.1, 3.2 & 3.3) directed these selections. Figure 3.3 shows adult hDMEC cell 
number is most stable between days 4 and 7 when seeded at a density of 8,000 cells 
well-1, this time frame corresponds with that of the hCMEC model. hCAECs were 
seeded into gelatin-coated 96 well plates at densities of 6,000 and 8,000 cells well-1 in 
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endothelial FGM. Previous work with hCMECs and adult hDMECs (figures 3.1, 3.2, 3.3) 
was used to guide the selection of these two densities. Figure 3.3 shows hCAEC 
number is most stable between days 4 and 7 when seeded at a density of 6,000 cells 
well-1. From day 4 until day 7, no significant fluctuations in cell number were seen 
suggesting a healthy equilibrium has been reached, a time frame we also see with 
hCMEC and hDMECs. These results already show endothelial heterogeneity; the 
cardiac cells (hCMEC & hCAEC) require a lower cell seeding number compared with 
the dermal endothelial cells (hDMEC). 
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Figure 3.3 Optimisation of endothelial seeding density.  
Endothelial cells were seeded on gelatin-coated 96 well plates at differing densities on 
day 0 and incubated for 3 days in endothelial FGM.  From day 3, cells were stained with 
Hoescht 33342 at 24 h intervals for 5 consecutive days and fluorescent images taken at 
the DAPI wavelength using an ImageXpress high content analysis system 
(MolecularDevices, Sunnyvale, CA, U.S.A., 20x objective). From these images nuclei 
were counted to give the number of cells well-1 at each time point. Data shown is from a 
single experiment mean of n=6 with SD error bars. hCMEC, human cardiac 
microvascular endothelial cells; hDMEC, human dermal microvascular endothelial cells; 
hCAEC, human coronary artery endothelial cells; FGM, full growth media. 
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3.2.4 Endothelial cellular stability over time course 
Having established optimal seeding densities of 6,000 cells well-1 (hCMEC and hCAEC) 
and 8,000 cells well-1 (hDMEC) with an incubation period of 4 days prior to cell 
treatment; mitochondrial staining and intracellular ATP content were used as a measure 
of intracellular health and monitored over this chosen time period. Endothelial cells were 
seeded on gelatin-coated 96 wells plates and incubated for 4 days. Every 24 h for 5 
consecutive days cells were stained with MitoTracker and Hoescht 33342 and imaged 
at the TRITC and DAPI wavelengths using an ImageXpress machine (Molecular 
Devices, Sunnyvale, CA, U.S.A., 20x objective). Automated algorithms were used to 
give the percentage mitochondrial staining per cell, which provides a measure of 
mitochondrial health over the time course. Following imaging, cells were lysed for 
intracellular ATP content using CellTiter- Glo reagent. Figure 3.4 shows mitochondrial 
health is unchanged over the course of the experiment for all endothelial models. ATP 
content relative to maximal ATP content varies over the time course in all endothelial 
models. hCMEC intracellular ATP content increases by 75% from day 4 to day 5 and 
decreases by 75% from day 5 to day 6. PromoCell have recorded the population 
doubling time of this cell type to be approximately 30-40 h, therefore this peak in ATP 
may be a result of a population doubling which should be considered in future 
cytotoxicity measures. Additionally cell culture media is refreshed between days 4 and 
5, this replenishment of metabolic nutrients could explain the shorterm increase in 
cellular ATP synthesis. hDMEC and hCAEC ATP content relative to maximal ATP 
content also peaks on day 5, as was seen with the hCMEC model (figure 3.4); this 
again could be a result of a population doubling as suggested by the manufacturer 
(PromoCell) or cell culture replenishment. At 24h intervals endothelial cells were stained 
for acetyl low density lipoprotein (Dil-acLDL) uptake and nuclei (Hoescht 33342), the 
cells were imaged at the TRITC and DAPI wavelengths using a ImageXpress high 
content analysis system and automated algorithms used to determine the percentage 
acLDL uptake per cell. AcLDL uptake is a characteristic specific to endothelial cells 
therefore it can be used to monitor the endothelial phenotype of the cell model. Figure 
3.4 shows acLDL uptake was stable for each endothelial model over the time course.  
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Figure 3.4 Endothelial cell health over treatment period.  
Endothelial cells were seeded on gelatin-coated 96 well plates at their optimal seeding 
densities (see section 3.2.3) and incubated for 3 days in endothelial FGM. Cells were 
then monitored at 24 h intervals over 5 consecutive days for various parameters of 
intracellular health. Cells were stained with MitoTracker and Hoescht 33342 and imaged 
at the TRITC and DAPI wavelengths using an ImageXpress high content analysis 
system (Molecular Devices, Sunnyvale, CA, U.S.A., 20x objective). Cells were stained 
for acLDL uptake and nuclei (Hoescht 33342), the cells were imaged at the TRITC and 
DAPI wavelengths. In both assays, automated algorithms were used to determine the 
percentage staining per cell. Cells were lysed for intracellular ATP content using 
CellTiter-Glo reagent (Promega, Southampton, U.K.). Data shown is from a single 
experiment mean of n=6 with SD error bars. hCMEC, human cardiac microvascular 
endothelial cells; hDMEC, human dermal microvascular endothelial cells; hCAEC, 
human coronary artery endothelial cells; FGM, full growth media. 
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3.2.5 Visualisation of endothelial health, confluency and phenotype 
Mitochondrial health was maintained throughout the treatment period for each 
endothelial monolayer model as discussed in section 3.2.4. Figure 3.5 displays this 
mitochondrial staining (MitoTracker dye) alongside stained nuclei (Hoescht 33342), 
these figures (only treatment period shown) show the maintenance of a healthy 
monolayer of cells for each endothelial model throughout the maximum treatment period 
of 72 h.  
Figure 3.5 Visualisation of endothelial mitochondrial health.  
Endothelial cells were seeded on gelatin-coated 96 well plates at their optimal seeding 
densities (see section 3.2.3) and incubated for 3 days in endothelial FGM. Cells were 
then monitored at 24 h intervals over 5 consecutive days (only 4 day treatment period 
shown here) for mitochondrial health. (a) hCMEC, (b) hDMEC and (c) hCAEC were 
stained with MitoTracker (shown in red) and Hoescht 33342 (shown in blue) and imaged 
at the TRITC and DAPI wavelengths using an ImageXpress high content analysis 
system (Molecular Devices, Sunnyvale, CA, U.S.A., 20x objective). Representative 
images of triplicate samples. Scale bar represents 50 m. 
a 
b 
c 
hCMEC 
hDMEC 
hCAEC 
Day 4 Day 5 Day 6 Day 7 
50 μm 
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In vivo endothelial cells are in close contact and exhibit acetyl low-density lipoprotein 
uptake, therefore the monolayer models were assessed for confluency using a 
phalloidin dye towards F-actin, a structure of the cytoskeleton and acLDL uptake using 
a fluorescently labelled acLDL dye. Figure 3.6 (a,b,c) shows F-actin staining of each 
endothelial monolayer model at the end of the compound treatment time course; we can 
see that the endothelial cells are in contact with one another and this was maintained 
until the end of the treatment period. Figure 3.6 (d,e,f) shows acLDL uptake for each 
endothelial monolayer model at the end of the treatment period. Each endothelial model 
maintains the ability to take up acLDL and therefore it’s endothelial phenotype. 
Figure 3.6 Visualisation of endothelial confluency and acLDL uptake.  
Endothelial cells were seeded on gelatin-coated 96 well plates at their optimal seeding 
densities (see section 3.2.3) and incubated for 3 days in endothelial FGM. Cells were 
then monitored at 24 h intervals over 5 consecutive days (only final day of treatment 
period shown here) for F-actin and acLDL uptake. (a) hCMEC, (b) hDMEC and (c) 
hCAEC were fixed with 3.7% (v/v) formaldehyde and stained with phalloidin 647 and 
Hoescht 33342 for F-actin and nuclei, respectively. (d) hCMEC, (e) hDMEC and (f) 
hCAEC were stained for acLDL uptake and nuclei (Hoescht 33342), the cells were 
imaged at the TRITC and DAPI wavelengths. hCMEC, human cardiac microvascular 
endothelial cells; hDMEC, human dermal microvascular endothelial cells; hCAEC, 
human coronary artery endothelial cells; FGM, full growth media; acLDL, acetyl low-
density lipoprotein. Representative images of triplicate samples. Scale bar represents 
50 m. 
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3.3 Development of primary human fibroblast monolayer models 
3.3.1 Optimisation of seeding density in fibroblast FGM 
Again the aim of these model optimisation experiments was to achieve a confluent 
fibroblast monolayer with reasonable cellular stability over the treatment period. Optimal 
cell number utility is beneficial both ethically and financially since these cells are primary 
sourced. Previous work with the endothelial monolayer models has allowed tight 
direction of these experiments. Both fibroblast models were developed in the 
manufacturers recommended full growth medias (FGM) to maintain consistency with the 
previously developed endothelial models; hCFs were cultured in F3 media (fibroblast 
growth medium 3 supplemented with 10% (v/v) foetal calf serum (FCS), basic FGF (1.0 
ng/ ml) and human recombinant insulin (5 μg/ ml) and NhDFs were cultured in F2 media 
(fibroblast growth medium 2 supplemented with 2% (v/v) foetal calf serum (FCS), basic 
FGF (1.0 ng/ ml) and human recombinant insulin (5 μg/ ml), both purchased from 
PromoCell (Heidelberg, Germany). 
 
hCFs were seeded into uncoated 96 well plates at densities of 6,000 and 8,000 cells 
well-1 in F3 media and incubated for 3 days as with the endothelial monolayer models. 
From day 3 for 5 consecutive days at 24h intervals, hCFs were stained with Hoescht 
33342 and fluorescent images taken at the DAPI wavelength using an ImageXpress 
high content analysis system (MolecularDevices, Sunnyvale, CA, U.S.A., 20x objective).  
A seeding density which forms a confluent fibroblast monolayer with minimal cell 
number fluctuations was desired. Figure 3.7 shows hCF number was most stable 
between days 4 and 7 when seeded at a density of 6,000 cells well-1; where as a steep 
rise and fall was displayed with a density of 8,000 cells well-1. This corresponds with the 
seeding/ stability pattern displayed by the cardiac endothelial cells (hCMEC & hCAEC) 
suggesting the cardiac derived cell types share similar growth rates. 
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The growth rate of NhDFs was known to be significantly quicker than the endothelial 
and cardiac fibroblasts therefore a wider range of seeding densities was selected for 
optimisation, 1,500; 3,000; 5,500 and 8,000 cells well-1. Again NhDFs were seeded into 
uncoated 96 well plates, this time in F2 media and incubated for 3 days as with the 
previous models. From day 3 for 5 consecutive days at 24h intervals, NhDFs were 
stained with Hoescht 33342 and fluorescent images taken at the DAPI wavelength 
using an ImageXpress high content analysis system (MolecularDevices, Sunnyvale, CA, 
U.S.A., 20x objective).  Figure 3.7 shows NhDF number was most stable between days 
4 and 7 when seeded at a density of 3,000 cells well-1; this reduced cell number 
compared with the previous monolayer models reflects the increased growth rate of this 
cell type. 
 
3.3.2 Fibroblast cellular stability over maximum treatment period 
Having established the fibroblast optimal seeding densities of 6,000 and 3,000 cells 
well-1 for hCFs and NhDFs respectively, with a pre-incubation period of 4 days, 
mitochondrial staining and intracellular ATP content were monitored over the proposed 
treatment period to ensure reasonable cellular stability. Fibroblasts were seeded onto 
uncoated 96 well plates and incubated for 3 days. Every 24 h for 5 consecutive days 
mitochondrial health and intracellular ATP content were monitored. Figure 3.8 shows 
mitochondrial health was unchanged over the treatment period (days 4-7). ATP content 
relative to maximal ATP content shows an increase from days 4 and 5 to days 6 and 7, 
suggesting a population doubling has occurred during this time frame. 
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Figure 3.7 Optimisation of fibroblast seeding density.  
Fibroblasts were seeded in 96 well plates at differing densities on day 0 and incubated 
for 3 days in their cell culture media. From day 3, cells were stained with Hoescht 33342 
at 24 h intervals for 5 consecutive days and fluorescent images taken at the DAPI 
wavelength using an ImageXpress high content analysis system (MolecularDevices, 
Sunnyvale, CA, U.S.A., 20x objective). From these images nuclei were counted to give 
the number of cells per well at each time point. Data shown is from a single experiment 
mean of n=6 with SD error bars. hCF, human cardiac fibroblasts; NhDF, normal human 
dermal fibroblasts 
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Figure 3.8 Fibroblast cell health over treatment period.  
(a) hCF and (b) NhDF. Fibroblasts were seeded on uncoated 96 well plates at their 
optimal seeding densities (see section 3.3.1) and incubated for 3 days. Cells were then 
monitored at 24 h intervals over 5 consecutive days for various parameters of 
intracellular health. Red; cells were stained with MitoTracker and Hoescht 33 342 and 
imaged at the TRITC and DAPI wavelengths using an ImageXpress high content 
analysis system (Molecular Devices, Sunnyvale, CA, U.S.A., 20x objective). Automated 
algorithms were used to determine the percentage staining per cell. Blue; cells were 
lysed for intracellular ATP content using CellTiter-Glo reagent (Promega, Southampton, 
U.K.). Data shown is from a single experiment mean of n=6 with SD error bars. hCF, 
human cardiac fibroblasts; NhDF, normal human dermal fibroblasts. 
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3.3.3 Visualisation of fibroblast health, confluency and phenotype 
Mitochondrial health was maintained throughout the treatment period for each fibroblast 
monolayer model as discussed in section 3.3.2. Figure 3.9 displays this mitochondrial 
staining (MitoTracker dye) alongside stained nuclei (Hoescht 33342), these figures (only 
treatment period shown) show the maintenance of a healthy monolayer of cells for each 
fibroblast model (hCF and NhDF) throughout the maximum treatment period of 72 h. 
This figure allows the confluency of the fibroblasts to be highlighted; both hCFs and 
NhDFs show a confluent monolayer with MitoTracker stain that was maintained over the 
treatment period. This figure also displays the significant heterogeneity between the two 
fibroblast cell types; NhDFs have a more spindle like cell morphology (figure 3.9b) 
compared to the larger more rounded hCFs (figure 3.9a).  
Figure 3.9 Visualisation of fibroblast mitochondrial health and confluency.  
Fibroblast cells were seeded on uncoated 96 well plates at their optimal seeding 
densities (see section 3.3.1) and incubated for 3 days in F2/3 media. Cells were then 
monitored at 24 h intervals over 5 consecutive days (only 4 day treatment period shown 
here) for mitochondrial health. (a) hCF and (b) NhDF were stained with MitoTracker 
(shown in red) and Hoescht 33342 (shown in blue) and images captured at the TRITC 
and DAPI wavelengths using an ImageXpress high content analysis system (Molecular 
Devices, Sunnyvale, CA, U.S.A., 20x objective). Representative images of triplicate 
samples. Scale bar represents 50 m.  
 
a 
b 
Day 4 Day 5 Day 6 Day 7 
50 μm 
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Unlike the endothelial cells that display an endothelial specifc trait in the form of acLDL 
uptake that can be monitored with flourescently labelled acLDL, no active marker of 
fibroblast health is available and antibody/ gene markers of fibroblast specific phenotype 
are difficult to come by. In recent years, however, research has suggested that discoidin 
domain receptor 2 (DDR2) can be used as a specific marker to cardiac derived 
fibroblasts. Figure 3.10 shows immunofluorescent staining for DDR2 in hCFs. 
 
 
 
 
 
 
 
 
Figure 3.10 Immunofluorescent staining of DDR2 in hCFs.  
hCFs were seeded on uncoated 96 well plates at 6,000 cells well-1 and incubated for 4 
days in F3 media. Cells were then fixed for 20 mins in 3.7% (v/v) formaldehyde before 
undergoing immunofluorescent staining for discoidin domain receptor 2 (DDR2) (goat 
anti-human DDR2 antibody, donkey anti-goat Alexa fluor 488 antibody) and nuclei 
(Hoescht 33342). Images captured at the FITC and DAPI wavelengths using an 
ImageXpress high content analysis system (Molecular Devices, Sunnyvale, CA, U.S.A., 
20x objective). hCF, human cardiac fibroblasts. Representative images of triplicate 
samples. At the same instrument settings no visible fluorescence from primary only or 
secondary only controls was visible. Scale bar represents 50 m.  
50 μm 
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3.4 Development of microtissue models to study drug-induced cardiotoxicity 
3.4.1 Cardiomyocyte- cardiac endothelial- cardiac fibroblast (CMEF) microtissue 
The aim of 3D cell culture is to increase the physiological relevance of the cells 
microenvironment and therefore create an in vitro model which better recapitulates the 
in vivo tissue. The utilisation of a round bottom ultra low adhesion (ULA) cell culture 
plate means that cells have a higher affinity for cell-cell adhesion than culture plate 
adhesion and a microtissue forms at the bottom of the well. The fundamentals of this 
technique are similar to the more traditional hanging drop technique but with 
advantages in robustness and user handling. Figure 3.11 is a diagram summarising the 
protocol for multicell microtissue formation. The initial step in microtissue development 
is selection of cell seeding number; literature has suggested that approximately 1000 
cells should form a microtissue of approximately 200 μm in diameter (Mehta et al., 
2012). This diameter is desirable to avoid a hypoxic centre when developing 
microtissues for drug safety assays. Figure 3.12 shows microtissue formation when 
seeded at 1000 and 500 cells well-1 using a ‘general’ starting ratio of 3 hESC-CMs: 1 
hCFs: 1 hCMECs. This ratio using a higher proportion of cardiomyocytes was selected 
to account for the proliferation of the primary fibroblast and endothelial cells- work was 
later done to optimise this ratio. The primary cells were subcultured prior to detachment 
for cell counting and subsequent suspension with thawed and counted cardiomyocytes 
(see materials and methods). 100 ul of mixed cell suspension was added to each well of 
a 96 well round bottom ULA plate and incubated at 37oC, 5% CO2. After 2-3 days the 
cells have aggregated to form one microtissue in each well. Figure 3.12 shows that with 
1000 cells in total the microtissues are surrounded by excess cells and cell debris, 
whereas with a total of 500 cells a microtissue of 200 μm forms with very few loose cells 
suggesting optimal use of cell numbers.  
 
 
 
 
 
 101 
 
Figure 3.11 Diagram outlining the protocol for microtissue formation.  
Endothelial and fibroblast cells are subcultured prior to microtissue formation. Primary 
cells are detached using Accutase solution at 37oC for 5 mins, subsequently counted 
and mixed with a suspension of thawed and counted cardiomyocytes (see materials and 
methods). 100 μl of mixed cell suspension was added to each well of a 96 well round 
bottom ULA plate and incubated at 37oC, 5% CO2. After 2-3 days the cells have 
aggregated to form one tight microtissue in each well. After 2 weeks the microtissues 
spontaneously beat. 
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Figure 3.12 CMEF microtissues seeded at (a) 1000 cells well-1 and (b) 500 cells 
well-1.  
Endothelial and fibroblast cells are subcultured prior to microtissue formation. Primary 
cells are detached using Accutase solution at 37oC for 5 mins, subsequently counted 
and mixed with a suspension of thawed and counted cardiomyocytes using a ‘general’ 
starting ratio of 3 hESC-CMs: 1 hCFs: 1 hCMECs (see materials and methods). 100 μl 
of mixed cell suspension was added to each well of a 96 well round bottom ULA plate 
and incubated at 37oC, 5% CO2 for two weeks. A full 96 well plate of each spheroid type 
was seeded to visualise variability across the plate. Images shown are representatives 
of the seeded plates. Microtissues imaged using a Leica DMLB microscope. 
 
Using this total cell number (500 cells well-1) the microtissue cell ratios could now be 
optimised with the aim of achieving a spontaneously beating vascularised microtissue 
displaying markers of each cell type and longevity. Literature suggests the myocardium 
comprises 70% non-myocytes with the majority of these being cardiac fibroblasts 
followed by cardiac microvascular endothelial cells (Brutsaert, 2003), this in combination 
with the proliferative nature of the primary cells was considered when selecting the cell 
ratios. Figure 3.13 summarises the trialled cell ratios (hESC-CMs: hCFs: hCMECs) and 
corresponding phase contrast image of the resulting CMEF microtissue. Various criteria 
a b 
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was used to select the optimal ratio; microtissue diameter of 200 μm, regular round 
shape, regular spontaneous contractions of ~1.5Hz, low cell debris/ excess cells and no 
visible necrosis/ hypoxia. Each ratio forms a microtissue of approximately 200 μm with 
mostly uniform shaping. A ratio of 4 hESC-CMs: 2 hCFs: 1 hCMEC was selected as it 
forms microtissues with the least debris, no visible necrosis, a consistent regular 
spontaneous contraction of approximately 1-1.5Hz (see chapter five) after incubation for 
14 days and good uniformity across the 96 well plate. The alternative microtissue ratios 
displayed some of these criteria but with less consistency.  
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Figure 3.13 CMEF microtissues seeded at differing ratios of hESC-CMs: hCFs: hCMECs.  
Endothelial and fibroblast cells are subcultured prior to microtissue formation. Primary cells are detached using Accutase 
solution at 37oC for 5 mins, subsequently counted and mixed with a suspension of thawed and counted cardiomyocytes at 
the following ratios of hESC-CMs: hCFs: hCMECs; 1:1:1, 2:1:1, 3:1:1, 4:1:1, 4:2:1, 4:1:2, 6:2:1, 6:1:2, 8:2:1 and 8:1:2 (see 
materials and methods for more details on culturing techniques). 100 μl of mixed cell suspensions was added to each well 
of a 96 well round bottom ULA plate and incubated at 37oC, 5% CO2 for two weeks. Images were taken on day 14, when 
the uniform spontaneous beat was present, using a Leica DMLB microscope. Representative images of 16 microtissues 
per ratio type. 
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Figure 3.14 Phase contrast image of CMEF microtissue. 
hCMECs and hCFs are subcultured prior to microtissue formation. Primary cells are 
mixed with a suspension of thawed and counted cardiomyocytes at a density of 500 
cells well-1 and a ratio of 4 hESC-CMs: 2 hCFs: 1 hCMECs. 100 μl of mixed cell 
suspension was added to each well of a 96 well round bottom ULA plate and incubated 
at 37oC, 5% CO2 for two weeks. Microtissues imaged using a Leica DMLB microscope. 
Scale bar represents 50 m. 
 
Structural characterisation of CMEF microtissues (shown in figures 3.15 and 3.16) using 
cardiac troponin I (cTNI) as a cardiomyocyte specific marker, alpha actinin N2 to 
highlight myocyte striations, CD31 as a endothelial specific marker and collagen I as a 
relatively specific cardiac fibroblast marker was performed via wholemount 
immunofluorescence on 4% (v/v) formaldehyde fixed microtissues. This allowed 
visualisation of the cellular arrangement within the microtissue; good spatial distribution 
of the cell markers can be seen (Figure 3.15) suggesting adequate interactions of the 
different cell types in forming the microtissue. Figures 3.15 and 3.16 also display a 
higher abundance of myocyte striations than seen in the CM microtissues (Figure 3.21). 
Figure 3.16 shows a fixed CMEF microtissue immunofluorescently stained for cTNI, 
CD31 and the cardiac specific fibroblast marker discoidin domain receptor 2 (DDR2) at 
20x and 40x objectives. At the 40x objective we can clearly visualise the arrangement of 
the cardiac troponin striations within the CMEF microtissue.  
50 μm 
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Figure 3.15 Structural characterisation of CMEF microtissues by immunofluorescent imaging.  
hCMECs and hCFs are subcultured prior to microtissue formation. Primary cells are mixed with a suspension of thawed 
and counted cardiomyocytes at a density of 500 cells well-1 and a ratio of 4 hESC-CMs: 2 hCFs: 1 hCMECs. 100 μl of 
mixed cell suspension was added to each well of a 96 well round bottom ULA plate and incubated at 37oC, 5% CO2 for 
two weeks before formaldehyde fixation and staining with cell specific markers. CD31, endothelial marker; Collagen-1, 
fibroblast marker; sarcomeric alpha actinin 2 (ACTN2), cardiomyocyte marker; Hoescht 33342, nuclei stain. At the same 
instrument settings no visible fluorescence from primary only or secondary only controls was visible. Immunofluorescence 
performed by Awel Williams (The University of Liverpool). Scale bar represents 50 m. 
50 μm 
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Figure 3.16 Visualisation of troponin striations within CMEF microtissues by 
immunofluorescent imaging.  
hCMECs and hCFs are subcultured prior to microtissue formation. Primary cells are 
mixed with a suspension of thawed and counted cardiomyocytes at a density of 500 
cells well-1 and a ratio of 4 hESC-CMs: 2 hCFs: 1 hCMECs. 100 μl of mixed cell 
suspension was added to each well of a 96 well round bottom ULA plate and 
incubated at 37oC, 5% CO2 for two weeks before formaldehyde fixation and staining 
with cell specific markers. CD31, endothelial marker; DDR2, cardiac fibroblast 
marker; cTNI, cardiomyocyte marker; Hoescht 33342, nuclei stain. At the same 
instrument settings no visible fluorescence from primary only or secondary only 
controls was visible. Immunofluorescence performed by Awel Williams (The 
University of Liverpool). Scale bar represents 50 m. 
 
50 μm 
50 μm 
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3.4.2 Cardiomyocyte- dermal endothelial- dermal fibroblast (DMEF) microtissue 
When investigating the role of cardiac endothelial and cardiac fibroblast cells in drug-
induced cardiovascular toxicity, various control spheroids will be needed in order to 
establish any non-myocyte cell type and/ or tissue origin specific toxicity. An 
alternative tri-culture microtissue was developed containing hESC-CMs with dermal 
microvascular endothelial cells (hDMECs, previously used as a monolayer model, 
see section 3.2) and normal dermal fibroblasts (NhDFs, previously used as a 
monolayer model, see section 3.3) called a DMEF microtissue. These microtissues 
were formed using the same method as the CMEF microtissues; cell number total of 
500 cells well-1 and a ratio of 4 hESC-CMs: 2 NhDFs: 1 hDMEC. Microtissues of 200 
μm diameter, uniform round shape and spontaneous contractions formed after 14 
days incubation. Figure 3.17 shows a phase contrast image of a representative 
DMEF microtissue taken using a Leica DMLB microscope at day 14. Morphologically 
no significant differences between these microtissues and the CMEF microtissues 
can be seen. Figure 3.18 shows the presence of dermal non-myocytes within the 
DMEF microtissues; hDMECs marked by CD31 expression and NhDFs marked by 
collagen-1 expression. Alpha actinin (ActN2) expression was used to highlight 
striations within the cardiomyocytes. DMEF microtissues display striations, however 
the level of organisation appears slightly reduced compared with CMEF microtissues 
(figure 3.16). 
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Figure 3.17 Phase contrast image of DMEF microtissue.  
hDMECs and NhDFs are subcultured prior to microtissue formation. Primary cells 
are mixed with a suspension of thawed and counted cardiomyocytes at a density of 
500 cells well-1 and a ratio of 4 hESC-CMs: 2 NhDFs: 1 hDMECs. 100 μl of mixed 
cell suspension was added to each well of a 96 well round bottom ULA plate and 
incubated at 37oC, 5% CO2 for two weeks. Microtissues imaged using a Leica DMLB 
microscope. Scale bar represents 50 m. 
 
 
50 μm 
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Figure 3.18 Structural characterisation of DMEF microtissues by immunofluorescent imaging.  
hDMECs and NhDFs were subcultured prior to microtissue formation. Primary cells were mixed with a suspension of thawed and 
counted cardiomyocytes at a density of 500 cells well-1 and a ratio of 4 hESC-CMs: 2 NhDFs: 1 hDMECs. 100 μl of mixed cell 
suspension was added to each well of a 96 well round bottom ULA plate and incubated at 37oC, 5% CO2 for two weeks before 
formaldehyde fixation and staining with cell specific markers. CD31, endothelial marker; Collagen-1, fibroblast marker; sarcomeric 
alpha actinin 2 (ACTN2), cardiomyocyte marker; Hoescht 33342, nuclei stain. At the same instrument settings no visible 
fluorescence from primary only or secondary only controls was visible. Immunofluorescence performed by Awel Williams (The 
University of Liverpool). Scale bar represents 50 m. 
50 μm 
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3.4.3 human ESC cardiomyocyte (CM) microtissue 
The DMEF microtissue described above can be used to distinguish any differences 
between cardiac and dermal non-myocytes, a model comprising solely 
cardiomyocytes was required in order to highlight compound sensitivities brought 
about by the non-myocyte cells. A starting cell density of 1000 cells well-1 was used 
alongside 500 cells well-1 as this forms microtissues of 200 μm diameter in the tri-
cultured instance and an additional density of 2000 cells well-1 was tested to account 
for the non-proliferative nature of the hESC-CMs. Figure 3.19 shows that 1000 cells 
well-1 forms a tight spheroid of 200 μm diameter with minimal cell debris, whereas 
the alternative densities do not efficiently aggregate to form good size microtissues.  
 
 
Figure 3.19 CM microtissues seeded at (a) 2000, (b) 1000 and (c) 500 cells per 
well.  
A vial of hESC-CMs are thawed, counted and 100 μL of cell suspension seeded into 
96 well round bottom ULA plate at densities of 2000, 1000 and 500 cells well-1 and 
incubated at 37oC, 5% CO2 for two weeks. Microtissues imaged using a Leica DMLB 
microscope. 
 
hESC-CM microtissues have spontaneous contractions of ~1Hz after 14 days; 
slightly slower frequency that tri-cultured microtissues (see chapter 5 for functional 
analysis). CM microtissues also lack the smooth appearance displayed by the tri-
culture spheroids suggesting the cells are not aggregating as strongly with solely 
cardiomyocytes, possibly due to a lack of extracellular matrix proteins normally 
secreted by fibroblasts. The CM microtissues display key cell markers; 
200 μm 
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immunofluorescence for the cardiac gap junction, connexin43 (GJA1) and cardiac 
troponin I (cTNI) shows gap junction formation and low levels of cardiac striations 
(figure 3.20). When immunostained for alpha actinin (ActN2) we also see low levels 
of striations (figure 3.21) compared with DMEF and CMEF microtissues (figure 3.16 
& 3.18). 
 
Figure 3.20 Structural characterisation of CM microtissues using 
immunofluorescent imaging.  
A vial of hESC-CMs were thawed, counted and 100 μL of cell suspension seeded 
into 96 well round bottom ULA plate at a density of 1000 cells well-1 and incubated at 
37oC, 5% CO2 for two weeks before formaldehyde fixation and staining for 
connexin43 showin in red, cTNI shown in green and nuclei shown in blue. At the 
same instrument settings no visible fluorescence from primary only or secondary 
only controls was visible. Scale bar represents 50 m. 
50 μm 
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Figure 3.21 Structural characterisation of CM microtissues using 
immunofluorescent imaging.  
A vial of hESC-CMs were thawed, counted and 100 μL of cell suspension seeded 
into 96 well round bottom ULA plate at a density of 1000 cells well-1 and incubated at 
37oC, 5% CO2 for two weeks before formaldehyde fixation and staining for 
sarcomeric alpha actinin 2 (ACTN2) shown in white and nuclei shown in blue. At the 
same instrument settings no visible fluorescence from primary only or secondary 
only controls was visible. Immunofluorescence performed by Awel Williams (The 
University of Liverpool). Scale bar represents 50 m. 
50 μm 
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3.4.4 Cardiomyocyte- cardiac fibroblast (CMF) and cardiomyocyte- cardiac 
endothelial (CME) microtissues 
DMEF and CM microtissues can be used to study cardiac and non-myocyte affects 
respectively, di-culture models of hESC-CMs and either endothelial (hCMECs; CME 
microtissues) or fibroblast cells (hCFs; CMF microtissues) have subsequently been 
developed to distinguish between endothelial or fibroblast effects. A seeding density 
of 500 cells well-1 was selected based on previous development of the tri-culture 
models. Various different ratios of hESC-CMs to non-myocyte cell were tested (data 
not shown), microtissues form well with a ratio of 2 hESC-CMs: 1 non-myocyte. This 
2:1 ratio differs slightly from the overall 4:3 ratio used for the tri-culture microtissues 
but has similarities in that extra cardiomyocytes were required to overcome the 
proliferative nature of the primary non-myocytes. Immunofluorescence of CD31 was 
used to highlight hCMECs within the CME microtissues (figure 3.22b,d) and DDR2 
was used to highlight hCFs within the CMF microtissues (figure 3.22a,c). A 
spontaneous contraction was used to highlight cardiomyocyte cell health within the 
microtissues. Again, under phase contrast, very little morphological difference can be 
seen between the di-culture and tri-culture microtissues (figures 3.14, 3.17 & 3.22). 
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Figure 3.22 Structural characterisation of CMF & CME microtissues by phase 
contrast & immunofluorescent imaging.  
hCMECs and hCFs were subcultured prior to microtissue formation. Primary cells 
were mixed with a suspension of thawed and counted cardiomyocytes at a density of 
500 cells well-1 and a ratio of 2 hESC-CMs: 1 hCFs (CMF microtissue) or 2 hESC-
CMs: 1 hCMECs (CME microtissue). 100 μl of mixed cell suspension was added to 
each well of a 96 well round bottom ULA plate and incubated at 37oC, 5% CO2 for 
two weeks before formaldehyde fixation and staining for cell specific markers. (a) 
Phase contrast image of CMF microtissue, (b) phase contrast image of CME 
microtissue, (c) Immunofluorecently labelled CMF microtissue displaying; DDR2, 
cardiac fibroblast marker shown in red and Hoescht, nuclei stain, shown in blue, (d) 
Immunofluorescently labelled CME microtissue displaying; CD31, endothelial marker 
shown in green and cTNI, cardiomyocyte marker shown in red. At the same 
instrument settings no visible fluorescence from primary only or secondary only 
controls was visible. Scale bar represents 50 m. 
a b 
c d 
50 μm 
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3.4.5 Expression of cell marker genes in microtissue models 
 
Cardiac troponin I gene TNNI3 was used as a cardiomyocyte cell marker alongside 
the connexin43 gene GJA1. The CD31 gene PECAM1 was used as an endothelial 
marker and the CD90 gene THY1 as a fibroblast marker. Total RNA was extracted 
and reverse transcribed into cDNA following which preamplification and qRT-PCR 
was performed. Figure 3.23 shows cell marker gene expression in individual cells, 
microtissue models and foetal heart tissue relative to adult ventricle tissue. This 
analysis shows each microtissue expresses similar levels of TNNI3 but less than 
adult ventricle. GJA1 expression was similar in all models. PECAM1 expression was 
approximately 10-fold higher in the CMEF model compared with all other microtissue 
models but still reduced compared with adult ventricle. THY1 expression was higher 
than adult ventricle in all microtissue models with CM microtissues sitting alongside 
foetal heart as the most upregulated models. 
 
 
Figure 3.23 Expression of cell marker genes in microtissue models. Total RNA 
extracted using RNeasy mini kit (Qiagen, Crawley, U.K.). Total RNA was diluted to 
20 ng and reverse transcribed using a SuperScript® III first-strand synthesis 
supermix kit (Life technologies). cDNA samples were preamplified using the 
TaqMan® PreAmp Master mix kit. QRT-PCR reactions were performed using 
TaqMan® Gene Expression probes and master mix to monitor amplification under 
standard cycling conditions. Gene expression is expressed as fold change relative to 
GAPDH and adult ventricle using the ΔΔCT method. Fold change relative to adult 
ventricle is plotted for tissues, adult ventricle and foetal heart; microtissues, CMEF, 
DMEF, CM, CME and CMF; and cells, hESC-CMs, hCFs, hCMECs. Triplicate 
experiments of duplicate samples, SD error bars. 
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3.5 Discussion 
The overall aim of this chapter was to develop in vitro cell based cardiac models for 
the study of drug-induced cardiovascular toxicity. As mentioned earlier routine 
cardiac safety screens primarily focus on cardiomyocytes in isolation, ignoring other 
cellular components of the myocardium such as the endothelial and fibroblast cells. 
 
3.5.1 Microvascular cardiac, dermal and macrovascular endothelial monolayer 
models 
Endothelial cells originating from the microvasculature of the human myocardium 
(hCMEC) have been used to generate a confluent and stable in vitro monolayer 
model which, as will be shown in the following chapter, enables the study of 
structural cardiotoxicity. The majority of current microvascular studies utilise 
endothelial cells originating from either dermal or umbilical sources since these 
tissues are often ‘waste’ products of plastic surgery or child birth. In recent years, 
however it has become increasingly apparent that the same cell type originating from 
different organs show considerable heterogeneity. While endothelial cells are united 
in certain common features, their heterogeneity is becoming increasingly apparent 
(Aird, 2007). For this reason monolayer models were developed using human dermal 
microvascular endothelial cells (hDMECs) and human macrovascular endothelial 
cells from the coronary artery (hCAECs).  
 
Recently, data indicates that the embryological origin of macro- and microvascular 
endothelium are distinct; evidence suggests that microvasculature arises from 
vasculogenesis whereby angiogenesis is responsible for the creation of 
macrovascular segments (Suburo & D’Amore, 2006), suggesting we should perhaps 
expect to see closer similarities between the microvascular cells; hCMECs and 
hDMECs than the coronary artery cells; hCAECs. However optimisation of the 
endothelial seeding density shows more hDMECs are needed to achieve a stable 
confluent monolayer (8,000 cells-1 well compared to 6,000 cells well-1 for cardiac 
originating endothelial cells). In addition to this, the intracellular ATP content over the 
treatment period displays a very similar pattern in the cardiac endothelials (hCMEC 
& hCAEC) but differs to the dermal endothelials (hDMECs). The seeding density and 
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peak in ATP content at day five suggests the cardiac cells share the same 
proliferation rate. This data suggests that in vitro the cardiac originating endothelial 
cells, despite macro- and microvascular origins, may share more homogeneity than 
the microvascular endothelial cells (hDMECs & hCMECs). The significance of these 
differences with regard to compound toxicities are not yet known, but suggest that a 
dermal source of endothelial cells for drug screening is not suitable for a cardiac 
study.  
 
A limitation to these monolayer models is the lack of any vascular structure. These 
models have been optimised to study structural cardiotoxicity using fluorescent-
based imaging (high content biology- see chapter four) for which a monolayer of 
cells works optimally. It may only be upon the formation of a vasculature that the 
heterogeneity of the macro- and microvascular endothelial cells becomes apparent. 
 
3.5.2 Cardiac and dermal fibroblast monolayer models  
As with endothelial cells, fibroblast heterogeneity is also becoming increasingly 
apparent (Souders, 2009) and yet many studies utilise fibroblasts from dermal 
origins for a vast array of organ toxicity studies. Monolayer models of cardiac and 
dermal fibroblasts have been developed for structural cardiovascular toxicity assays 
in order to assess whether their suggested heterogeneity affects their prediction of 
structural cardiotoxicity. This will be assessed in chapter four.   
 
Interestingly, the first clear difference between the fibroblasts is their morphology; the 
dermal fibroblasts have a spindle-like structure whereas the cardiac fibroblasts 
appear larger and rounder. This was surprising given that the endothelial cells 
showed no clear morphological differences. Secondly, the dermal fibroblasts 
(NhDFs) required a lower seeding density (3,000 cells well-1 as opposed to 6,000 
cells well-1 for hCFs) suggesting a quicker proliferation rate. This data shows once 
again the heterogeneity between cells of cardiac and dermal origin. 
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3.5.3 Development of microtissues for drug-induced cardiotoxicity testing 
Current preclinical in vitro models focus primarily on a single cell type cultured in a 
restrictive two-dimensional (2D) format only suitable for short-term toxicity studies 
due to rapid de-differentiation (Harmer et al., 2012; Pollard et al., 2010). In the past 
few years there have been significant advances in the field of in vitro three-
dimensional (3D) cellular models. The environment created by a 3D culture model 
allows reconstitution of the natural cellular physiology by promoting the complex cell-
cell and cell-matrix network communications found in vivo (Breslin & O'Driscoll, 
2013). The utilisation of a round bottom ultra low adhesion (ULA) cell culture plate 
overcomes the handling difficulty of the traditional hanging drop technique while 
maintaining the same principles. Microtissues have advantages over other 3D cell 
culture techniques in that they allow the cells to position themselves into a 3D format 
of their chosing and can generally be formed using a lower cell number than 
monolayer and scaffold models allow.  
 
The microtissues developed within this chapter show sutble differences in 
morphology. Firstly, the incorporation of fibroblasts into the spheroid models, 
whether cardiac or dermal derived fibroblasts, improves cell aggregation and 
therefore spheroid formation but also appears to visibly enable better 
synchronisation of the spontaneous contractions (discussed further in chapter 5). 
Since the main function of fibroblasts is to maintain the extracellular matrix (ECM) 
(Souders, 2009), which provides a scaffold for tissue formation in vivo, it is likely that 
they are using this ability to improve cell contacts during spheroid formation this 
could potentially help enable efficient conductance of the cardiomyocyte 
contractions. In addition to this role, cardiac fibroblasts are also becoming known for 
their electrocompetence. Recent findings suggest cardiac specific fibroblasts are 
capable of conducting electrical currents between cardiomyocytes (Kamkin et al., 
2005). Chapter five will cover functional analysis of the microtissues. 
 
Immunofluorescent analysis of the microtissue models showed differences in 
striations. The cardiac tri-cultured CMEF microtissues show more elongated 
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striations than the dermal tri-cultured DMEF microtissues whose striations were less 
frequent and appeared shorter. During cardiomyocyte maturation the cells become 
larger and contractile machinery develops into a highly organised structure creating 
more defined striations throughout the cardiomyocyte (Robertson et al., 2013). 
Interestingly the CM microtissues show no clear striations, this was the first sign that 
co-culturing can promote cardiomyocyte maturation (discussed further in chapter 
five). 
Disappointingly the microtissues displayed no obvious vascularisation when 
analysed by immunofluorescence. This could be due to the size of the microtissues; 
a microtissue of 200 μm was desired since sizes greater than this can develop 
hypoxic/necrotic centres. The small microtissue diameter means there is no 
requirement for a vascular system to transport oxygen or nutrients; therefore 
perhaps a larger microtissue is needed to induce vascularisation. 
 
Curiously, all microtissue models only begin to spontaneously contract around 14 
days post-seeding, whereas the hESC-CMs monolayer model begins to contract 
around 3-4 days post-seeding. During the 3-4 days post-seeding of the monolayer 
model, the cardiomyocytes are attaching to the tissue culture plates and setting up 
cellular interactions to form a synchronised monolayer. The increased time period of 
the microtissues could suggest the formation of more complex cell interactions.  
 
3.5.4 Conclusion 
This chapter has seen the development of dermal and cardiac non-myocyte 
monolayer models that can be utilized to study individual cell sensitivities to drug-
induced cardiotoxcity but also the development of three dimensional (3D) 
microtissue models. Structural and gene expression analysis have shown these 3D 
models represent human in vitro models that better reconstitute the in vivo cellular 
physiology and can be used to provide improved in vivo relevance to our current in 
vitro toxicity assays. The use of these models will be discussed in chapters four and 
five. 
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 122 
4.1 Introduction 
Numerous drugs are now being highlighted for their toxic effects upon non-myocyte 
cells (Ajithkumar et al., 2011; Gianni et al., 2008; Mellor et al., 2011; Minami et al., 
2010; Palella, 2011; Senkus, 2011), although very little is known with regard to the 
cardiac microvasculature and its potential role in cardiotoxicity. Given the known 
heterogeneity of endothelial cells originating from different vascular beds and the 
increasing emergence of fibroblast heterogeneity research, the use of large-vessel or 
non-cardiac derived cells may provide relatively little useful information regarding 
cardiac toxicity. For example, angiogenesis is a process largely confined to the 
microvasculature therefore the in vitro study of human endothelial cells of 
microvascular origin, as opposed to large vessel endothelial cells, may enhance 
target relevance when considering the toxicity of kinase inhibitors designed to block 
tumour angiogenesis per se.   
 
The first aim of this chapter will be to assess the sensitivities of human endothelial 
and fibroblast cells from cardiac (human cardiac microvascular endothelial cells, 
hCMECs and human cardiac fibroblasts, hCFs) and dermal origins (human dermal 
microvascular endothelial cells, hDMECs and human dermal fibroblasts, NhDFs) as 
well as endothelial cells from macrovasculature (human coronary artery endothelial 
cells, hCAECs) to highlight their capabilities in predicting drug-induced 
cardiovascular toxicities. The ultimate aim of this chapter will be to compare the 
structural cardiotoxin sensitivities of the myocardial non-myocytes (microvascular 
endothelial and fibroblasts) with those of the cardiomyocytes to gain a possible 
insight into the role of non-myocytes in drug-induced cardiovascular toxicity. In order 
to assess the sensitivities of the non-myocyte cells a high content biology approach 
combining a cytotoxicity assay previously developed by Pointon et al (Pointon et al., 
2013) to successfully predict structural cardiotoxicity in hESC-CMs will be utilised. 
 
High content biology (HCB) is essentially the visual monitoring of phenotypic 
changes within a whole cell, utilising fluorescent images as the basic unit of 
molecular discovery (Pointon et al., 2013). Various cellular and subcellular structures 
can be monitored simultaneously by utilising cellular dyes exhibiting fluorescence at 
different wavelengths. HCB is a popular choice for high-throughput drug screening 
due to the level of information that can be obtained from a single experiment. The 
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cellular and subcellular targets of toxicity and molecular mechanisms of toxicity are 
thought to vary from agent to agent. Currently the molecular mechanisms of 
structural cardiotoxins remain poorly understood. Mitochondrial damage either 
directly or indirectly (e.g. sorafenib) (Will et al., 2008) is thought to be one major 
route of cellular toxicity. Endoplasmic reticulum (ER) stress (Kerkelä et al., 2006; 
Minamino & Kitakaze, 2010) and disruption in calcium (Ca2+) homeostasis are also 
thought to be important mechanisms of structural cardiotoxicity within the 
myocardium.  
 
The final part of this chapter will utilise various microtissue models for assessment of 
intracellular ATP content following exposure to a set of known structural cardiotoxins. 
The aim of these experiments being to investigate compound sensitivities in an 
environment which permits interactions between the non-myocyte and myocyte cells.  
 
4.2 Assay development 
4.2.1 Compound classification 
Compound classification of structural cardiotoxins was gathered using two 
commercially available clinical databases: Pharmapendium and Biowisdom. 
Classical terminologies for cardiac injury (i.e. cardiomyopathy, myocarditis, heart 
failure) were used to identify compounds in Pharmapendium with clinical adverse 
event reports for cardiotoxicity, whereas Biowisdom enables automated full-text 
searches of literature, again using the same classical terminologies. A compound 
was classified as a structural cardiotoxin if it was associated with structural 
cardiotoxicity in the two databases (Pointon et al., 2013). Additionally, all 
classifications were manually checked for the occurrence of structural cardiotoxicity 
in the FDA approval package. Therapeutic plasma exposure levels (Cmax) were 
obtained from Pharmapendium for all compounds with the exception of fluorouracil 
(Bocci et al, 2000). For AstraZeneca’s proprietary compounds, the classification was 
based on the occurrence of histopathological abnormalities in one month pre-clinical 
toxicology studies.   
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Compounds were selected that are chemically diverse representatives of the 
different classes of structural cardiotoxins. For example sunitinib malate and 
sorafenib tosylate are both tyrosine kinase inhibitors, however their specific targets 
differ. Doxorubicin and idarubicin were selected as representatives of the 
anthracycline family, while fluorouracil is the sole representative of the anti-
metabolite family.  
 
4.2.2 Controls: the effect of foetal calf serum and DMSO 
Protein binding can have a marked effect upon compound distribution therefore the 
initial step in developing the toxicity assay was to establish whether the foetal calf 
serum (FCS) present within the cell culture media has a significant effect upon 
compound dose response; if protein binding is occurring then we would expect to 
see less sensitivity of the cell model when FCS is present. Sunitinib malate was 
selected as a representative of the kinase inhibitor family and doxorubicin as a 
representative of the anthracycline family of compounds. Both compounds are 
known to cause structural cardiotoxicity. hCMECs were seeded on gelatin-coated 96 
well plates at 6,000 cells well-1 and incubated for 3 days before treatment with a 6-
point concentration set of sunitinib or doxorubicin (100 – 0.032 μM) in endothelial full 
growth media (Endo FGM) which contains 5% FCS and endothelial serum free 
media (Endo SFM). An early time point of 6 h (figure 4.1a & b) and a late time point 
of 72 h (figure 4.1c & d) of compound treatment was performed, following which cells 
were lysed for intracellular ATP content using CellTiter-Glo reagent (Promega, 
Southampton, U.K.) as a measure of cytotoxicity. At the early and late time points, 
no difference in dose response can be seen for sunitinib or doxorubicin when 5% 
FCS is present; the data points correlate closely as do the IC50 values. Sunitinib has 
an IC50 of 10 μM and 2 μM at 6 h and 72 h, respectively, in both media conditions. 
Doxorubicin has an IC50 of 1 μM and 0.02 μM at 6 h and 72 h respectively, in both 
media conditions. 
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All structural cardiotoxins that were studied were reconstituted to a stock 
concentration of 20 mM in dimethyl sulfoxide (DMSO) and subsequently diluted in 
cell culture media to a final concentration of 0.5% (v/v) DMSO and top compound 
concentration of 100 μM. A 0.5% concentration of DMSO within the assay 
maintained compound solubility. A control experiment was performed to assess the 
toxicity of DMSO. hCMECs and hCFs were seeded in 96 well plates at their optimal 
seeding densities and incubated for 3 days in their full growth cell culture media (see 
chapter 3 for model optimisation details). Cells were subjected to a range of DMSO 
concentrations (0.1, 0.25, 0.5, 0.75 & 1%) for 72 h, then lysed for intracellular ATP 
content using CellTiter-Glo reagent (Promega, Southampton, U.K.) as an indicator of 
cytotoxicity. Figure 4.1e shows intracellular ATP content relative to 0% DMSO for 
both hCMECs and hCFs after 72 h. 0.1, 0.25 and 0.5% DMSO show no significant 
decrease in ATP content in either cell type. Final DMSO concentrations higher than 
0.5% (v/v) begin to decrease the relative cellular ATP content. 
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Figure 4.1 Assay controls: the effect of 5% FCS and DMSO.  
hCMECs were seeded at 6,000 cells well-1 on gelatin-coated 96 well plates for 3 
days. Cells were then treated with sunitinib (100 – 0.032 μM) for 6 h (a) and 72 h (b) 
or doxorubicin (100 – 0.032 μM) for 6 h (b) and 72 h (d) in endo FGM or endo SFM 
or (e) DMSO (0.1-1%) in endo FGM. Intracellular ATP content was assessed using 
CellTiter-Glo® luminescent cell viability kit (Promega, Southampton, U.K.) and 
luminescence was recorded using a Wallac 1450 Microbeta Trilux Scintillation 
Counter (PerkinElmer Life Sciences, Fremont, CA, U.S.A.). ATP values shown are 
relative to 0.5% DMSO control (a,b,c,d) or media without vehicle (e),  single 
experiment mean of n=3 with SD error bars. hCMEC, human cardiac microvascular 
endothelial cells. hCMEC, human cardiac microvascular endothelial cells; FCS, 
foetal calf serum; FGM, full growth media; SFM, serum free media.  
a 
c 
10-10 10-9 10-8 10-7 10-6 10-5 10-4 10-3 10-2
0.0
0.5
1.0
1.5
2.0
[Sunitinib] M
A
T
P
 R
es
po
ns
e 
re
la
tiv
e 
to
 c
on
tr
ol
10-10 10-9 10-8 10-7 10-6 10-5 10-4 10-3 10-2
0.0
0.5
1.0
1.5
2.0
[Sunitinib] M
A
T
P
 R
es
po
ns
e 
re
la
tiv
e 
to
 c
on
tr
ol
10-10 10-9 10-8 10-7 10-6 10-5 10-4 10-3 10-2
0.0
0.5
1.0
1.5
[Doxorubicin] M
A
T
P
 R
es
po
ns
e 
re
la
tiv
e 
to
 c
on
tr
olb 
d 
1
0.
75 0.
5
0.
25 0.
1 0
0.0
0.5
1.0
% DMSO
A
T
P
  
re
la
tiv
e
 t
o
 c
o
n
tr
o
l
hCMEC hCF
10-10 10-9 10-8 10-7 10-6 10-5 10-4 10-3
0.0
0.5
1.0
1.5
[Doxorubicin] M
A
T
P
 R
e
s
p
o
n
s
e
 r
e
la
tiv
e
 t
o
 c
o
n
tr
o
l
e 
With foetal calf serum (FCS) 
Without foetal calf serum (FCS) 
  127 
4.2.3 Assay work flow 
All human primary cells studied (hCMECs, hCFs, hDMECs, hCAECs & NhDFs) were 
thawed from the manufacturers (PromoCell, Germany) cryovial and pre-cultured 
before seeding into black-walled 96 well plates (endothelial cells on gelatin-coated 
plates). Cells were incubated for 3 days at 37oC, 5% CO2 before compound 
treatment (see materials and methods). Following 6, 24 or 72 hour treatment, cells 
were stained with fluorescent dyes towards MMP, ER integrity, Ca2+ mobilisation and 
membrane permeability for 1 hour at 37oC, 5% CO2. Dye was then washed off and 
each well of cells fluorescently imaged using TRITC, FITC, DAPI and Cy5 filter 
settings on an ImageXpress high content analysis system (Molecular Devices, 
Sunnyvale, CA, U.S.A., 20x objective). Immediately after imaging cells were lysed for 
intracellular ATP content using CellTiter-Glo reagent (Promega, Southampton, U.K.). 
This cytotoxicity assay represents an additional measure of cell necrosis and 
apoptosis. Fluorescent images were analysed using metaXpress software (Molecular 
Devices, Sunnyvale, CA, U.S.A) to provide a series of measurements for each 
fluorescent probe; mean cell integrated intensity for each wavelength measured. The 
sum of these numerical measurements from 4 image fields within a single well was 
combined to give an overall quantification of each fluorescent signal from each well 
therefore each compound concentration. Dose response curves for ATP content and 
the HCB parameters were generated and used to calculate IC50 / EC50’s. hESC-CMs 
data was obtained from Pointon et al., 2013. Figure 4.2 summarises this assay work 
flow. 
 
4.2.4 Endothelial and fibroblast characterization 
Acetyl low-density lipoprotein (AcLDL) uptake is a phenotype characteristic of 
endothelial cells, therefore all cell models were assessed for acLDL uptake at each 
assay time point to ensure endothelial phenotype (Data not shown; see chapter 3 for 
more detail). Similarly, discoidin domain receptor 2 (DDR2) was used as a cardiac 
specific fibroblast marker to ensure cardiac phenotype of the hCFs (Data not shown; 
see chapter 3 for more detail). 
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Figure 4.2 Assay work flow.  
hCMECs, hCFs, hDMECs, hCAECs & NhDFs were thawed from the manufacturers 
(PromoCell, Germany) cryovial and pre-cultured before seeding into black-walled 96 
well plates (endothelial cells on gelatin-coated plates). Cells were incubated with a 6-
point concentration (0.03-100 μM) compound treatment for 6, 24 or 72 h then stained 
with fluorescent dyes towards Mitochondrial membrane potential (MMP), 
Endoplasmic Reticulum (ER) integrity, Ca2+ mobilisation (Ca2+) and membrane 
permeability for 1 hour at 37oC, 5% CO2.  Cells were fluorescently imaged using 
TRITC, FITC, DAPI and Cy5 filter settings on an ImageXpress high content analysis 
system (Molecular Devices, Sunnyvale, CA, U.S.A., 20x objective). Immediately after 
imaging cells were lysed for intracellular ATP content using CellTiter-Glo reagent 
(Promega, Southampton, U.K.).  
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4.3 Detecting structural cardiotoxicity in non-myocyte cells 
4.3.1 Generating therapeutically relevant data from dose response curves 
Each cell model (hCMEC, hDMEC, hCAEC, hCF and NhDF) was treated with a 6-
point concentration set (100 – 0.032 μM) of each compound for 6, 24 or 72 h before 
being stained for MMP, ER integrity, Ca2+ mobilization and dead cells. Immediately 
after imaging the cells were lysed for intracellular ATP content using CellTiter-Glo 
reagent. Concentration-effect curves were plotted for each parameter of each 
compound treatment using GraphPad Prism (LA Jolla, CA) and expressed relative to 
vehicle (0.5% DMSO). Figure 4.3 shows representative fluorescent images of 
hCMECs displaying the effect of doxorubicin on fluorescent staining. With 
doxorubicin treatment a decrease in ER integrity (ER tracker) and mitochondrial 
membrane potential (MMP) (TMRE) fluorescence was seen while an initial increase 
in Ca2+ mobilization (Fluo-4 AM) was seen. Figure 4.4 shows cellular ATP content 
relative to control for each compound at each time point in hCMECs. As the dose 
response curves show in the case of some compounds i.e. sorafenib tosylate (IC50), 
full toxicity can be predicted as early as 6 h since beyond this time point there was 
no significant shift in the dose response curve. For other compounds such as 
Doxorubicin, 72 h was needed in order to predict toxicity (IC50). Figure 4.5 shows a 
similar trend for the high content biology (HCB) parameters. Here the most sensitive 
parameter either MMP, Ca2+ or ER integrity at each time point 6, 24 and 72 h is 
plotted for each compound. Figure 4.5 shows 72 h compound exposure is required 
to predict fluorouracil toxicity whereas 6 h exposure is adequate for Idarubicin 
toxicity. From the concentration- effect curves generated for each parameter, the 
molar concentration of test compound producing 50% inhibition (IC50) or 50% 
response (EC50) was generated (summary of IC50‘s for each cell type can be found in 
the appendix; tables 1, 2 and 3). In order to relate this therapeutically, all IC50 values 
were divided by the total Cmax (see table 2.4, materials & methods) of the test 
compound to give the therapeutic index (TI); a ratio of the amount of therapeutic 
agent that causes the therapeutic effect to the amount that causes toxicity.  
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Figure 4.3 Representative images of hCMECs stained for MMP, ER integrity 
and Ca2+ mobilization following treatment with 0.16 μM doxorubicin.  
hCMECs were seeded at 6,000 cells well-1 on gelatin-coated 96 well plates and 
incubated for 3 days in endo FGM before compound treatment. After 72 h, cells were 
incubated for 1 h in serum- free media with TMRE (30 pM) to measure MMP, ER-
Tracker™ blue-white (1 nM) to measure ER integrity, Fluo-4 AM (1 nM) to measure 
Ca2+ mobilization and TOTO®-3 (1 nM) to indicate dead cells. Following staining, 
cells were subjected to automated live-cell fluorescent image acquisition using an 
ImageXpress high content analysis system (Molecular Devices, 20x objective).  
Fluorescent images were captured according to the optimal excitation and emission 
wavelengths of each probe. Red, Mitochondrial membrane potential (MMP); Blue, 
ER integrity; Green, Ca2+ mobilization. TOTO-3 staining not shown due to high 
background levels in the absence of high cell death. Representative images of 
duplicate samples over triplicate experiments. Scale bar represents 50 m. 
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Figure 4.4 Intracellular ATP content concentration-effect curves for 8 structural cardiotoxins in hCMECs following 6,  24 
and 72 h exposure.  
hCMECs were seeded at 6,000 cells well-1 on gelatin-coated 96 well plates and incubated for 3 days in endo FGM before 
compound treatment. Cells were treated with a 6-point concentration set (100 – 0.032 μM) of either (a) imatinib mesylate, (b) 
fluorouracil, (c) doxorubicin HCl, (d) lapatinib, (e) sorafenib tosylate, (f) sunitinib malate, (g) dasatinib or (h) idarubicin for 6 (shown 
in purple), 24 (shown in green) and 72 h (shown in red) before being stained for MMP, ER integrity, Ca2+ mobilization and dead 
cells. The cells were lysed for intracellular ATP content using CellTiter-Glo reagent. Concentration-effect curves were plotted for all 
8 compounds using GraphPad Prism (LA Jolla, CA) and expressed relative to vehicle (0.5% DMSO). Data represents the mean 
ATP measurements of duplicate wells on separate plates from three separate experiments for each timepoint. hCMEC, human 
cardiac microvascular endothelial cells; FGM, full growth media. SD error bars. 
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Figure 4.5 Most sensitive HCB parameter concentration-effect curves for 8 structural cardiotoxins in hCMECs following 6, 
24 and 72 h exposure.  
hCMECs were seeded at 6,000 cells well-1 on gelatin-coated 96 well plates and incubated for 3 days in endo FGM before 
compound treatment. Cells were treated with a 6-point concentration set (100 – 0.032 μM) of either (a) imatinib mesylate, (b) 
fluorouracil, (c) doxorubicin HCl, (d) lapatinib, (e) sorafenib tosylate, (f) sunitinib malate, (g) dasatinib or (h) idarubicin for 6 (shown 
in purple), 24 (shown in green) and 72 h (shown in red) after which cells were incubated for 1 hour in serum- free media with TMRE 
(30 pM) to  measure MMP, ER-Tracker™ blue-white (1 nM) to measure ER integrity, Fluo-4 AM (1 nM) to measure Ca2+ 
mobilization and TOTO®-3 (1 nM) to indicate dead cells. Automated live-cell fluorescent image acquisition using an ImageXpress 
high content analysis system (Molecular Devices, 20x objective). Fluorescent images were analysed using metaXpress software 
(Molecular Devices, Sunnyvale, CA, U.S.A) to quantify mean cell integrated intensity for each wavelength measured. 
Concentration-effect curves were plotted using GraphPad Prism (LA Jolla, CA) and expressed relative to vehicle (0.5% DMSO) 
(n=3). The imaging parameter with the lowest IC50 is shown. Data represents the mean of duplicate wells on separate plates from 
three separate experiments for each timepoint. hCMEC, human cardiac microvascular endothelial cells; FGM, full growth media. 
SD error bars. 
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4.3.2 HCB combined with a cytotoxicity assay allows earlier prediction of 
toxicity 
From the concentration- effect curves, all IC50 values were divided by the total 
Cmax of the test compound to give the therapeutic index (TI); a ratio of the 
amount of therapeutic agent that causes the therapeutic effect to the amount 
that causes toxicity. A value of 1 arises when the IC50 concentration is equal 
to the Cmax concentration for that compound. Only the compounds that have a 
therapeutic index (TI) below 1 have shown therapeutically relevant toxicity. 
For each test compound the TI of each parameter (MMP, ER, Ca2+ and ATP) 
was plotted as a dot plot showing each cell type (hCFs, NhDFs, hCMECs, 
hDMECs, hCAECs and hESC-CMs) at each time point (6, 24 & 72 h) using 
GraphPad Prism (La Jolla, CA) (figure 4.6-4.12) with a red line drawn to 
indicate a therapeutic index value of 1.  
 
 
If we first consider the tyrosine kinase inhibitor imatinib mesylate (figure 4.6) 
whose pharmacological targets are Bcl-Abr, platelet-derived growth factor 
(PDGF) and c-kit, the most striking characteristic of this plot is the specific 
potency of imatinib in cardiac fibroblasts; after a 72hexposure imatinib has a 
TI value of 0.0001 in hCFs detected by MMP, ER and Ca2+. This TI value is 
lower than all other cell types tested and the ATP parameter for hCFs (10,000 
fold lower) and significantly lower than the TI displayed by hESC-CMs (TI; 10, 
p=0.0445). This differentiation between the HCB parameters and ATP shows 
early prediction of imatinib structural toxicity indicated by changes in MMP, 
ER integrity and Ca2+ mobilisation within the hCFs prior to gross cell death 
indicated by a loss of intracellular ATP.  
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Figure 4.6 Therapeutically relevant toxicity of imatinib mesylate in 
endothelial, fibroblast and cardiomyocytes.  
Cells were treated with a 6-point concentration set (100 – 0.032 μM) of 
imatinib mesylate for 6 h, 24 hand 72 h before being stained and imaged for 
MMP, ER integrity, Ca2+ mobilization then lysed for cellular ATP content using 
CellTiter-Glo reagent. Concentration-effect curves were plotted to calculate 
IC50 values, which were then divided by the total Cmax to give the therapeutic 
index (TI). hCF, human cardiac fibroblasts; NhDFs, normal human dermal 
fibroblasts; hCMEC, human cardiac microvascular endothelial cells; hDMECs, 
human dermal microvascular endothelial cells; hCAECs, human coronary artery 
endothelial cells; hESC-CMs, human embryonic stem cell derived cardiomyocytes 
 
Interestingly with lapatinib (figure 4.7), an epidermal growth factor receptor 
(EGFR) inhibitor, we see significantly enhanced sensitivity of all non-myocytes 
when compared with hESC-CMs at the 6 and 24 h timepoints (p< 0.0001). 
After at least 24 h exposure dermal fibroblasts (NhDFs) have shown structural 
changes with an overall TI value of ~ 0.02; approximately 10-fold less than 
cardiac fibroblasts (hCFs). A similar pattern exists between the endothelial 
cells; despite them showing less sensitivity overall, after 24 h lapatinib has 
induced changes in the ER integrity of the hDMECs with a TI value of 0.3, 
approximately 10-fold less than any parameter in the other endothelial cell 
6 24 72 6 24 72 6 24 72 6 24 72 6 24 72 6 24 72
0.00001
0.0001
0.001
0.01
0.1
1
10
100
1000
T
h
e
ra
p
e
u
ti
c
 I
n
d
e
x
/ 
T
I
MMPER integrity Ca2+ mobilizationATP content
hCF's NhDF's hCMEC's hDMEC's hCAEC's
Imatinib
hESC-CM's
 Hrs  
  135 
types (hCMECs & hCAECs). After 72 h this toxicity is reduced in relevance 
(TI; ~2), possibly due to a cell doubling, a caveat of the endothelial cell model. 
After a 72 h exposure to lapatinib the cardiomyocytes have also undergone 
changes in ER integrity in combination with Ca2+ mobilisation, once again 
prior to gross cell death.  
 
 
Figure 4.7 Therapeutically relevant toxicity of lapatinib in endothelial, 
fibroblast and cardiomyocytes.  
Cells were treated with a 6-point concentration set (100 – 0.032 μM) of 
lapatinib for 6 h, 24 h and 72 h before being stained and imaged for MMP, ER 
integrity, Ca2+ mobilization then lysed for cellular ATP content using CellTiter-
Glo reagent. Concentration-effect curves were plotted to calculate IC50 values, 
which were then divided by the total Cmax to give the therapeutic index (TI). 
hCF, human cardiac fibroblasts; NhDFs, normal human dermal fibroblasts; hCMEC, 
human cardiac microvascular endothelial cells; hDMECs, human dermal 
microvascular endothelial cells; hCAECs, human coronary artery endothelial cells; 
hESC-CMs, human embryonic stem cell derived cardiomyocytes. 
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Sorafenib, sunitinib and dasatinib are multi-tyrosine kinase inhibitors. The 
therapeutic index values of sorafenib are shown in figure 4.8, all cell models 
show therapeutically relevant toxicity to sorafenib. The endothelial cells show 
no significant difference in sensitivities (p>0.99) and their MMP, ER, Ca2+ and 
ATP TI values all tightly correlate suggesting gross cell death has occurred as 
early as 6 h. In contrast the fibroblasts, particurlarly NhDFs, have displayed 
therapeutically relevant structural toxicity (MMP, ER and Ca2+) and not 
intracellular ATP depletion. This fibroblast therapeutic toxicity was significantly 
enhanced compared to hESC-CMs at the 6 and 24 hr timepoints (p<0.0001). 
 
Figure 4.8 Therapeutically relevant toxicity of sorafenib in endothelial, 
fibroblast and cardiomyocytes.  
Cells were treated with a 6-point concentration set (100 – 0.032 μM) of 
sorafenib for 6 h, 24 h and 72 h before being stained and imaged for MMP, 
ER integrity, Ca2+ mobilization then lysed for cellular ATP content using 
CellTiter-Glo reagent. Concentration-effect curves were plotted to calculate 
IC50 values, which were then divided by the total Cmax to give the therapeutic 
index (TI). hCF, human cardiac fibroblasts; NhDFs, normal human dermal 
fibroblasts; hCMEC, human cardiac microvascular endothelial cells; hDMECs, 
human dermal microvascular endothelial cells; hCAECs, human coronary artery 
endothelial cells; hESC-CMs, human embryonic stem cell derived cardiomyocytes. 
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Sunitinib (figure 4.9) has shown therapeutically relevant toxicity in the 
NhDFs as early as 6 h exposure, detected by a change in MMP (TI; 1), after 
24 h this toxicity was lead by changes to the ER integrity (TI; 0.1). However, 
after 72 h of compound exposure the NhDFs appear to have recovered from 
these structural changes and the TI values of all parameters sit at 100. The 
only cell type  which displays maintained structural toxicity was the 
cardiomyocytes (hESC-CMs), Ca2+ mobilisation has a TI value of 0.005 after 
72 h exposure; another example of mechanistic prediction using high content 
biology. 
 
Figure 4.9 Therapeutically relevant toxicity of sunitinib in endothelial, 
fibroblast and cardiomyocytes.  
Cells were treated with a 6-point concentration set (100 – 0.032 μM) of 
sunitinib for 6 h, 24 h and 72 h before being stained and imaged for MMP, ER 
integrity, Ca2+ mobilization then lysed for cellular ATP content using CellTiter-
Glo reagent. Concentration-effect curves were plotted to calculate IC50 values, 
which were then divided by the total Cmax to give the therapeutic index (TI). 
hCF, human cardiac fibroblasts; NhDFs, normal human dermal fibroblasts; hCMEC, 
human cardiac microvascular endothelial cells; hDMECs, human dermal 
microvascular endothelial cells; hCAECs, human coronary artery endothelial cells; 
hESC-CMs, human embryonic stem cell derived cardiomyocytes. 
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Dasatinib (figure 4.10), the final tyrosine kinase tested, shows no 
therapeutically relevant toxicity in any of the cell models except hESC-CMs; 
after a 24 h exposure a therapeutically relevant change in MMP was seen (TI; 
0.7). Following a 72 h exposure this toxicity was no longer relevant, 
something which displays the importance of multiple time points. 
 
Figure 4.10 Therapeutically relevant toxicity of dasatinib in endothelial, 
fibroblast and cardiomyocytes.  
Cells were treated with a 6-point concentration set (100 – 0.032 μM) of 
dasatinib for 6 h, 24 h and 72 h before being stained and imaged for MMP, 
ER integrity, Ca2+ mobilization then lysed for cellular ATP content using 
CellTiter-Glo reagent. Concentration-effect curves were plotted to calculate 
IC50 values, which were then divided by the total Cmax to give the therapeutic 
index (TI). hCF, human cardiac fibroblasts; NhDFs, normal human dermal 
fibroblasts; hCMEC, human cardiac microvascular endothelial cells; hDMECs, 
human dermal microvascular endothelial cells; hCAECs, human coronary artery 
endothelial cells; hESC-CMs, human embryonic stem cell derived cardiomyocytes. 
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Fluorouracil is a member of the anti-metabolite drug class and irreversibly 
inhibits the thymidylate synthase enzyme. The most striking characteristic of 
figure 4.11 is the complete correlation of all of the HCB parameters and while 
the endothelial cell toxicity was predicted by the HCB parameters, fibroblast 
toxicity was either not relevant (hCFs) or intracellular ATP predicted (NhDFs). 
The hESC-CMs, however show the most sensitivity to fluorouracil with MMP, 
Ca2+ and ER predicting toxicity at TI values of ~0.01 after a 72 h exposure. 
 
 
Figure 4.11 Therapeutically relevant toxicity of fluorouracil in 
endothelial, fibroblast and cardiomyocytes.  
Cells were treated with a 6-point concentration set (100 – 0.032 μM) of 
fluorouracil for 6 h, 24 h and 72 h before being stained and imaged for MMP, 
ER integrity, Ca2+ mobilization then lysed for cellular ATP content using 
CellTiter-Glo reagent. Concentration-effect curves were plotted to calculate 
IC50 values, which were then divided by the total Cmax to give the therapeutic 
index (TI). hCF, human cardiac fibroblasts; NhDFs, normal human dermal 
fibroblasts; hCMEC, human cardiac microvascular endothelial cells; hDMECs, 
human dermal microvascular endothelial cells; hCAECs, human coronary artery 
endothelial cells; hESC-CMs, human embryonic stem cell derived cardiomyocytes. 
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The final group of compounds tested for structural cardiotoxicity were the 
anthracyclines, doxorubicin and idarubicin. Figure 4.12a and figure 4.12b 
show therapeutically relevant toxicity in all cell models with doxorubicin 
exposure, the most sensitive being the hESC-CMs after 72 h (ATP TI; 
0.0001), however, idarubicin shows hCF and hESC-CM specific potency. 
hCFs show a TI of 0.0001 (ER & Ca2+) after 72 h exposure to idarubicin, 100-
fold lower than the next most sensitive cell model, hESC-CM with a lowest TI 
value of 0.01 (ER). 
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Figure 4.12 Therapeutically relevant toxicity of (a) doxorubicin and (b) 
idarubicin in endothelial, fibroblast and cardiomyocyte cells.  
Cells were treated with a 6-point concentration set (100 – 0.032 μM) for 6, 24 
and 72 h before staining and imaging for MMP, ER integrity, Ca2+ mobilization 
then lysed for cellular ATP content using CellTiter-Glo reagent. Concentration-
effect curves were plotted to calculate IC50 values, which were then divided by 
the total Cmax to give the therapeutic index (TI). hCF, human cardiac fibroblasts; 
NhDFs, normal human dermal fibroblasts; hCMEC, human cardiac microvascular 
endothelial cells; hDMECs, human dermal microvascular endothelial cells; hCAECs, 
human coronary artery endothelial cells; hESC-CMs, human embryonic stem cell 
derived cardiomyocytes. 
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4.4 Relative sensitivities of endothelial cells from different vascular beds 
to structural cardiotoxins 
From the concentration- effect curves of the 8 structural cardiotoxins (imatinib, 
fluorouracil, doxorubicin, lapatinib, sorafenib, sunitinib, dasatinib and 
idarubicin), all IC50 values were divided by the total Cmax of the test compound 
to give the therapeutic index (TI); a ratio of the amount of therapeutic agent 
that causes the therapeutic effect to the amount that causes toxicity. The 
parameter with the lowest TI was selected for each compound in each cell 
type and correlation graphs of hCMEC against hCAECs and hDMECs were 
generated using GraphPad Prism. Figure 4.13 shows a global comparison 
whereby the endothelial cell sensitivities to all 8 structural cardiotoxins are 
compared at (a) 6 h, (b) 24 h and (c) 72 h. This type of analysis was used to 
highlight any correlations in sensitivity. 
 
After 6 h exposure (figure 4.13a), each data point correlates tightly with the 
line of unity suggesting there is very little difference in the compound 
sensitivity of these three cell types. Each endothelial cell was sensitive below 
therapeutically relevant levels to sorafenib and fluorouracil (TI; <0.2 & <0.7 
respectively). Slight differences in sensitivity to doxorubicin can be seen at 
this point also; the hCAEC and hDMEC were relevantly sensitive to 
doxorubicin (TI; <0.6) where as the hCMECs were not (TI; 1.85) (Figure 
4.13a) (IC50, TI). 
 
Following 24 h of exposure (figure 4.13b), slightly less correlation around the 
line of unity can be seen. Each endothelial cell type now shows 
therapeutically relevant sensitivity to doxorubicin (TI; <0.2), however lapatinib 
shows therapeutically relevant toxicity specifically in the hDMECs (TI; 0.26) 
but not in the hCMECs (TI; 3.95) or hCAECs (TI; 3.7). Fluorouracil remains 
therapeutically relevant in the hDMECs and hCAECs (TI; <0.35) but the IC50 
of hCMECs has risen slightly to above Cmax (greater than 1) (TI; 1.45). 
Sorafenib remains equally potent in the hCMECs and hDMECs (TI; 0.1), 
where as the hCAECs appear less sensitive at 24 h (TI; 1.19). 
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Figure 4.13c shows afters 72 h exposure the endothelial cells correlate even 
tighter around the line of unity suggesting no significant difference in 
sensitivities between the cell models at this time point. All three endothelial 
cell models were sensitive to doxorubicin (TI; <0.2) and sorafenib (TI; 0.15) at 
therapeutically relevant levels following 72 h exposure. 
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Figure 4.13 Global comparison of endothelial structural cardiotoxin 
sensitivities following 6, 24 & 72 h exposure to 8 structural cardiotoxins.  
Cells were seeded at their optimal seeding densities and incubated for 3 days 
prior to treatment with 8 structural cardiotoxins for (a) 6 h, (b) 24 h and (c) 72 
h. Cells were labelled with fluorescent probes for MMP, ER integrity, Ca2+ 
mobilization and lysed for cellular ATP content. Concentration-effect curves 
were plotted for all compounds and expressed relative to vehicle (0.5% 
DMSO). IC50 values were obtained and divided by the total Cmax for each 
test compound to give the therapeutic index (TI). The parameter with the 
lowest TI was selected and correlation graphs were generated using 
GraphPad Prism. hCMEC, human cardiac microvascular endothelial cells; 
hDMECs, human dermal microvascular endothelial cells; hCAECs, human 
coronary artery endothelial cells. 
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4.5 Relative sensitivities of cardiac and dermal fibroblast cells to 
structural cardiotoxins 
From the concentration- effect curves of the 8 structural cardiotoxins (imatinib, 
fluorouracil, doxorubicin, lapatinib, sorafenib, sunitinib, dasatinib and 
idarubicin), all IC50 values were divided by the total Cmax of the test compound 
to give the therapeutic index (TI); a ratio of the amount of therapeutic agent 
that causes the therapeutic effect to the amount that causes toxicity. The 
parameter with the lowest TI was selected for each compound in each cell 
type and correlation graphs of hCFs against NhDFs were generated using 
GraphPad Prism. Figure 4.14 shows a global comparison of the fibroblast cell 
sensitivities to the 8 structural cardiotoxins after 6, 24 and 72 h exposure.  
 
After 6 h exposure (figure 4.14a) both fibroblast cell models show equal 
sensitivity to lapatinib (TI; 0.3), gradually this sensitivity increases in the 
NhDFs i.e. IC50 values become lower in NhDF’s (TI 24 & 72; 0.02 & 0.0001, 
respectively). Imatinib, sorafenib and sunitinib show differential sensitivities 
between the cardiac and dermal fibroblasts at the 6 h time point; imatinib and 
sorafenib have displayed therapeutically relevant toxicity in the hCF model 
(TI; 0.6 & 0.3, respectively) but not the NhDFs that have a TI value at least 
10-fold higher (TI; 23 & 4, respectively). Sunitinib, although not therapeutically 
relevant, has a TI value approximately 10-fold lower in the NhDFs than the 
hCFs (TI; 10 & 1.2, respectively).  
 
Figure 4.14b shows the 24 h global fibroblast comparison, here we see 
imatinib has maintained its hCF specific sensitivity when compared with 
NhDFs (TI; 0.22 & 3.24, respectively), sorafenib is now equally as toxic to 
both fibroblast models (TI; 0.06), therapeutically relevant doxorubicin toxicity 
has developed in both models (TI; <0.2) and NhDF have displayed increased 
sensitivity to lapatinib while the hCFs have reduced in sensitivity (TI; 0.02 & 
0.67, respectively). 
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After 72h exposure the fibroblast models have shown even more variation in 
their sensitivity; while only the hCFs show therapeutically relevant sensitivity 
to imatinib, sunitinib and idarubicin (hCFs TI; 0.0001, 0.66, 0.001, respectively 
& NhDFs TI; 28, 47, 67, respectively), the NhDFs are 1,000-fold more 
sensitive to sorafenib and lapatinib (NhDFs TI; 0.0001). Dasatinib has no 
therapeutically relevant toxicity in either model (TI; >250) and both NhDF’s 
and hCF’s have equal sensitivity to doxorubicin (TI; 0.02 & 0.01, respectively). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Global comparison of fibroblast structural cardiotoxin 
sensitivities following 6, 24 & 72 h exposure to 8 structural cardiotoxins.  
Fibroblasts were seeded in 96 well plates and incubated for 3 days prior to 
treatment with 8 structural cardiotoxins for (a) 6 h, (b) 24 h and (c) 72 h. Cells 
were labelled with fluorescent probes for MMP, ER integrity, Ca2+ mobilization 
and lysed for cellular ATP content. Concentration-effect curves were plotted 
for all compounds and expressed relative to vehicle (0.5% DMSO). IC50 
values were obtained and divided by the total Cmax for each test compound to 
give the therapeutic index (TI). The parameter with the lowest TI was selected 
and correlation graphs were generated using GraphPad Prism. hCF, human 
cardiac fibroblasts; NhDF, normal human dermal fibroblasts. 
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4.6 Relative sensitivities of non-myocytes and myocytes to structural 
cardiotoxins 
From the concentration- effect curves of the 8 structural cardiotoxins (imatinib, 
fluorouracil, doxorubicin, lapatinib, sorafenib, sunitinib, dasatinib and 
idarubicin), all IC50 values were divided by the total Cmax of the test compound 
to give the therapeutic index (TI); a ratio of the amount of therapeutic agent 
that causes the therapeutic effect to the amount that causes toxicity. The 
parameter with the lowest TI was selected for each compound in each cell 
type and correlation graphs of cardiac non-myocytes (hCFs & hCMECs) 
against cardiomyocytes (hESC-CMs) were generated using GraphPad Prism. 
Figure 4.15 shows a global comparison of the cardiac myocyte and non-
myocyte cell sensitivities to the 8 structural cardiotoxins after 6 and 72 h 
exposure.  
 
If we compare figure 4.15 (a) and (b) we can clearly see an overall shift in 
data points from the right hand side of the correlation graph at the 6 h 
timepoint (a) to the left hand side at the 72 h timepoint (b). This means the 
compounds either have an IC50 greater than Cmax (top right box, figure 4.15a) 
and are therefore not therapeutically relevant, or have therapeutic relevance 
solely in one or both of the non-myocytes (hCF or hCMEC) (bottom right box, 
figure 4.15a). After 72 h exposure all the compounds (except imatinib) show 
therapeutically relevant toxicity either in the myocyte and non-myocyte models 
(bottom left box, figure 4.15b) or solely the myocytes (top left box, figure 
4.15b). Overall this suggests the non-myocytes are sensitive to structural 
cardiotoxicity earlier than the cardiomyocytes.   
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Figure 4.15 Comparison of myocyte (hESC-CMs) and non-myocyte 
(hCFs & hCMECs) structural cardiotoxin sensitivities at 6 and 72 h.  
Cells were treated with a 6-point concentration (0.03-100 μM) response of 8 
structural cardiotoxins for (a) 6 h and (b) 72 h. Cells were then labelled with 
fluorescent probes for MMP, ER integrity, Ca2+ mobilization and lysed for 
cellular ATP content. Concentration-effect curves were plotted and expressed 
relative to vehicle (0.5% DMSO). From here IC50 values were obtained and 
divided by the total Cmax for each test compound to give the therapeutic index 
(TI). The parameter with the lowest TI was selected for each compound in 
each cell type and correlation graphs were generated using GraphPad Prism 
(LA Jolla, CA). hCF, human cardiac fibroblasts; hCMEC, human cardiac 
microvascular endothelial cells; hESC-CM, human embryonic stem cell 
cardiomyocytes.  
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The only test compound to show a therapeutically relevant toxicity specific to 
one of the cell models across both acute and chronic exposure is imatinib in 
the hCF model (figure 4.15a & b) (6 hr TI; 0.6 & 72 hr TI; 0.0001). At 6 h the 
hCF model also shows sensitivity to lapatinib but following 72 h the 
cardiomyocytes have also developed this relevant toxicity. At the 6 h timepoint 
we see fluorouracil sensitivity solely in the hCMECs (TI; 0.4), but after 72 h 
the cardiomyocytes have also developed sensitivity. Both non-myocytes are 
sensitive to sorafenib after 6 h but again the cardiomyocytes develop this 
toxicity at 72 h. At 72 h exposure (figure 4.15b) we see doxorubicin, lapatinib 
and sorafenib therapeutically relevant sensitivity across all cardiac cell 
models, sunitinb and idarubicin toxicity was relevant specifically in the cardiac 
fibroblasts and cardiomyocytes.  
 
4.7 Detection of structural cardiotoxins in microtissue models 
The previous sections have discussed the structural cardiotoxin sensitivities of 
2D cell models (hCMECs, hDMECs, hCAECs, hCFs, NhDFs and hESC-CMs) 
comprised of an individual cell type and has suggested the non-myocytes are 
sensitive to structural cardiotoxins earlier than the cardiomyocytes but with the 
majority toxicity eventually present within the cardiomyocytes. Given the 
dependency of cardiomyocytes on the microvascular system for the supply of 
oxygen and nutrients, the next question was to investigate whether this early 
non-myocyte toxicity could translate into enhanced cardiomyocyte toxicity. In 
order to assess this an in vitro model with increased physiological relevance 
was required whereby the cardiomyocytes can directly interact with the non-
myocytes (hCFs & hCMECs). 3D cell culture allows better recapitulation of a 
cells ‘3D’ in vivo morphology. Round bottom ultra low adhesion (ULA) cell 
culture plates were used to form microtissues. Chapter 3 discusses 
microtissue development in detail. Briefly however, 500 cells at a ratio of 4 
hESC-CMs: 2 fibroblasts: 1 endothelial cell (tri-culture; cardiac MEF (CMEF) 
& dermal MEF (DMEF)) or 2 hESC-CMs: 1 endothelial or fibroblast cell (di-
cultures; endothelial CME or fibroblast CMF) or solely hESC-CMs were 
seeded into each well of an ULA plate in 100 μl of cell culture media. 
Following 2 weeks of incubation at 37oC, 5% CO2, the cells have aggregated 
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to form a tight 200 μm spontaneously beating microtissue. The microtissues 
have uniform size and shape with possible longevity beyond 2 months (data 
not shown) however the toxicity assays discussed here were performed with 
microtissues up to 4 weeks post seeding. 
 
All microtissue models were exposed for 6 and 72 h to 5 structural 
cardiotoxins selected for their different cell model sensitivities. Fluorouracil 
displayed therapeutically relevant toxicity specifically in the endothelial cells 
after a 6 h exposure (figure 4.15a). Imatinib displayed therapeutically relevant 
toxicity specifically in the cardiac fibroblasts at both 6 and 72 h exposure 
(figure 4.15a & b). Sunitinib was highlighted for its therapeutically relevant 
toxicity specifically in the cardiac fibroblasts and cardiomyocytes (figure 
4.15b). Lapatinib and doxorubicin were selected as compounds with different 
mechanistic targets that cause relevant toxicity in all cardiac cell models 
(figure 4.15a & b). All models were treated with a 6-point concentration set 
(100 – 0.032 μM) of compound for 6 or 72 h then intracellular ATP content 
was used as a measure of cytotoxicity; microtissues were lysed on a plate 
shaker for 20 mins in CellTiter-Glo reagent (Promega, Southampton, U.K.). 
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From the concentration-effect curves in figure 4.16 and the plotted IC50 values 
in figure 4.21, we can see that exposure to fluorouracil has no effect on 
intracellular ATP content at either timepoint (6 (figure 4.16a) or 72 h (figure 
4.16b)) in any of the cell models tested (IC50 > 100 μM).  
 
 
 
 
 
 
Figure 4.16 Intracellular ATP concentration-effect curves of CM 
monolayer and CM, CMEF, CME, CMF microtissues following (a) 6 h and 
(b) 72 h exposure to fluorouracil.  
Cells were seeded into each well of an ULA plate at optimal ratio and density 
in 100 μl of cell culture media and incubated for 2 weeks. All models were 
treated with a 6-point concentration set (100 – 0.032 μM) of compound for 6 
or 72 h then intracellular ATP content was used as a measure of cytotoxicity 
(CellTiter Glo, Promega, Southampton, U.K.). CM monolayer, human 
embryonic stem cell cardiomyocytes; CM, hESC-CM microtissue; CMEF, 
hESC-CM/ hCF/ hCMEC; CME, hESC-CM/ hCMEC; CMF, hESC-CM/ hCF. 
 
10-9 10-8 10-7 10-6 10-5 10-4 10-3
0.0
0.5
1.0
1.5
[Fluorouracil] M
A
T
P
 r
e
s
p
o
n
s
e
 r
e
la
ti
v
e
 
to
 c
o
n
tr
o
l
hESC monolayer CMEFCM
CMFCME
10-9 10-8 10-7 10-6 10-5 10-4 10-3
0.0
0.5
1.0
1.5
[Fluorouracil] M
A
T
P
 r
e
s
p
o
n
s
e
 r
e
la
ti
v
e
 
to
 c
o
n
tr
o
l
hESC monolayer CMEFCM
CMFCME
10-9 10-8 -7 10-6 10-5 10-4 0-3
0.0
0.5
1.0
1.5
[Lapatinib] M
A
T
P
 r
e
s
p
o
n
s
e
 r
e
la
ti
v
e
 
to
 c
o
n
tr
o
l
CM monolayer CMEFCM
CME CMF
a b 
  153 
Doxorubicin has no effect on intracellular ATP content in the cell models after 
a 6 h exposure (figure 4.17a). However after 72 h exposure all models were 
sensitive to doxorubicin (IC50 < 0.4 μM). The CM monolayer model (hESC-
CMs) leads with the lowest IC50 at 72 h (0.02 μM; figure 4.21), a 10-fold 
increase in sensitivity compared with the microtissue models (IC50’s > 0.2 μM; 
figure 4.21). 
 
Figure 4.17 Intracellular ATP concentration-effect curves of CM 
monolayer and CM, CMEF, CME, CMF microtissues following (a) 6 h and 
(b) 72 h exposure to doxorubicin.  
Cells were seeded into each well of an ULA plate at optimal ratio and density 
in 100 μl of cell culture media and incubated for 2 weeks. All models were 
treated with a 6-point concentration set (100 – 0.032 μM) of compound for 6 
or 72 h then intracellular ATP content was used as a measure of cytotoxicity 
(CellTiter Glo, Promega, Southampton, U.K.). CM monolayer, human 
embryonic stem cell cardiomyocytes; CM, hESC-CM microtissue; CMEF, 
hESC-CM/ hCF/ hCMEC; CME, hESC-CM/ hCMEC; CMF, hESC-CM/ hCF. 
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Figures 4.18a and 4.21 show lapatinib sensitivity in the CM monolayer model after 6 
h exposure (IC50, 21.25 μM), however the ATP content of the microtissue models 
was not affected (IC50 > 100 μM). Following 72 h exposure (figure 4.18b) we see a 
slightly lower IC50 (figure 4.21) in the microtissue models compared with the CM 
monolayer model (microtissues IC50< 5 μM; CM monolayer IC50, 13.8 μM). 
 
 
 
 
 
Figure 4.18 Intracellular ATP concentration-effect curves of CM monolayer and 
CM, CMEF, CME, CMF microtissues following (a) 6 h and (b) 72 h exposure to 
lapatinib.  
Cells were seeded into each well of an ULA plate at optimal ratio and density in 100 
μl of cell culture media and incubated for 2 weeks. All models were treated with a 6-
point concentration set (100 – 0.032 μM) of compound for 6 or 72 h then intracellular 
ATP content was used as a measure of cytotoxicity (CellTiter Glo, Promega, 
Southampton, U.K.). CM monolayer, human embryonic stem cell cardiomyocytes; 
CM, hESC-CM microtissue; CMEF, hESC-CM/ hCF/ hCMEC; CME, hESC-CM/ 
hCMEC; CMF, hESC-CM/ hCF. 
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Sunitinib decreased intracellular ATP content in all cell models at both 6 h (figure 
4.19a) and 72 h (figure 4.19b) exposure with very little variation in the IC50 values 
(figure 4.21) 
 
 
 
 
 
Figure 4.19 Intracellular ATP concentration-effect curves of CM monolayer and 
CM, CMEF, CME, CMF microtissues following (a) 6 h and (b) 72 h exposure to 
sunitinib.  
Cells were seeded into each well of an ULA plate at optimal ratio and density in 100 
μl of cell culture media and incubated for 2 weeks. All models were treated with a 6-
point concentration set (100 – 0.032 μM) of compound for 6 or 72 h then intracellular 
ATP content was used as a measure of cytotoxicity (CellTiter Glo, Promega, 
Southampton, U.K.). CM monolayer, human embryonic stem cell cardiomyocytes; 
CM, hESC-CM microtissue; CMEF, hESC-CM/ hCF/ hCMEC; CME, hESC-CM/ 
hCMEC; CMF, hESC-CM/ hCF. 
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All cell models show a decrease in intracellular ATP content following imatinib 
exposure for 6 and 72 h. The concentration-effect curves (figure 4.20) and the plot of 
IC50 values (figure 4.21) show a pattern whereby the CMF model was slightly more 
sensitive at both time points (6 h IC50, 6 μM; 72 h IC50, 2 μM) than all other models (6 
h IC50, >10 μM; 72 h IC50, >15 μM), with the CME model following closely after 72 h 
exposure (IC50, 4 μM). 
 
 
 
 
Figure 4.20 Intracellular ATP concentration-effect curves of CM monolayer and 
CM, CMEF, CME, CMF microtissues following (a) 6 h and (b) 72 h exposure to 
imatinib.   
Cells were seeded into each well of an ULA plate at optimal ratio and density in 100 
μl of cell culture media and incubated for 2 weeks. All models were treated with a 6-
point concentration set (100 – 0.032 μM) of compound for 6 or 72 h then intracellular 
ATP content was used as a measure of cytotoxicity (CellTiter Glo, Promega, 
Southampton, U.K.). CM monolayer, human embryonic stem cell cardiomyocytes; 
CM, hESC-CM microtissue; CMEF, hESC-CM/ hCF/ hCMEC; CME, hESC-CM/ 
hCMEC; CMF, hESC-CM/ hCF. 
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Figure 4.21 Intracellular ATP IC50 values for CM monolayer and CM, CMEF, 
CME, CMF microtissues following 6 and 72 h exposure to 5 structural 
cardiotoxins.  
Cells were seeded into each well of an ULA plate at optimal ratio and density in 100 
μl of cell culture media and incubated for 2 weeks. All models were treated with a 6-
point concentration set (100 – 0.032 μM) of compound for 6 or 72 h then intracellular 
ATP content was used as a measure of cytotoxicity (CellTiter Glo, Promega, 
Southampton, U.K.). Concentration-effect curves were plotted using GraphPad 
Prism and IC50 values calculated. CM monolayer, human embryonic stem cell 
cardiomyocytes; CM, hESC-CM microtissue; CMEF, hESC-CM/ hCF/ hCMEC; CME, 
hESC-CM/ hCMEC; CMF, hESC-CM/ hCF. 
 
 
 
 
Hrs 
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4.8 Discussion  
 
This chapter describes the utilization of a high content biology and cytotoxicity assay 
approach to measure structural cardiotoxin sensitivities in non-myocyte cells from 
various different tissue beds. The first aim was to determine the need for non-
myocytes from a cardiac origin in structural cardiotoxicity prediction and secondly to 
compare the sensitivities of cardiac non-myocytes with cardiomyocytes in order to 
establish a role for non-myocytes in drug-induced structural cardiotoxicity. 
 
4.8.1 Combining HCB with a cytotoxicity assay to increase predictive strength 
The data from this chapter firstly shows that the combination of high content biology 
(HCB) with a cytotoxicity endpoint improves the overall predictive strength of the 
assay. This was also shown by Pointon et al (2013) using multiple cardiomyocyte 
cell models. For example imatinib mesylate toxicity in hCFs was predicted by the 
high content biology parameters while doxorubicin toxicity in hESC-CMs was 
predicted by ATP content. Secondly, we have seen that HCB can predict these 
toxicities prior to gross cell death and therefore has the potential to provide insight 
into the mechanism of toxicity (Pointon et al., 2013). As will be discussed further on 
in this section, the non-myocytes showed cytotoxic sensitivity to the structural 
cardiotoxins at the acute time point of 6 h therefore most mechanistic insight was 
lost. In hindsight an earlier time point may have allowed better elucidation of the 
mechanisms of structural toxicity taking place in the non-myocytes but this was not 
necessary for a global study comparing many different cell types and their 
sensitivities.  
 
The utilisation of an early and late timepoint also improves the predictive strength of 
the assay. For example the therapeutic index of fluorouracil increases with increased 
exposure in endothelial cells. Fluorouracil irreversibly inhibits the enzyme 
thymidylate synthase therefore enzyme turnover between the early and late 
timepoint could explain the reduction in potency. An assay solely utilising a late time 
point would have missed the endothelial fluorouracil therapeutically relevant 
sensitivity all together. 
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4.8.2 Structural cardiotoxin sensitivities in non-myocytes from cardiac, dermal and 
macrovascular origin. 
No major difference in structural compound sensitivities were observed between the 
endothelial cells from different vascular beds. This is perhaps not surprising given 
the limitations of the cell model. Endothelial cells are highly adaptive cells designed 
to rapidly respond to changes in their microenvironment in order to maintain the flow 
of oxygen and nutrients to their tissue (and removal of waste products). A major but 
unavoidable draw back of this study is that the primary endothelial cells have been 
removed from their specific microenvironments in vivo and cultured alone in vitro 
under general endothelial cell culture conditions. The endothelial cell models were 
cultured in almost identical conditions therefore it is not surprising that they should 
respond to compounds in an almost identical manner. This highlights the need for 
more complex in vitro cell models that better reconstitute the in vivo cellular 
physiology when studying drug toxicity. 
 
Interestingly, much more variation in structural cardiotoxin sensitivity was observed 
between the cardiac and dermal fibroblasts, this suggests that the fibroblasts 
perhaps are not as dependent upon their microenvironment for their phenotype as 
the endothelial cells are. For example the compound imatinib mesylate, an inhibitor 
of the Bcr-Abl, PDGF & c-kit receptors, shows at the therapeutically relevant level 
cardiac fibroblast specific structural toxicity detected by the high content biology 
parameters. PDGF receptors are known to play an important role in cardiac fibrosis 
and angiogenesis (Takeda & Manabe, 2011) therefore inhibition of this signalling 
could present one mechanism of imatinib cardiotoxicity. Bcr-Abl silencing in 
myocytes and fibroblasts showed no significant difference in imatinib sensitivity 
suggesting this is not the mechanism of cardiotoxicity (Wolf et al., 2010). This 
cardiac fibroblast specific toxicity highlights a) the need for cell models derived from 
the tissue of interest and b) a potential role for non-myocytes in drug-induced 
cardiovascular toxicity. 
 
  160 
Lapatinib, sorafenib, sunitinib and although not therapeutically relevant, dasatinib 
show enhanced structural toxicity in the dermal fibroblasts compared to the other 
non-myocytes. Many tyrosine kinase inhibitors are now being highlighted for their 
incidence of skin rashes (Huang et al., 2008), the data in this chapter suggests that 
dermal fibroblasts could be the target of this skin toxicity. 
 
4.8.3 Role of non-myocytes in drug-induced structural cardiovascular toxicity 
As described above the endothelial cells displayed no significant difference in their 
compound responses, while the fibroblasts showed variation; imatinib was more 
potent in the cardiac fibroblasts and lapatinib more potent in the dermal fibroblasts. 
These findings were potentially disappointing although unsurprising. However, when 
the sensitivities of the cells from the myocardium (hCFs, hCMECs and hESC-CMs) 
were globally compared we see that the non-myocytes are sensitive to structural 
cardiotoxicity at the acute time point of 6 h, whereas the hESC-CMs display toxicity 
only after 72 h. In vivo the early compound toxicity of the non-myocytes could 
potentially translate into enhanced cardiomyocyte sensitivity. Fibroblasts are in close 
proximity to myocytes and their ability to manipulate the ECM provides them with the 
potential to influence cardiomyocyte phenotype. Cardiomyocytes are highly energetic 
cells that require an abundance of oxygen and nutrients from the dense 
microvasculature. Loss or damage to the microvasculature would ultimately affect 
cardiomyocyte health and mechanical output.  
 
4.8.4 Structural cardiotoxicity in cardiac microtissues 
In order to overcome some of the limitations of the cell models used within this 
chapter, co-cultured microtissue models were utilised to study structural 
cardiotoxicity. Chapter three saw the development of multiple microtissue models 
comprising different co-culture compositions. hESC-CMs were cultured alone and 
co-cultured with either or both cardiac fibroblasts and cardiac microvascular 
endothelial cells as three dimensional (3D) microtissues. These models have 
improved in vivo relevance compared with the monolayer assays previously used, 
since they conform the cells into their natural 3D structure and allow multicellular 
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interactions. Microtissues were exposed to a subset of the initial structural 
cardiotoxin compound set and cytotoxicity measured using an intracellular ATP 
measurement. Compound selection was based upon potency in the non-myocyte 
monolayer models. Ideally this assay would have been combined with the high 
content biology approach however, high throughout imaging of 3D samples is 
technically challenging for automated imaging platforms with regard to locating and 
focusing on 3D samples. This limited the study quite dramatically since the only 
available endpoint was ATP content and this parameter was not particularly 
predictive of toxicity in the monolayer models. For example, no sensitivity to 
fluorouracil by the microtissue models was detected by measuring ATP content. This 
is not surprising given that previous monolayer sensitivities were detected by the 
high content biology parameters and not ATP content.  
 
Despite this ATP measurement allowed some differences in microtissue sensitivities 
to be detected. The cardiomyocyte-cardiac fibroblast microtissues showed enhanced 
sensitivity to the tyrosine kinase inhibitors imatinib and sunitinib. This imatinib 
response supports the earlier findings with the hCF monolayer model in suggesting 
cardiac fibroblasts are the target of imatinib cardiotoxicity. Interestingly, however, the 
cardiac tri-culture model CMEF shows a reduction in imatinib sensitivity compared 
with the di-culture models suggesting a tri-cultured environment provides some 
protection against this toxicity. Doxorubicin shows a similar pattern except the most 
sensitive microtissue was the cardiomyocyte-cardiac endothelial microtissue 
suggesting the endothelial cells play a role in doxorubicin cardiotoxicity potentially 
through redox disruption since we know endothelial cells utilise nitric oxide as a 
signalling factor with cardiomyocytes or disruption of the endothelial mitochondrial 
membrane potential (Chiusa et al., 2012). However, once again when tri-cultured we 
see less sensitivity suggesting some protection is at play.  
 
4.8.5 Conclusion 
The ultimate conclusion from this chapter is non-myocyte cells are involved in drug-
induced cardiotoxicity and can be used to enhance our current preclinical safety 
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assessments. These sensitivities are not limited to any one class of compounds. 
Tyrosine kinase inhibitors, anthracyclines and enzyme inhibitors have been studied 
and each class has shown toxicity. However, co-cultured microtissue models, 
despite assay limitations, have suggested that more in vivo relevant models are not 
as sensitive to these toxicities and therefore they may not translate in vivo.  
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Chapter Five 
 
 
Contractile maturity in cardiac 
microtissue models 
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5.1 Introduction 
As well as structural cardiotoxicity, drug induced cardiovascular toxicity results 
from functional effects (acute alteration of the mechanical function of the 
myocardium) on the heart. These adverse effects can also result in conditions 
such as arrhythmia or a more serious reduction in left ventricular ejection 
fraction (LVEF), which can lead to heart failure and death (Brana & 
Tabernero, 2010; Gianni et al., 2008; Mellor et al., 2011). This chapter will 
firstly describe the detection of positive and negative inotropic agents in 
cardiac microtissues. A positive inotrope acts to increase the force of 
cardiomyocyte contraction while a negative inotrope reduces cardiomyocyte 
contraction. Data suggests that only a matured adult CM can respond to a 
positive inotrope with positive inotropy and positive chronotropy (increase in 
contraction rate); hESC-CMs are suggested to respond with only positive 
chronotropy (Lieu et al., 2009; Robertson et al., 2013). For a cardiomyocyte to 
respond with positive inotropy they are thought to require an extensive t-
tubule network to ensure that the entire cell depolarizes rapidly and 
homogeneously, a larger intracellular Ca2+ store and more dependence upon 
ryanodine receptors for calcium-induced calcium release (CICR). Immature 
CM’s rely on extracellular Ca2+ therefore their Ca2+ transients are smaller and 
slower, lacking the synchrony needed to increase contraction force 
(Robertson et al., 2013). Microtissues will also be assessed for an increase in 
sarcoplasmic reticulum function by caffeine-induced calcium release, see 
section 1.3.3 for details on caffeine effects on cardiomyocyte Ca2+ 
homeostasis.  
 
The current widely used contractility assay uses canine cardiomyocytes and 
applies them to the IonOptix cell geometry system that utilizes video-based 
detection of sarcomere shortening (Harmer et al, 2012). This technique relies 
upon optical intensity data that translates into transients of peaks and troughs. 
These contractility transients are analysed using IonWizard software to 
provide quantification of contractility (contraction displacement 
measurements). This animal model, however is a relatively poor predictor of 
human specific responses. The microtissues will be applied to a similar 
contractility assay to study their responses to known inotropes and caffeine. 
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These compound responses will be used alongside a gene expression study 
of all microtissues in order to highlight any cardiac maturity brought about by 
a) 3D culturing and b) multicellular culturing.  
The ultimate aim of this chapter is to show that the cardiac microtissues can 
provide a human relevant contractile mature alternative for studying drug-
induced functional cardiotoxicity in vitro. 
 
 
5.2 Microtissue functional characterisation 
5.2.1 Spontaneous contractions 
Human ESC-cardiomyocytes (hESC-CMs) were cultured either alone (CM 
microtissues) or with human cardiac microvascular endothelial cells 
(hCMECs) and human cardiac fibroblasts (hCFs) (CMEF microtissues) in 96 
well round-bottomed ultra-low adhesion plates. This method can allow the 
production of microtissues with uniform size and shape. After two weeks all 
cultures formed a single spontaneously beating microtissue with a 200 μm 
diameter in each well. Microtissues were transferred onto 0.1% (w/v) gelatin-
coated 13 mm plastic coverslips (Thermanox,) within a 12 well plate and 
incubated at 37oC, 5% CO2 for at least one hour before mounting onto the 
IonOptix contractility system. Contractile properties of spheroids were 
assessed using a video-based edge detection method (IonOptix™, Dublin, 
Ireland). A gelatin-attached microtissue was placed in a perfusion chamber 
(FHC Inc., Bowdoinham, ME, USA) mounted on the stage of an inverted 
Nikon TE200 microscope (Nikon UK, Surrey, UK). Microtissues were 
continuously perfused from a gravity fed system with warmed microtissue 
media. Figure 5.1 shows a 10 secrecording of spontaneous contractions in 
CM and CMEF microtissues using video-based edge detection. The rate of 
contraction varies between the microtissue types; CM microtissues contract 
0.4 beats per sec (b/s) (figure 5.1a) whereas the CMEF microtissues have a 
rate of 0.9 b/s (figure 5.1b). 
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Figure 5.1 Spontaneous contractions in (a) CM and (b) CMEF 
microtissues.  
hESC-CMs were cultured either alone (CM microtissues) or with hCMECs and 
hCFs (CMEF microtissues) in 96 well round-bottomed ULA plates. After 2-3 
days the cells have aggregated to form one tight microtissue in each well. 
After 2 weeks the microtissues spontaneously beat. Microtissues were 
transferred onto 0.1% gelatin-coated coverslips for at least one hour before 
mounting onto the IonOptix contractility system. Contractile properties were 
assessed using a video-based edge detection method (IonOptix™, Dublin, 
Ireland).  
 
5.2.2 Calcium and contraction response to electrical pacing  
Microtissues were loaded with 0.2 µmol/L Fura-2-acetoxymethyl ester 
(Invitrogen), a calcium-sensitive, ratiometric fluorescence dye, for 10 mins at 
RT and kept in the dark. An IonOptix system was used to conduct the 
experiments, including the Xenon arc lamp, hyperswitch and myopacer for 
myocyte stimulation and fluorescence excitation, myocam-S for the 
measurement of edge contraction, and a fluorescence system interface to 
integrate the different components (IonOptix Ltd). The Xenon arc lamp and 
fluorescence hyperswitch containing a galvonised mirror were used to 
alternate between wavelengths of 340 and 380 nM at a high frequency. 
Calcium fluorescence was recorded at 510 nm. Calcium traces represent the 
ratio of calcium bound: calcium free Fura-2- acetoxymethyl ester dye, and 
hence changes in free intracellular calcium. Simultaneous edge contraction 
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(a) CM Microtissue (b) CMEF Microtissue 
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and calcium recordings for the microtissues were taken while perfusing with 
the microtissue media solution and field stimulating with suprathreshold 
voltage (7V) at various pacing frequencies (0.5, 1, 2 and 3Hz) with a bipolar 
pulse of 6 ms duration, using a pair of platinum wires placed on opposite 
sides of the microscope chamber connected to a MyoPacer EP stimulator 
(IonOptix™). Microtissues responded to an increase in electrical stimulation 
frequency by decreasing transient peak height and increasing contraction 
frequency (figure 5.2a (CMEF) & 5.2b (CM)). The alignment of the calcium-
contraction transients shows that edge detection is a reliable measure of 
microtissue contraction in both CMEF (figure 5.2a) and CM (figure 5.2b) 
microtissues; peak bound calcium immediately precedes microtissue peak 
contraction.  
Figure 5.2 Representative edge contraction and calcium transients in (a) 
CMEF and (b) CM microtissues paced at 0.5Hz, 1Hz, 2Hz and 3Hz.  
hESC-CMs were cultured either alone (CM microtissues) or with hCMECs and 
hCFs (CMEF microtissues) in 96 well round-bottomed ULA plates. After 2-3 
days the cells have aggregated to form one tight microtissue in each well. 
After 2 weeks the microtissues spontaneously beat. Microtissues were 
transferred onto 0.1% (w/v) gelatin-coated coverslips for at least one hour 
before loading with 0.2 µmol/L Fura-2 for 30 mins and then mounted onto the 
IonOptix contractility system. Contractile properties and calcium fluorescence 
were assessed using the IonOptix system with field stimulation at 0.5, 1, 2, 
3Hz with 7V for 6 ms. 
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Figure 5.3 shows quantification of the contraction (figure 5.3a) and calcium 
(figure 5.3b) transient peak heights from triplicate microtissues. The CM 
microtissues have a significantly higher peak amplitude at 1Hz than the CMEF 
microtissues (p=0.0053) but overall significantly lower maximum bound 
calcium (calcium peak height) (p<0.001), this already suggests a difference in 
calcium handling between the two microtissue types. 
 
5.2.3 Validation of assay design and detection of negative inotropy in 
microtissues 
The L-type calcium channel blocker verapamil was used as a typical 
‘negative’ inotrope to test the capability of the Ionoptix in detecting changes in 
contraction displacement using video capture of the microtissue edge to 
measure changes in contraction displacement. Compound response was 
measured from one microtissue on triplicate occasions. After microtissues 
were added to the microscope stage, perfusion with microtissue media (with 
0.1% (v/v) DMSO as the vehicle control) was started immediately. At this time 
field stimulation was also started (1Hz) and the microtissues allowed to 
acclimatise for at least 2 mins at 37oC. A period of 30s of basal contractions 
were recorded for each microtissue before test compounds were applied in a 
cumulative manner with each concentration applied for 250 s or until steady-
state was achieved. Figure 5.4 displays representative basal contraction 
transients of CMEF (figure 5.4a) and CM microtissues (figure 5.4b) followed 
by their contractility response to 1 μM verapamil. These 20s transient 
snapshots display a reduction in transient peak height in both microtissue 
types with 1 μM verapamil showing firstly the microtissues are capable of 
responding to a negative inotrope with a decrease in contraction displacement 
but also that this can be recorded using the IonOptix video-based edge 
detection.  
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Figure 5.3 Quantification of (a) contraction and (b) calcium transient 
peak height at 0.5, 1, 2 and 3Hz.  
hESC-CMs were cultured either alone (CM microtissues) or with hCMECs and 
hCFs (CMEF microtissues) in 96 well round-bottomed ULA plates. After 2-3 
days the cells have aggregated to form one tight microtissue in each well. 
After 2 weeks the microtissues spontaneously beat. Microtissues were 
transferred onto 0.1% (w/v) gelatin-coated coverslips for at least one hour 
before loading with 0.2 µmol/L Fura-2 for 30 mins and then mounted onto the 
IonOptix contractility system. Contractile properties and calcium fluorescence 
were assessed using the IonOptix system with field stimulation at 0.5, 1, 2, 
3Hz with 7V for 6 ms. 
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Figure 5.4 Contractility response of (a) CMEF and (b) CM microtissues to 
1 μM verapamil.  
hESC-CMs were cultured either alone (CM microtissues) or with hCMECs and 
hCFs (CMEF microtissues) in 96 well round-bottomed ULA plates. After 2 
weeks the microtissues spontaneously beat. MT’s were attached to gelatin-
coated coverslips, mounted onto the IonOptix contractility system and field 
stimulated at 1.5Hz. The negative inotrope verapamil was applied in a 
cumulative manner with each concentration applied for 250s or until steady 
state. 20s of basal contraction transients (0.1% DMSO) (left side) and 20s of 1 
μM verapamil contraction transients (right side) are shown. 
 
Analysis was performed using the IonWizard™ software. For each test 
condition, data for 10 to 15 contractions were averaged to give a single 
representative monotonic contractility transient. From this analysis, 3 key 
parameters were used to quantify microtissue dynamics: 1) peak height, 
which indicates the percentage of peak contraction relative to the resting 
length. 2) Maximum contraction velocity, calculated as the maximum rate of 
change in peak height during the contraction phase. 3) Maximum relaxation 
velocity, calculated as the maximum rate of change in peak height during the 
relaxation phase.  Figure 5.5 illustrates these parameters of a contraction 
transient.  
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Figure 5.5 Illustration of contraction transient parameters.  
Peak height, which indicates the percentage of peak contraction relative to the 
resting length. Maximum contraction velocity, calculated as the maximum rate 
of change in peak height during the contraction phase. Maximum relaxation 
velocity, calculated as the maximum rate of change in peak height during the 
relaxation phase.  
 
The verapamil concentration-effect curves for each of these parameters in 
CMEF and CM microtissues relative to 0.1% (v/v) DMSO are displayed in 
figure 5.6a,b & c. Each parameter shows a dose-dependent decline with 
verapamil; peak height was selected as the most reproducible parameter. 
These responses are not significantly different (p>0.1). 
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Figure 5.6 Verapamil concentration-effect curves for the 3 key transient 
parameters in CM and CMEF microtissues.  
hESC-CMs were cultured either alone (CM microtissues) or with hCMECs and 
hCFs (CMEF microtissues) in 96 well round-bottomed ULA plates. After 2 
weeks the microtissues spontaneously beat. Microtissues were attached to 
gelatin-coated coverslips, mounted onto the IonOptix contractility system and 
field stimulated at 1.5Hz. The negative inotrope verapamil was applied in a 
cumulative manner with each concentration applied for 250s or until steady 
state. 10-15 contraction transients were average for each test condition and 
the resulting monotonic contractility transient analysed to quantify maximum 
contraction velocity (max.cont.vel), peak height and maximum relaxation 
velocity (max.rel.vel), data is triplicate and relative to 0.1% (v/v) DMSO. SD 
error bars. 
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5.2.4 Detection of positive inotropy in microtissues 
Having shown that both the single cell (CM) and multicell (CMEF) 
microtissues can respond to the negative inotrope verapamil, they were then 
assessed for their contractility response to a positive inotrope. A positive 
inotrope acts to increase contraction displacement; the beta-adrenergic 
receptor agonist dobutamine was selected as a test agent. As with the 
verapamil test in the previous section, the microtissues were applied to the 
IonOptix contractility system and field stimulated at 1.5Hz with flow of warm 
microtissue media. A period of 30s of basal contractions were recorded for 
each microtissue before dobutamine was applied in a cumulative manner with 
each concentration applied for 250 s or until steady-state was achieved. 
Figure 5.7 displays representative basal contraction transients of CMEF 
(figure 5.7a) and CM microtissues (figure 5.7b) followed by their contractility 
response to 10 μM dobutamine. These 20s transient snapshots display a 
increase in transient peak height in CMEF microtissues with the positive 
inotrope, interestingly the CM microtissues show no increase in peak height. 
From this we can see that, firstly, the video-based edge detection method is 
capable of recording an increase in microtissue contraction displacement as 
seen with CMEF, but the CM microtissues cannot respond with positive 
inotropy to dobutamine. A wider panel of inotropic agents with different 
mechanisms of action needs to be tested to determine the significance of this 
finding. 
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Figure 5.7 Contractility response of (a) CMEF and (b) CM microtissues to 
10 μM dobutamine.  
hESC-CMs were cultured either alone (CM microtissues) or with hCMECs and 
hCFs (CMEF microtissues) in 96 well round-bottomed ULA plates. After 2 
weeks the microtissues spontaneously beat. Microtissues were attached to 
gelatin-coated coverslips, mounted onto the IonOptix contractility system and 
field stimulated at 1.5Hz. The positive inotrope dobutamine was applied in a 
cumulative manner with each concentration applied for 250s or until steady 
state. 20s of basal contraction transients (0.1% DMSO) (left side) and 20s of 
10 μM dobutamine contraction transients (right side) are shown. 
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5.3 CMEF microtissues provide enhanced in vitro to in vivo correlation 
5.3.1 Response of CMEF and CM microtissues to a panel of positive inotropic 
agents 
CMEF and CM microtissues respond with decreased contraction 
displacement to the negative inotrope verapamil (figure 5.4a & b), however 
only CMEF respond with increased contraction displacement to the positive 
inotrope dobutamine (figure 5.7a). The contractile function of CM and CMEF 
microtissues were assessed against a panel of negative and positive inotropic 
agents. Positive inotropic agents with different mechanisms of action were 
selected. The microtissues were utilised between 2 and 4 weeks post seeding 
with verapamil response assessed throughout this time period to control for 
functional changes within the microtissues. As described in the previous 
section 5.2.3, the microtissues were attached to gelatin-coated coverslips, 
mounted on the IonOptix contractility system where they were field stimulated 
at 1-1.5Hz with microtissue media perfusion at 37oC. A period of at least 30s 
of basal contractions were recorded for each microtissue before test 
compound was applied in a cumulative manner with each concentration 
applied for 250 s or until steady-state was achieved. Analysis was performed 
using the IonWizard™ software. For each test condition, data for 10 to 15 
contractions were averaged to give a single representative monotonic 
contractility transient from which peak height was calculated using 
IonWizard™ software. Figure 5.8 shows CMEF and CM microtissue 
concentration-effect curves for isoproterenol, milrinone, epinephrine, 
glibenclamide and levosimenden. These curves show that all positive inotropy 
went undetected in CM microtissues. CMEF microtissues, however, 
responded to each positive inotrope with an increase in contraction 
displacement (peak height).  
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Figure 5.8 Concentration-effect curves of CMEF and CM microtissues in 
response to positive inotropes.  
hESC-CMs were cultured either alone (CM microtissues) or with hCMECs and 
hCFs (CMEF microtissues) in 96 well ULA plates. After 2 weeks microtissues 
were attached to gelatin-coated coverslips, mounted onto the IonOptix 
contractility system and field stimulated at 1-1.5Hz, with a bipolar pulse of 
6 ms duration and perfused at 37oC. Test compounds were applied in a 
cumulative manner with each concentration applied for 250 s or until steady-
state. For each test condition, data for 10 to 15 contractions were averaged to 
give a single representative monotonic contractility transient. Each plot shows 
the effect on peak height relative to 0.1% (v/v) DMSO (n=3). SD error bars. 
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5.3.2 The response of CMEF microtissues to a wider panel of inotropic agents 
Since the CMEF microtissues can correctly predict the direction of inotropy, 
they were assessed against a wider panel of inotropic agents to gain better 
insight into their predictive strength. A total of 24 compounds were selected 
for testing based on their in vivo effect; 12 negative inotropes, 7 positive 
inotropes and 5 negative controls. Each of these compounds were tested in 
triplicate on separate CMEF microtissues. The aim was to determine whether 
this model could potentially offer a human relevant replacement for the current 
canine assay (Harmer et al, 2012). Data is summarised in table 5.1, for each 
compound the clinical target, top test concentration and IC50/EC50 for peak 
height is shown. Representative concentration-effect curves for 12 of the 24 
compounds are displayed in figure 5.9, peak height is relative to 0.1% (v/v) 
DMSO control. The CMEF microtissues correctly predicted negative inotropy 
for atenolol, doxorubicin and lapatinib; compounds which had no effect on 
canine cardiomyocyte contractility (Harmer et al, 2012). These compounds 
were subsequently tested in the CM microtissue model to assess whether the 
negative inotropy is a trait of the hESC-CMs or the tri-cultured microtissue. 
Table 5.1 shows the CM microtissues responded with negative inotropy to the 
anthracycline doxorubicin, but were unresponsive to atenolol and lapatinib. 
Despite responding to verapamil the CM microtissues did so with a 10-fold 
increased IC50 (1 μM), therefore diltiazem, also an L-type Ca2+ channel 
blocker, was tested in the CM microtissue model. Diltiazem behaved as a 
negative inotrope in CM microtissues but again with less potency (CM, 2.47 
μM; CMEF, 0.38 μM). Paracetamol wrongly presented as a negative inotrope 
in the canine cardiomyocytes, had no inotropy effect in the CMEF 
microtissues (Table 5.1). Ivabradine and Phentolamine wrongly presented as 
negative inotropes in both assay models. Table 5.1 shows correctly predicted 
compounds in blue and incorrectly predicted compounds in pink, based on in-
vivo effects. Comparison of the CMEF data (92% correctly predicted) with 
canine cardiomyocyte assay data from Harmer et al (75% correctly predicted), 
shows improved in vitro to in vivo correlation with the multicellular CMEF 
model. 
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Figure 5.9 Representative concentration-effect curves of CMEF microtissues in response to inotropic and control agents.  
hESC-CMs were cultured with hCMECs and hCFs (CMEF microtissues) in 96 well ULA plates. After 2 weeks microtissues were 
mounted onto the IonOptix contractility system and field stimulated at 1-1.5Hz and perfused at 37oC. Test compounds were applied 
in a cumulative manner with each concentration applied for 250 s or until steady-state. For each test condition, data for 10 to 15 
contractions were averaged to give a single representative monotonic contractility transient. Each plot shows the effect on peak 
height relative to 0.1% (v/v) DMSO (n=3), SD error bars.  
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Table 5.1 Contraction peak height IC50/ EC50’s in CMEF microtissues, CM microtissues and canine cardiomyocytes. 
Compounds were subdivided into their in vitro effects; no effect, -ve inotrope, +ve inotrope. IC50/ EC50’s for CMEF, CM microtissues and canine CM are 
shown for contraction velocity, peak height and relaxation velocity for each compound tested. Data is the mean of tripl icate experiments. The parameter with 
the lowest IC50/ EC50 is used to compare the models. Top concentration tested is shown (Top Test Conc.). NE = no effect, - = not tested. 
Compound Target
Top 
Test 
Conc.
Lowest 
IC50/ EC50 
CMEF 
Microtissue
Lowest 
IC50/ EC50 
Canine CM
Lowest 
IC50/ EC50 
CM 
Microtissue
In vivo 
effect
Contraction 
Velocity 
(CV)
Peak 
Height 
(PH)
Relaxation 
Velocity 
(RV)
Amoxicillin β-lactam antibiotic 100 NE NE NE NE NE - NE
Paracetamol Cyclooxygenase inhibitor 100 NE NE NE NE 44.98 ↓ - NE
Sildenafil PDE-5 inhibitor 30 NE NE NE NE NE - NE
Enalapril Angiotensin-converting enzyme inhibitor 100 NE NE NE NE NE - NE
Tolbutamide ATP-sensitive potassium channel inhibitor 100 NE NE NE NE NE - NE
Atenolol β1 receptor antagonist 100 NE 0.94 NE 0.94 ↓ NE NE -ve inotrope
Diltiazem L-type Ca2+ channel blocker 100 0.42 0.38 7.78 0.38 ↓ 7 ↓ 2.47 ↓ -ve inotrope
Doxorubicin Interacts with DNA 100 1.03 1.16 2.79 1.16 ↓ NE 1.16 ↓ -ve inotrope
Flecainide Class Ic (Cardiac Na+ channel block) 100 7.05 11.14 10.46 11.14 ↓ 7 ↓ - -ve inotrope
Haloperidol Dopamine D2-receptor antagonist 30 2.42 0.29 2.28 0.29 ↓ 1 ↓ - -ve inotrope
Lapatinib EGFR and HER2/neu inhibitor 100 0.86 0.94 0.95 0.86 ↓ NE NE -ve inotrope
Nifedipine L-type Ca2+ channel blocker 10 0.24 0.33 0.31 0.24 ↓ 0.18 ↓ -ve inotrope
Sunitinib Multi-targeted receptor tyrosine kinase inhibitor 30 18.33 18.82 20.12 18.33 ↓ 5 ↓ - -ve inotrope
Verapamil L-type Ca2+ channel blocker 10 0.21 0.11 0.11 0.11 ↓ 0.35 ↓ 1 ↓ -ve inotrope
Bepridil L-type Ca2+ channel blocker 10 2 2 0.3 0.3 ↓ 1.4 ↓ - -ve inotrope
Ivabradine Inhibits the pacemaker 100 30.3 32.71 35.9 30.3 ↓ 20 ↓ - NE
Phentolamine Non-selective alpha adrenergic receptor antagonist 100 20 20 20 20 ↓ 15 ↓ - NE
Epinephrine Non-selective adrenergic receptor agonist 1 NE 0.07 NE 0.07 ↑ 0.1 ↑ 0.0012 ↑ +ve inotrope
Glibenclamide ATP-sensitive potassium channel inhibitor 100 0.8 0.96 24.01 0.8 ↑ 1.58 ↑ NE +ve inotrope
Levosimenden calcium sensitiser (binds to cardiac troponin C) 10 0.13 0.15 0.14 0.13 ↑ 0.09 ↑ NE +ve inotrope
Digoxin inhibits Na+ / K+ ATPase membrane pump 10 3.54 10.00 10 3.54 ↑ 2.6 ↑ 0.4 +ve inotrope
Dobutamine β1-adrenergic agonist 10 8.38 0.29 0.83 0.29 ↑ 1 ↑ 0.03 ↓ +ve inotrope
Isoproterenol betaadrenergic receptor agonist 0.1 0.0004 0.003 0.08 0.0004 ↑ 0.002 ↑ 0.00009 ↓ +ve inotrope
Milrinone PDE-3 inhibitor 100 NE 83.68 NE 83.68 ↑ 0.9 ↑ NE +ve inotrope
Correlates with in vivo effect ↓ Decrease in CF
No correlation with in vivo effect ↑ Increase in CF
EC50 / IC50  µM
No effect
-ve inotropy
+ve inotropy
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5.4 Contractile maturity is dependent upon the cardiac tri-culture system 
To investigate the apparent contractile maturity of the CMEF microtissues; 
hESC-CMs were cultured in ULA plates with hCMECs (CME microtissues) or 
hCFs (CMF microtissues) and additionally in a tri-culture with human dermal 
microvascular endothelial cells (hDMECs) and human dermal fibroblasts 
(NhDFs) (DMEF microtissues). Once again, 200 μm spontaneously beating 
microtissues formed after two weeks and displayed uniform size, shape and 
even cell marker distribution (data shown in chapter 3). Their response to 
positive and negative inotropes was assessed using the IonOptix contractility 
assay. Only CMEF and CMF showed negative inotropy with atenolol (IC50; 1 
μM, p<0.0009) (figure 5.10a). Similarly, only CMEF and CME responded with 
negative inotropy to lapatinib (IC50; 2 μM, p=0.003) (figure 5.10b). An increase 
in contraction magnitude in response to positive inotropic agents was not 
detected in CM, CMF, CME or DMEF (figure 5.11a & b). The mature 
contractile response to positive inotropy therefore remains a trait of the CMEF 
microtissues (Dobutamine IC50; 0.3 μM, Digoxin IC50; 2 μM). 
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Figure 5.10 Response of CMEF, CM, DMEF, CME & CMF microtissues to 
negative inotropes atenolol and lapatinib. hESC-CMs were cultured either 
alone (CM microtissue), with hCMECs (CME microtissue) or hCFs (CMF 
microtissue) or both (CMEF microtissues) or hDMECs and NhDFs (DMEF 
microtissue) with in 96 well ULA plates. After 2 weeks microtissues were 
mounted onto the IonOptix contractility system and field stimulated at 1-1.5Hz. 
Test compounds were applied in a cumulative manner with each 
concentration applied for 250 s or until steady-state. For each test condition, 
data for 10 to 15 contractions were averaged to give a single representative 
monotonic contractility transient. Each plot shows the effect on peak height 
relative to 0.1% (v/v) DMSO (n=3), SD error bars. 
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Figure 5.11 Response of CMEF, CM, DMEF, CME & CMF microtissues to 
positive inotropes digoxin and dobutamine. hESC-CMs were cultured 
either alone (CM microtissue), with hCMECs (CME microtissue) or hCFs 
(CMF microtissue) or both (CMEF microtissues) or hDMECs and NhDFs 
(DMEF microtissue) with in 96 well ULA plates. After 2 weeks microtissues 
were mounted onto the IonOptix contractility system and field stimulated at 1-
1.5Hz. Test compounds were applied in a cumulative manner with each 
concentration applied for 250 s or until steady-state. For each test condition, 
data for 10 to 15 contractions were averaged to give a single representative 
monotonic contractility transient. Each plot shows the effect on peak height 
relative to 0.1% (v/v) DMSO (n=3), SD error bars. 
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5.5 Cardiac non-myocytes promote gene upregulation in CMEF 
microtissues 
All microtissue models were subjected to gene expression analysis in order to 
determine whether the enhanced contractile performance of the CMEF 
microtissues correlates to an increase in gene maturity. A selection of 
structural and functional genes were selected based on maturation stages of 
cardiomyocytes (Robertson et al., 2013) and in-house next generation 
sequencing (NGS) data generated for adult ventricle tissue, foetal heart 
tissue, hESC-CMs, hCMECs, hDMECs and hCFs, looking for genes 
specifically upregulated in adult ventricle and foetal heart. Microtissues were 
harvested for RNA extraction 2 weeks post seeding. Microtissues were pooled 
and washed in pre-warmed DPBS before lysis in buffer RLT containing 1% 
(v/v) 2-mercaptoethanol. Total RNA was extracted from cells using the 
RNeasy mini kit (Qiagen, Crawley, U.K.) and quantified using a NanoDrop 
spectrophotometer (NanoDrop Technologies). Total RNA was diluted to 20 ng 
and reverse transcribed using a SuperScript® III first-strand synthesis 
supermix kit (Life technologies) following manufacturers instructions. cDNA 
samples were preamplified using the TaqMan® PreAmp Master mix kit with 
TaqMan® Probes.  QRT-PCR reactions were performed in a 7900 HT Fast 
Real-Time PCR System (Applied Biosystems, Foster City, CA, U.S.A.), 2.5 μl 
of preamplified cDNA was used with TaqMan® Gene Expression probes 
(Table 2.8) and master mix to monitor amplification under standard cycling 
conditions. Gene expression is expressed as fold change relative to GAPDH 
and adult ventricle using the ΔΔCT method. Fold change relative to adult 
ventricle is plotted for adult, foetal, CMEF, DMEF, CM, CME, CMF and 
monolayer models (hESC-CMs, hCFs, hCMECs). 
 
This investigation revealed two levels of mRNA upregulation: (i) an initial state 
of maturity which was promoted by a three dimensional (3D) culture 
environment, and (ii) an enhanced maturity state which was induced by 
culturing with both hCMECs and hCFs.  
 
  184 
The gene expression pattern of MYH6 and MYH7 is traditionally used to 
monitor maturity in cardiomyocytes; during development there is a switch from 
high gene expression of MYH7 and low MYH6 to high MYH6 and low MYH7 
in the fully matured cardiomyocyte. Figure 5.12 shows higher expression of 
MYH7 in foetal heart compared to adult ventricle and higher levels of MYH6 in 
adult ventricle than foetal heart, as would be expected. Both CM and CMEF 
show a downregulation of MYH7 and an upregulation of MYH6 when 
compared to hESC-CM monolayer expression. Cardiac troponin I (cTNI) and 
connexin43 (GJA1) mRNA levels were upregulated in both CM and CMEF 
microtissue models when compared to hESC-CM monolayer cells. 
 
Table 5.2 Gene reference 
Gene Encodes 
MYH6 Myosin heavy chain 6 
MYH7 Myosin light chain 7 
TNNI3 Cardiac troponin I 
GJA1 Connexin43 
ATP2A2 SERCA Ca2+ ATPase, slow twitch 
ATP5B Mitochondrial ATP synthase 
KCNQ1 Potassium voltage gated channel 
KCNJ2 Potassium inwardly rectifying channel 
ADRB1 β-adrenergic receptor 1 
S100A1 S100A1 calcium binding protein 
TCAP Titin-cap protein 
NOS3 Endothelial nitric oxide synthase 3 
PDE3A Phosphodiesterase 3A 
Reference table summarising the genes studied in this chapter with the 
corresponding protein complex encoded. 
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Figure 5.12 Expression of MYH7 and MYH6 in cardiac tissue, 
microtissues and monolayer cells.  
Total RNA extracted using RNeasy mini kit (Qiagen, Crawley, U.K.). Total 
RNA was diluted to 20 ng and reverse transcribed using a SuperScript® III 
first-strand synthesis supermix kit (Life technologies). cDNA samples were 
preamplified using the TaqMan® PreAmp Master mix kit. QRT-PCR reactions 
were performed using TaqMan® Gene Expression probes and master mix to 
monitor amplification under standard cycling conditions. Gene expression is 
expressed as fold change relative to GAPDH and adult ventricle using the 
ΔΔCT method. Fold change relative to adult ventricle is plotted for tissues, 
adult ventricle and foetal heart; microtissues, CMEF, DMEF, CM, CME and 
CMF; and cells, hESC-CMs, hCFs, hCMECs. n=3, error bars represent SD. 
T
N
N
I3
M
ic
ro
t i
s
s
u
e
s
C
e
lls
0 .0 0 0 1
0 .0 0 1
0 .0 1
0 .1
1
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 A
d
u
lt
 V
e
n
tr
ic
le
T N N I3
T
is
s
u
e
M
ic
ro
t i
s
s
u
e
s
C
e
lls
0 .1
1
1 0
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 A
d
u
lt
 V
e
n
tr
ic
le
G J A 1
T
is
s
u
e
M
ic
ro
t i
s
s
u
e
s
C
e
lls
0 .0 0 0 0 1
0 .0 0 0 1
0 .0 0 1
0 .0 1
0 .1
1
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 A
d
u
lt
 V
e
n
tr
ic
le
A d u lt v e n tr ic le
F o e ta l h e a r t
C M E F
C M
h E S C -C M 's
h C M E C
h C F
S 1 0 0 A 1
D M E F
C M E
C M F
T
is
s
u
e
M
ic
ro
t i
s
s
u
e
s
C
e
lls
0 .0 1
0 .1
1
1 0
1 0 0
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 A
d
u
lt
 V
e
n
tr
ic
le
M Y H 7
T
is
s
u
e
M
ic
ro
t i
s
s
u
e
s
C
e
lls
0 .0 0 1
0 .0 1
0 .1
1
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 A
d
u
lt
 V
e
n
tr
ic
le
M Y H 6
T
is
s
u
e
M
ic
ro
t i
s
s
u
e
s
C
e
lls
0 .0 0 0 0 1
0 .0 0 0 1
0 .0 0 1
.0 1
0 .1
1
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 A
d
u
lt
 V
e
n
tr
ic
le
A d u lt v e n tr ic le
F o e ta l h e a r t
C M E F
C M
h E S C -C M 's
h C M E C
h C F
S 1 0 0 A 1
D M E F
C M E
C M F
  186 
The SERCA Ca2+ ATPase (ATP2A2) and mitochondrial synthase (ATP5B) 
were upregulated at the gene level alongside adrenergic receptor β1 
(ADRB1). The levels of these genes were upregulated either towards adult 
ventricle or foetal heart dependent upon intial expression level. Similarly, 
various ion channels including K+ inwardly-rectifying channel (KCNJ2), K+ 
voltage-gated channel (KCNQ1) mRNA levels were found to be upregulated 
by 3D culturing. 
 
 
 
 
 
 
 
Figure 5.13 Expression of ATP2A2 and ATP5B in cardiac tissue, 
microtissues and monolayer cells.  
Total RNA extracted using RNeasy mini kit (Qiagen, Crawley, U.K.). Total 
RNA was diluted to 20 ng and reverse transcribed using a SuperScript® III 
first-strand synthesis supermix kit (Life technologies). cDNA samples were 
preamplified using the TaqMan® PreAmp Master mix kit with TaqMan® 
Probes. QRT-PCR reactions were performed using TaqMan® Gene 
Expression probes and master mix to monitor amplification under standard 
cycling conditions. Gene expression is expressed as fold change relative to 
GAPDH and adult ventricle using the ΔΔCT method. Fold change relative to 
adult ventricle is plotted for tissues, adult ventricle and foetal heart; 
microtissues, CMEF, DMEF, CM, CME and CMF; and cells, hESC-CMs, 
hCFs, hCMECs. n=3, error bars represent SD. 
T
is
s
u
e
M
ic
ro
t i
s
s
u
e
s
C
e
lls
0 .0 1
0 .1
1
1 0
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 A
d
u
lt
 V
e
n
tr
ic
le
A T P 2 A 2
T
is
s
u
e
M
ic
ro
t i
s
s
u
e
s
C
e
lls
0 .0 1
0 .1
1
1 0
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 A
d
u
lt
 V
e
n
tr
ic
le
A T P 5 B
T
is
s
u
e
M
ic
ro
t i
s
s
u
e
s
C
e
lls
0 .0 0 0 0 1
0 .0 0 0 1
0 .0 0 1
0 .0 1
0 .1
1
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 A
d
u
lt
 V
e
n
tr
ic
le
A d u lt v e n tr ic le
F o e ta l h e a r t
C M E F
C M
h E S C -C M 's
h C M E C
h C F
S 1 0 0 A 1
D M E F
C M E
C M F
  187 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14 Expression of KCNQ1, KCNJ2 and ADRB1 in cardiac tissue, 
microtissues and monolayer cells.  
Total RNA extracted using RNeasy mini kit (Qiagen, Crawley, U.K.). Total 
RNA was diluted to 20 ng and reverse transcribed using a SuperScript® III 
first-strand synthesis supermix kit (Life technologies). cDNA samples were 
preamplified using the TaqMan® PreAmp Master mix kit. QRT-PCR reactions 
were performed using TaqMan® Gene Expression probes and master mix to 
monitor amplification under standard cycling conditions. Gene expression is 
expressed as fold change relative to GAPDH and adult ventricle using the 
ΔΔCT method. Fold change relative to adult ventricle is plotted for tissues, 
adult ventricle and foetal heart; microtissues, CMEF, DMEF, CM, CME and 
CMF; and cells, hESC-CMs, hCFs, hCMECs. n=3, error bars represent SD. 
T
is
s
u
e
M
ic
ro
t i
s
s
u
e
s
C
e
lls
0 .0 1
0 .1
1
1 0
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 A
d
u
lt
 V
e
n
tr
ic
le
K C N J 2
T
is
s
u
e
M
ic
ro
t i
s
s
u
e
s
C
e
lls
0 .0 0 0 1
0 .0 0 1
0 .0 1
0 .1
1
1 0
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 A
d
u
lt
 V
e
n
tr
ic
le
K C N Q 1
T
is
s
u
e
M
ic
ro
t i
s
s
u
e
s
C
e
lls
0 .0 0 1
0 .0 1
0 .1
1
1 0
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 A
d
u
lt
 V
e
n
tr
ic
le
A D R B 1
T
is
s
u
e
M
ic
ro
t i
s
s
u
e
s
C
e
lls
0 .0 0 0 0 1
0 .0 0 0 1
0 .0 0 1
0 .0 1
0 .1
1
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 A
d
u
lt
 V
e
n
tr
ic
le
A d u lt v e n tr ic le
F o e ta l h e a r t
C M E F
C M
h E S C -C M 's
h C M E C
h C F
S 1 0 0 A 1
D M E F
C M E
C M F
  188 
A selection of genes showed enhanced upregulation specifically in the CMEF 
microtissues. An S100 Ca2+ binding protein (S100A1) and titin cap (TCAP) 
were found to have enhanced upregulation in the CMEF microtissues (figure 
5.15); only the CMEF microtissues showed mRNA expression of S100A1 
above that of the foetal heart, an increase of at least 10 fold relative to other 
microtissue types. Nitric oxide synthase 3 (NOS3), an endothelial derived 
form of NOS and phosphodiesterase 3 (PDE3A) were also found to have 
enhanced upregulation within the CMEF microtissues (figure 5.15).  
 
5.6 S100A1 upregulation correlates with calcium handling maturity 
Having studied the maturity of the microtissues at the gene expression level 
(section 5.5), this highlighted an upregulation of the S100A1 gene specifically 
in the CMEF microtissues. This was the only gene upregulated specifically in 
the CMEF’s relative to the other microtissues at a level that was above foetal 
heart tissue, towards adult cardiomyocytes. S100A1 is suggested to modulate 
SR function in the mature cardiomyocyte. A high caffeine concentration of 10 
mM was used to study SR function. Caffeine opens the RyRs and releases 
the SR ca2+ stores into the cytosolic domain. In the myocardium the strength 
of the contraction (inotropy) is dependent upon the magnitude of the Ca2+ 
released into the cytosol. In immature cardiomyocytes we see a lack of SR 
function therefore dysfunctional excitation contraction coupling upon caffeine-
induced calcium release (caff-ICR). 
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Figure 5.15 Expression of S100A1, TCAP, NOS3 and PDE3A in cardiac 
tissue, microtissues and monolayer cells.  
Total RNA extracted using RNeasy mini kit (Qiagen, Crawley, U.K.). Total 
RNA was diluted to 20 ng and reverse transcribed using a SuperScript® III 
first-strand synthesis supermix kit (Life technologies). cDNA samples were 
preamplified using the TaqMan® PreAmp Master mix kit. QRT-PCR reactions 
were performed using TaqMan® Gene Expression probes and master mix to 
monitor amplification under standard cycling conditions. Gene expression is 
expressed as fold change relative to GAPDH and adult ventricle using the 
ΔΔCT method. Fold change relative to adult ventricle is plotted for tissues, 
adult ventricle and foetal heart; microtissues, CMEF, DMEF, CM, CME and 
CMF; and cells, hESC-CMs, hCFs, hCMECs. n=3, error bars represent SD. 
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CMEF, CM and DMEF microtissues were exposed to a high concentration of 
caffeine (10 mM) and contraction response recorded using the IonOptix cell 
geometry measurement system (figure 5.16). CMEF microtissues displayed a 
caffeine response reminiscent of the mature behavioral pattern expected; an 
acute increase in transient peak height (contraction displacement) as a result 
of caffeine-ICR followed by an abrupt halt in contractions once SR Ca2+ stores 
are depleted. CM and DMEF microtissue contractions were abruptly halted by 
caffeine, however, the acute increase in contraction displacement did not 
occur. 
  
 
 
 
Figure 5.16 Contractile response of (a) CMEF, (b) DMEF and (c) CM 
microtissue models to 10 mM caffeine.  
Microtissues were formed and incubated for 14 days prior to transfer and 
attachment to gelatin-coated coverslips for application to the IonOptix cell 
geometry system. 10 mM caffeine in 5050 microtissue media was applied and 
contractile response recorded until steady state. 
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To investigate the role of S100A1, a knockdown of S100A1 using siRNA was 
performed in CMEF microtissues and its effect on the mature CMEF caffeine 
response studied. A partial knockdown was desired to replicate loss of the 
upregulation but not any potential housekeeping roles of S100A1. 
Microtissues were formed and incubated for 14 days prior to use. Microtissues 
were transfected with 10 nM S100A1 siRNA or scrambled siRNA (negative 
control) using Lipofectamine™ RNAiMAX transfection reagent. Microtissues 
were incubated with the transfection solution at 37 °C, 5% CO2 for 24 h prior 
to use. At this point microtissues were transferred and attached to gelatin-
coated coverslips for application to the IonOptix cell geometry system. 10 mM 
caffeine in microtissue media was applied to the microtissues and contractile 
response recorded until steady state. Microtissues not used for contractile 
analysis were pooled and lysed for total RNA extraction. Following cDNA 
generation and amplification, qRT-PCR was performed to quantify the 
expression level of S100A1 in the CMEF microtissues transfected with 10 nM 
S100A1 siRNA, expression shown in figure 5.15 is fold change relative to the 
scrambled siRNA control CMEF’s. S100A1 mRNA levels have been 
significantly downregulated by approximately 0.4 fold compared to the 
scrambled control (p<0.0001) (figure 5.17).  
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Figure 5.17 Expression of S100A1 in CMEF knockdown model.  
Microtissues were formed and incubated for 14 days prior to transfection with 
10 nM S100A1 siRNA or 10 nM scrambled siRNA (negative control) using 
Lipofectamine™ RNAiMAX transfection reagent. Microtissues were incubated 
with the transfection solution at 37 °C, 5% CO2 for 24 h prior to use. Total 
RNA extracted using RNeasy mini kit (Qiagen, Crawley, U.K.). Total RNA was 
diluted to 20 ng and reverse transcribed using a SuperScript® III first-strand 
synthesis supermix kit (Life technologies). cDNA samples were preamplified 
using the TaqMan® PreAmp Master mix kit with TaqMan® Probes. QRT-PCR 
reactions were performed using TaqMan® Gene Expression probes and 
master mix to monitor amplification under standard cycling conditions. Data is 
expressed as fold change relative to GAPDH and CMEF scrambled siRNA 
control using the ΔΔCT method from triplicate experiments, SD error bars 
shown. 
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Figure 5.18 displays representative contractility traces of the caffeine 
responses exerted by the control microtissues (figure 5.18a) and the 
S100A1KD CMEF’s (figure 5.18b). These traces show that the control 
CMEF’s are still able to respond to caffeine with an acute increase in 
contraction displacement, however the S100A1kd CMEF’s show loss of this 
characteristic.  
 
Figure 5.18 Response of CMEF S100A1 knockdown model to 10 mM 
caffeine.  
Microtissues were formed and incubated for 14 days prior to transfection with 
10 nM S100A1 siRNA or 10 nM scrambled siRNA (negative control) using 
Lipofectamine™ RNAiMAX transfection reagent. Microtissues were incubated 
with the transfection solution at 37 °C, 5% CO2 for 24 h prior to use. 
Microtissues were transferred and attached to gelatin-coated coverslips for 
application to the IonOptix cell geometry system. 10 mM caffeine in 5050 
microtissue media was applied and contractile response recorded until steady 
state. (a) scrambled siRNA control CMEF microtissue, (b) S100A1 CMEF 
knockdown microtissue model. 
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5.7 Discussion 
The ultimate aim of this chapter was to assess the contractile maturity of the 
microtissues and establish their ability to predict drug-induced functional 
cardiotoxicity.  
 
5.7.1 Detection of inotropy direction in CMEF microtissues 
To assess the contractile maturity of the microtissues, firstly the basal spontaneous 
contractions were compared. Figure 5.1 showed clearly that the CMEF microtissues 
have a faster basal contraction rate than the CM microtissues. Literature suggests 
that an increase in the spontaneous contraction rate of hESC-CMs can occur with 
prolonged time in culture (Robertson et al., 2013). One hypothesis could be that 
prolonged culture is permitting further differentiation of the mixed population stem 
cell derived cardiomyocytes (ventricular and/or nodal cardiomyocytes) and hence the 
increased beat rate. Given the microtissues are cultured for equal periods it could be 
the adult cardiac non-myocytes are promoting this differentiation earlier in the CMEF 
microtissue model. Another interesting difference between the monoculture CM 
microtissue and the tri-cultured CMEF microtissue was their calcium transient 
amplitudes. CMEF microtissues display significantly higher Ca2+ transient 
amplitudes, this was the first indicator that the Ca2+ handling differs between the 
microtissue models and that calcium handling maturation may have ocurred. The 
next step in assessing the contractile maturity of the microtissues was their response 
to positive and negative inotropic agents. It has been suggested that immature 
cardiomyocytes such as hESC-CMs cannot increase their contraction displacement 
in response to positive inotropic agents (Robertson et al., 2013). The CMEF 
microtissues responded with increased contraction displacement to all positive 
inotropes whereas none of the other microtissue models could increase their 
displacement of contraction when positive inotropes were applied. These differences 
in their responses suggest maturation has been promoted in the CMEF microtissues.  
 
Major morphological changes occur from embryonic cardiomyocytes through to 
adult. The sarcoplasmic reticulum (SR) are relatively sparse in the immature 
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myocyte with inositol 1,4,5-trisphosphate (IP3)-gated Ca2+ release channels (IP3Rs) 
playing significant roles in calcium mobilization from the SR (Robertson et al., 2013). 
This lack of SR function could be one mechanism limiting an immature 
cardiomyocytes response to positive inotropic agents. In normal excitation-
contraction coupling a relatively small amount of extracellular Ca2+ enters the 
cardiomyocyte via L-type Ca2+ channels after depolarization and binds to the RyRs 
to release a much greater amount of Ca2+ from the intracellular calcium stores of the 
SR (Bers, 2002). This results in a fast synchronous rise in free cytosolic Ca2+. The 
immature cardiomyocyte however relies on the diffusion of extracellular Ca2+ across 
the cell cytoplasm (Robertson et al., 2013), this lacks the fast synchronisity of the 
mature cardiomyocyte. This could be one reason why immature cardiomyocytes 
such as the hESC-CM cannot increase their contraction displacement in response to 
positive inotropic agents and suggests that maturation of SR function has been 
promoted within the CMEF microtissues. 
 
Both CM and CMEF microtissue models responded to the negative inotrope 
verapamil. Interestingly, verapamil, which acts to block the L-type Ca2+ channels of 
the cell membrane thereby blocking Ca2+ entry into the cell, was more potent in the 
CMEF model. This was also seen further into the chapter when diltiazem, also an L-
type Ca2+ channel blocker, was tested and the same pattern displayed. Immature 
CM’s rely heavily on extracellular Ca2+ for excitation-contraction coupling, therefore it 
was surprising that the CMEF were more sensitive. However, this could support the 
idea of Ca2+ handling maturity in the CMEF model; more efficiency and reliance upon 
Ca2+ handling may result in more sensitivity to disruption. 
 
Since the CMEF model displayed contractile maturity compared with the CM 
microtissues, it was selected for assessment with a wider panel of positive and 
negative inotropes. This model showed not only the correct detection of inotropy 
direction, but also predicted negative inotropy of compounds previously undetected 
in the ”gold standard” canine cardiomyocyte assay. Therefore the CMEF model is a 
human relevant model with in vivo physiological relevance and in vitro contractile 
maturity that can be used to better predict cardiac toxicity.  
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5.7.2 Promotion of maturity in microtissues 
The next step was to define how the contractile maturity of the CMEF model was 
promoted. The first question was whether both endothelial and fibroblasts are 
needed and whether they need to be from a cardiac origin. The two negative 
inotropes lapatinib and atenolol, previously undetected in CM microtissues and 
canine cardiomyocyte contractility assessment, were tested alongside the two 
positive inotropes digoxin and dobutamine. The CMEF microtissues were the only 
model to respond to the positive inotropes, therefore a tri-culture of cardiac 
originating cells is required to achieve contractile maturity. Neither DMEF nor CM 
microtissues responded to either of the negative inotropes while the CMEF again 
responded to both. Curiously, the di-culture microtissue, CME, responded to 
lapatinib while the di-culture microtissue, CMF, responded to atenolol. The first 
interesting aspect is that each of these negative inotropic responses must be cardiac 
specific since the dermal microtissue did not respond. However by utilising the di-
culture models, we have highlighted a potential role for endothelial cells in lapatinib 
inotropy and fibroblasts in atenolol inotropy. 
 
Gene expression analysis of all microtissues using adult ventricle (AV) and foetal 
heart as mature and relatively mature references, respectively, we were able to 
identify two promoters of maturity; three dimensional cell culture and co-culture with 
adult cardiac specific cells. Given the lack of response from the non-CMEF 
microtissues to positive inotropes it was perhaps surprising to see that at the gene 
level there is actually some degree of gene maturity towards AV and/ or foetal heart 
when compared to the monolayer hESC-CMs. In many ways this should not be 
surprising as it is widely accepted that 3D cell culturing can promote a more mature 
cell phenotype in vitro.  
 
An interesting aspect of the gene expression study was the upregulation of S100A1 
above foetal heart, towards AV, specifically in the CMEF microtissues.  S100A1 is a 
Ca2+ binding protein of the EF-hand type and a member of the S100 protein family 
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with known roles in striated muscle sarcoplasmic reticulum (SR) Ca2+ handling. 
Given its preferential cardiac expression and localisation patterns close to the SR 
and contractile filaments of cardiomyocytes, S100A1 has become a target of interest 
with respect to cardiac contractility. S100A1 has been shown to regulate and 
improve the function of key proteins involved in the control of SR Ca2+ handling as 
well as myofilament and mitochondrial function, thereby enhancing the heart's 
inotropic and lusitropic state [reviewed in (Most et al, 2007; Ritterhoff & Most, 2012; 
Rohde et al, 2010)]. Additionally studies have highlighted a correlation between 
S100A1 protein expression and β-adrenergic inotropy response (Bennett, 2014). The 
upregulation of S100A1 in CMEF relative to other microtissue models and combined 
unique response to positive inotropes suggests a critical role for S100A1 during 
cardiomyocyte contraction. The role of S100A1 in CMEF contractile maturity was 
then assessed using gene knockdown. 
 
5.7.3 Potential role of S100A1 in sarcoplasmic reticulum function 
Caffeine is commonly used in electrophysiology to study sarcoplasmic reticulum 
(SR) function; it acts to increase the open probability of the SR ryanodine receptors 
thereby releasing calcium into the cytoplasm. In many ways caffeine-induced 
calcium release (caffeine-ICR) is a replication of calcium-induced calcium release 
(CICR). During excitation-contraction coupling a small amount of Ca2+ enters the 
cytoplasm, activates the ryanodine receptors and initiates a huge release of Ca2+ 
from the SR stores, this release is known as CICR. Only mature cardiomyocytes are 
thought to have this functional CICR pathway and reliance upon SR RyRs. As 
caffeine quickly releases Ca2+ from the functional SR you see a sharp increase in 
inotropy, until the stores are empty at which point contraction stops (during unpaced 
conditions; paced conditions would allow Ca2+ entry via the L-type Ca2+ channels). 
The CMEF microtissues displayed this behavioural pattern, whereas the CM and 
DMEF microtissues experienced a slow decrease in inotropy. These findings support 
the theory that the lack of positive inotropy displayed by the CM and DMEF models 
was due to immature Ca2+ handling and that cardiac non-myocytes have promoted 
SR function and therefore synchronisation of Ca2+ signalling to increase contraction 
displacement.  
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Caffeine-induced calcium release (caff-ICR) was then used to assess the role of the 
Ca2+ binding protein S100A1 and its potential role in SR function. A knockdown of 
the S100A1 gene was performed in the CMEF model; a knockdown rather than 
knockout was desired to study as closely as possible the upregulation of S100A1 
rather than its general presence. A reduction in the expression of S100A1 resulted in 
a caff-ICR response phenotypically the same as the DMEF model, therefore loss of 
the contractile maturity. This suggests a critical role for S100A1 in SR function and 
hence contractile maturity of the CMEF model. 
 
5.7.4 Conclusion 
The ultimate conclusion from this chapter is adult cardiac non-myocyte cells can be 
used to promote contractile maturity of embryonic stem cell-derived cardiomyocytes 
in vitro when co-cultured as a three dimensional microtissue. The induction of 
maturity is very much multi-parameter dependent requiring a) both non-myocyte cell 
types, b) cells of cardiac origin and c) a 3D culture environment. However, it should 
be noted that despite achieving a functionally relevent degree of maturity, this in vitro 
myocardial model still lacks many of the characteristics of fully matured myocardial 
tissue.  
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The aim of this thesis was to investigate the role of non-myocytes in drug-induced 
cardiovascular toxicity. Current methods of drug safety screening primarily focus on 
cardiomyocytes in isolation (Harmer et al., 2012; Pollard et al., 2010), ignoring other 
cellular components of the myocardium. Given the high level of drug attrition 
resulting from cardiotoxic events, the need for more physiologically relevant in vitro 
models has arisen. The first aim of this investigation was to determine whether non-
myocyte cells (microvascular endothelial and fibroblasts) from the myocardium 
exhibit sensitivity to known structural cardiotoxins and whether this sensitivity is also 
displayed in dermal-derived and macrovascular-derived non-myocytes. 
The second aim of this investigation was to incorporate these myocardial derived 
non-myocytes into a cell-based 3D in vitro model alongside cardiomyocytes for use 
in preclinical drug-induced cardiotoxicity screening. This model has been evaluated 
for its structural, gene expression and electrophysiological maturity. 
 
6.1 The role of non-myocytes in drug-induced structural cardiovascular 
toxicity 
 
The cardiomyocytes and non-myocytes studied in this thesis were evaluated for their 
individual sensitivities to known structural cardiotoxins utilizing high content biology 
in combination with a cytoxicity assay measuring ATP content. This combined 
approach increases the overall predictive strength of the toxicity screen (see chapter 
3 and Pointon et al., 2013).  
 
Despite studying both structural and cytotoxic endpoints, no cardiac microvascular 
specific endothelial toxicity was detected. These findings are not particurlaly 
surprising if we consider the limitations of this study. Endothelial cells are highly 
adaptive cells designed to rapidly respond to changes in their microenvironment in 
order to maintain the flow of oxygen and nutrients to their tissue (and removal of 
waste products) (Aird, 2007a; b; Aird, 2012). A major but unavoidable draw-back of 
this study is that the primary endothelial cells have been removed from their specific 
microenvironments in vivo and cultured alone in vitro under general endothelial cell 
culture conditions. The endothelial cell models were cultured in almost identical 
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conditions therefore it is not surprising that they should respond to compounds in an 
almost identical manner. Traditional in vitro cell culture involves cell attachment to 
plastic labware; this restricts the cell to an almost 2D morphology. A major in vivo 
characteristic of endothelial cells is their formation of vessel structures throughout 
their tissue. In vitro the endothelial cells lack this 3D morphology, blood flow through 
the vessels and intercellular communications; in vitro endothelial cells, therefore, 
could almost be considered immature compared with their in vivo counterparts. This 
highlights the need for more complex in vitro cell models when studying drug toxicity. 
 
Interestingly, much more variation in structural cardiotoxin sensitivity was observed 
between the cardiac and dermal fibroblasts, this suggests that the fibroblasts 
perhaps are not as dependent upon their microenvironment for their phenotype as 
the endothelial cells. The cardiac fibroblasts displayed enhanced sensitivity to 
imatinib mesylate when compared to dermal fibroblasts. However, interestingly the 
dermal fibroblasts showed overall the most sensitivity to tyrosine kinase inhibitors 
suggesting they could be a target during incidences of skin toxicity reported by these 
compounds e.g. skin rashes following lapatinib dosage (Moy & Goss, 2007). 
However, keratinocytes are an alternative target since they are known to express 
epidermal growth factor receptors (EGFR) targeted by these compounds (Kolev et 
al, 2008). These findings suggest that in vitro preclinical safety assessments should 
utilise cells derived from the tissue of interest whenever possible otherwise important 
toxicities could be missed. 
 
When the sensitivities of the cells from the myocardium (hCFs, hCMECs and hESC-
CMs) were globally compared we see that the non-myocytes are sensitive to 
structural cardiotoxicity at the acute time point of 6 h, whereas the hESC-CMs 
display toxicity only after 72 h. In vivo the early compound toxicity of the non-
myocytes could potentially translate into enhanced cardiomyocyte sensitivity. 
Fibroblasts are in close proximity to myocytes and their ability to manipulate the 
ECM provides them with the potential to influence cardiomyocyte phenotype 
(Souders et al., 2009). Cardiomyocytes are highly energetic cells that require an 
abundance of oxygen and nutrients from the dense microvasculature. Loss or 
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damage to the microvasculature would ultimately affect cardiomyocyte health and 
mechanical output. On the other hand, in the in vivo environment the cardiomyocytes 
could potentially have a protective effect over the non-myocytes (Chen et al., 2010) 
and therefore this early sensitivity is prevented. The exposure of co-cultured 
microtissue models to structural cardiotoxins in chapter four suggests that a 
protection mechanism exists between cardiomyocytes and non-myocytes since the 
tri-cultured microtissues displayed less sensitivity than di- or mono-cultured 
microtissues. Data from chapters three and five suggests the promotion of maturity 
in CMEF microtissue therefore it may be that mature cardiac tissue is better 
equipped to respond to stress conditions elicited by cardiotoxins.  
 
Our current single cell type preclinical in vitro models lack the complexity required to 
establish whether these early events enhance or protect against cardiotoxicity. The 
microtissue models represent a human relevant in vitro model that better 
reconstitutes the in vivo cellular physiology. These models have improved in vivo 
relevance compared with the monolayer assays previously used, since they conform 
the cells into their natural 3D structure and allow multicellular interactions. However 
current assay endpoints available to study compound toxicities in microtissues are 
limited. Microtissues can be difficult to manipulate for image-based endpoints and 
chemical reaction-based assays often lack the sensitivity required to detect 
responses from the low cell numbers present within microtissues. An additional 
limitation of the microtissues was a lack of vessel formation by the endothelial cells. 
The mature myocardium has a dense vascular network formed by the endothelial 
cells. Without this arrangement the endothelial cells may lack the maturity and 
physiological relevance required for accurate toxicity prediction. One possible 
explanation for this poor vessel formation is the diameter of the microtissue. They 
were designed to have a diameter small enough to prevent a hypoxic core; literature 
suggests oxygen and nutrients can diffuse through a microtissue of up to 200 μm in 
diameter therefore evading the need for a vascular structure (Breslin & O'Driscoll, 
2013). This lack of vascularisation therefore limits the use of these microtissues in 
structural cardiovascular toxicity screening. In hindsight larger microtissues may 
have induced a vascular network and overcome the sensitivity issues of chemical-
based assays. Despite this electrophysiological assessment of the microtissues 
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suggests that the CMEF microtissues are functionally matured and therefore provide 
an improved in vitro model for functional cardiotoxicity screening. 
6.2 Non-myocytes promote contractile maturity in cardiac microtissues 
 
To assess the contractile maturity of the microtissues, firstly the basal spontaneous 
contractions were compared; CMEF microtissues have a faster basal contraction 
rate than the CM microtissues. Literature suggests that an increase in the 
spontaneous contraction rate of hESC-CMs is an indicator of maturity (Robertson et 
al., 2013). Another interesting difference between the monoculture CM microtissue 
and the tri-cultured CMEF microtissue is their calcium transient amplitudes. CM 
microtissues display significantly lower Ca2+ transient amplitudes, suggesting 
immature calcium handling compared with the CMEF microtissues.  
 
It has also been suggested that immature cardiomyocytes such as hESC-CMs 
cannot increase their contraction displacement in response to positive inotropic 
agents (Robertson et al., 2013). Major morphological changes occur from embryonic 
cardiomyocytes through to adult. Sarcoplasmic reticulum (SR) are found to be 
relatively sparse in the immature myocyte with inositol 1,4,5-trisphosphate (IP3)-
gated Ca2+ release channels (IP3Rs) playing significant roles in calcium mobilization 
from them. This lack of SR function has been suggested as one mechanism limiting 
an immature cardiomyocytes response to positive inotropic agents. In normal 
excitation-contraction coupling a relatively small amount of extracellular Ca2+ enters 
the cardiomyocyte via L-type Ca2+ channels after depolarization and binds to the 
RyRs to release a much greater amount of Ca2+ from the intracellular calcium stores 
of the SR. This results in a fast synchronous rise in free cytosolic Ca2+. The 
immature cardiomyocyte however relies on the diffusion of extracellular Ca2+ across 
the cell cytoplasm, this lacks the fast synchronisty of the mature cardiomyocyte 
(Robertson et al., 2013). This could be one reason why immature cardiomyocytes 
such as the hESC-CM cannot increase their contraction displacement in response to 
positive inotropic agents. The tri-cultured cardiac microtissue (CMEF) was the only 
model to respond to positive inotropes. This model (CMEF) showed, not only the 
correct detection of inotropy direction but also predicted negative inotropy of 
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compounds previously undetected in the gold standard canine cardiomyocyte assay. 
Therefore the CMEF model is a human relevant model with in vivo physiological 
relevance and in vitro contractile maturity that can be used to predict cardiac toxicity. 
This investigation highlights the need for cardiac originating non-myocytes to be 
incorporated into our pre-clinical cardiac safety screens. 
 
Gene expression analysis of all microtissues using adult ventricle and foetal heart as 
mature and maturing references, respectively, we were able to identify two 
promoters of maturity. Given the lack of response from the non-CMEF microtissues 
to positive inotropes it was interesting to see that at the gene level there is actually 
some degree of gene maturity towards AV and/ or foetal when compared to the 
monolayer hESC-CMs. In many ways this should not be surprising as it is widely 
accepted that 3D cell culturing can promote a more mature cell phenotype in vitro. 
  
The most intriguing aspect of the gene expression study in chapter five was perhaps 
the upregulation of S100A1 above foetal heart, towards AV, specifically in the CMEF 
microtissues.  S100A1 is a Ca2+ binding protein of the EF-hand type and a member 
of the S100 protein family with known roles in striated muscle sarcoplasmic reticulum 
(SR) Ca2+ handling. Given its preferential cardiac expression and localisation 
patterns close to the SR and contractile filaments of cardiomyocytes, S100A1 has 
become a target of interest with respect to cardiac contractility. S100A1 has been 
shown to regulate and improve the function of key proteins involved in the control of 
SR Ca2+ handling as well as myofilament and mitochondrial function, thereby 
enhancing the heart's inotropic and lusitropic state [reviewed in (Most et al, 2007; 
Ritterhoff & Most, 2012; Rohde et al, 2010)]. Additionally studies have highlighted a 
correlation between S100A1 protein expression and β-adrenergic inotropy response 
(Bennett, 2014). Caffeine response with gene knockdown experience has suggested 
the gene upregulation of S100A1 plays a major role in the contractile maturity 
established within the CMEF microtissue. 
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6.3 Future work 
In further work, it would be interesting to look at structural cardiotoxin sensitivities in 
non-myocytes at an earlier timepoint than six hours to allow improved mechanistic 
insight from the high content biology. This could help to highlight any common 
toxicity mechanism between non-myocytes and cardiomyocytes and ultimately 
provide knowledge for future drug development. 
 
Despite displaying increased maturity, the CMEF microtissues are still an immature 
cardiac model. The size of the microtissues could be increased and additional cell 
types such as pericytes could be incorporated to help induce vasculaturisation. In 
vivo the myocardium is under constant electrical pacing conditions therefore the in 
vitro culture of microtissues under constant electrical pacing may be another step to 
help promote further model maturity. It may also be interesting to expose 
microtissues to structural cardiotoxins under electrical pacing conditions to see 
whether this affects the toxicity we see. Pointon et al (2013) showed a reduction in 
cardiomyocyte structural cardiotoxin sensitivity when co-administered with BTS, a 
negative inotrope. These findings suggest increased cardiomyocyte activity, for 
example electrical pacing, could enhance structural compound sensitivities. 
 
 
6.4 Overall conclusions 
 
This investigation has suggested a role for non-myocytes in early drug-induced 
structural and functional cardiotoxicity. Structural compound toxicity assessments 
were limited by current available models and assay endpoints for 3D models, 
however cell type specific toxicities were detected and utilization of microtissues 
suggests the role of non-myocytes in drug-induced structural cardiovascular toxicity 
could in fact be one of protection. Incorporation of non-myocytes into co-cultured 
microtissue models for the study of functional cardiotoxicity has highlighted the 
importance of utilizing firstly non-myocytes but also non-myocytes of cardiac origin in 
our in vitro cardiotoxicity screens. This investigation has successfully shown adult 
cardiac non-myocyte cells can be used to promote contractile maturity of embryonic 
stem cell-derived cardiomyocytes in vitro when co-cultured as a three dimensional 
microtissue and that the induction of cardiac maturity is very much multi-parameter 
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dependent. The incorporation of more complex cell models into in vitro cardiac safety 
screening is needed to improve drug attrition at the early stages of drug 
development. 
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Table 1. Summary of structural cardiotoxin IC50’s at 6 hrs 
6 hr Imatinib Fluorouracil Doxorubicin  Sorafenib Lapatinib Sunitinib Dasatinib Idarubicin 
hCMEC''s 
       
  
MMP 16.59 1.95 28.35 9.23 11.36 2.42 8.26 13.35 
ER 15.29 2.00 28.35 9.28 13.58 2.49 8.43 6.52 
Ca2+ 15.48 2.11 28.35 9.18 13.92 2.40 9.05 31.68 
ATP 198.52 1000.00 78.50 3.28 9.57 3.28 26.03 16.81 
hDMECs 
        MMP 10.15 3.26 14.81 7.11 10.67 1.63 8.50 1.62 
ER 10.07 3.26 8.28 7.45 10.67 2.83 7.67 1.81 
Ca2+ 10.03 3.26 9.57 7.58 10.67 1.63 8.50 4.00 
ATP 77.31 66.67 69.32 2.79 8.28 36.29 40.17 20.52 
hCAECs 
        MMP 5.97 3.00 3.50 6.43 18.39 15.37 6.81 14.33 
ER 5.96 3.00 3.49 6.49 5.57 15.38 6.81 14.33 
Ca2+ 6.10 3.00 3.50 6.57 12.61 3.73 6.81 14.33 
ATP 9.44 35.33 14.65 2.86 47.49 33.14 68.04 22.57 
hCFs 
        MMP 2.87 21.68 6.52 0.30 0.40 44.36 1109.18 179.04 
ER 3.64 21.68 6.52 0.38 0.50 67.01 1121.74 23.31 
Ca2+ 3.62 21.68 6.52 0.43 0.50 71.13 1150.95 37.91 
ATP 3.05 21.68 6.52 3.59 0.31 40.30 2117.24 85.11 
NhDFs 
        MMP 28.24 21.68 6.52 6.04 0.18 1.20 13824.65 812.09 
ER 28.24 21.68 6.52 6.04 0.18 191.26 13824.65 812.09 
Ca2+ 28.24 21.68 6.52 6.04 1.50 163.57 13824.65 812.09 
ATP 23.37 462.53 35.24 4.07 8.02 136.17 4887.47 115.67 
hESC-CMs 
        MMP 26.68 100 28.31 100 46.4 83.46 85.79 7.2 
ER 100 100 100 100 100 100 100 90.68 
Ca2+ 100 100 27.05 100 83.9 100 100 2.56 
ATP 41.52 100 100 73.06 21.25 51.63 56.35 21.9 
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Table 2. Summary of structural cardiotoxin IC50’s at 24 hrs 
24 hr Imatinib Fluorouracil Doxorubicin  Sorafenib Lapatinib Sunitinib Dasatinib Idarubicin 
hCMEC''s 
       
  
MMP 23.78 6.67 0.73 1.76 16.50 6.52 13.56 24.00 
ER 23.99 6.67 0.77 15.75 21.50 6.50 15.64 0.70 
Ca2+ 23.99 6.67 0.62 10.98 21.50 7.24 16.79 0.69 
ATP 88.47 165.27 15.60 4.76 17.54 31.42 28.66 3.23 
hDMECs 
        MMP 4.13 1.25 2.84 2.40 16.59 0.88 2.72 9.62 
ER 4.13 1.22 2.78 2.32 1.09 0.89 4.17 1.36 
Ca2+ 4.13 1.23 2.09 3.56 16.63 0.58 2.24 0.86 
ATP 47.72 3171.73 12.13 2.19 18.08 7.59 66.00 3.44 
hCAECs 
        MMP 21.92 1.62 2.92 19.69 19.68 2.41 1.97 1.98 
ER 21.92 1.62 2.92 34.02 16.17 2.33 16.30 2.33 
Ca2+ 19.29 1.62 2.92 19.69 15.47 2.55 1.97 2.33 
ATP 73.45 293.33 94.17 28.10 28.88 27.69 101.77 42.03 
hCFs 
        MMP 0.25 21.68 0.13 0.06 3.84 9.22 297.13 4.46 
ER 0.25 21.68 0.03 0.06 3.06 9.43 167.35 4.36 
Ca2+ 0.24 21.68 0.13 0.06 3.17 8.79 155.34 4.27 
ATP 22.98 21.68 6.52 3.56 0.67 66.53 5242.30 481.61 
NhDFs 
        MMP 3.25 21.68 0.44 0.06 0.02 0.41 12.45 10.15 
ER 3.24 21.68 0.36 0.07 0.02 0.08 12.51 3.35 
Ca2+ 3.26 21.68 0.43 0.08 0.02 0.44 12.27 12.37 
ATP 110.79 15921.42 6.48 2.66 12.56 207.59 8865.28 408.32 
hESC-CMs 
        MMP 94.28 100 3.47 100 54.64 86.9 0.5 4.6 
ER 100 100 100 63.92 100 100 100 4.11 
Ca2+ 100 100 6.2 100 100 94.57 76.89 8.62 
ATP 32.33 100 29.18 48.33 10.1 35.53 35.02 8.4 
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Table 3. Summary of structural cardiotoxin IC50’s at 72 hrs 
72 hr Imatinib Fluorouracil Doxorubicin  Sorafenib Lapatinib Sunitinib Dasatinib Idarubicin 
hCMECs 
        MMP 35.33 7.01 2.87 12.40 10.35 6.25 13.68 0.36 
ER 35.33 7.01 2.85 12.50 8.38 5.84 14.17 0.37 
Ca2+ 35.33 7.01 3.30 12.31 10.86 6.29 15.05 0.38 
ATP 41.42 76.67 0.57 1.53 4.80 3.76 14.19 1.65 
hDMECs 
        MMP 9.79 13.45 13.41 3.09 5.33 4.54 10.47 0.63 
ER 10.00 13.38 13.41 3.07 7.83 4.58 5.44 0.65 
Ca2+ 10.00 13.45 13.42 4.26 9.99 4.63 8.84 0.73 
ATP 20.50 3246.67 0.63 1.48 5.38 2.47 13.56 2.83 
hCAECs 
        MMP 36.67 16.40 2.79 7.41 13.34 8.73 3.28 1.14 
ER 36.67 16.40 2.81 7.01 9.68 7.79 3.28 1.16 
Ca2+ 36.67 16.40 3.80 7.20 9.68 8.83 3.28 1.18 
ATP 43.15 908.23 3.13 1.35 6.15 5.04 15.02 3.74 
hCFs 
        MMP 0.00 21.68 0.01 0.12 1.15 35.34 2140.75 0.01 
ER 0.00 21.68 0.02 0.16 2.40 33.86 2308.72 0.00 
Ca2+ 0.00 21.68 0.02 0.17 1.27 37.65 6764.40 0.00 
ATP 1.58 21.68 0.10 0.58 0.33 13.13 283.13 0.63 
NhDFs 
        MMP 28.24 21.68 0.08 0.00 0.00 47.01 13824.65 471.58 
ER 28.24 21.68 0.02 0.00 0.05 65.65 8972.20 459.48 
Ca2+ 28.24 21.68 0.32 0.00 0.05 56.46 10550.28 475.48 
ATP 141.91 0.50 0.50 3.64 12.01 126.82 7812.77 77.63 
hESC-CMs 
        MMP 26.000 0.090 10.600 2.900 12.500 0.510 0.770 0.013 
ER 52.0 0.06 >100 48.1 0.05 9.8 57.0 0.002 
Ca2+ 20.4 0.03 40.8 7.8 0.08 0.001 18.3 0.013 
ATP 16.4 48.3 0.53 19.7 12.5 19.4 62.0 9.4 
